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The emergence of high throughput technologies is enabling the characterization of cancer 
genomes at unprecedented resolution and scale. However, such data suffer from the typical 
limitations of observational studies, which are frequently challenged by their inability to differentiate 
between causality and correlation. Recently, several datasets of genome-wide functional assays 
performed on tumor cell lines have become available. Given the ability of these assays to 
interrogate cancer genomes for the function of each individual gene, these data can provide vital 
cues to identify causal events and, with them, novel drug targets.  Unfortunately, current analytical 
methods have been unable to overcome the challenges posed by these assays, which include poor 
signal to noise ratio and wide-spread off-target effects.  
Given the largely orthogonal strengths and weaknesses of descriptive analysis of genetic and 
genomic observational data from cancer genomes and genome-wide functional screening, I 
hypothesized that integrating the two data types into unified computational models would 
significantly increase the power of the biological analysis. In this dissertation I use integrative 
approaches to tackle two crucial problems in cancer research: the identification of driver genes and 
the discovery of tumor lethalities. I use the resulting methods to study breast cancer, the second 
most common form of this disease. 
The first part of the dissertation focuses on the analysis of regions of copy number alteration for 
the identification of driver genes. I first describe how a simple integrative method enabled the 
identification of BIN3, a novel driver of metastasis in breast cancer. I then describe Helios, an 
unsupervised method for the identification of driver genes in regions of SCNA that integrates 
different data sources into a single probabilistic score. Applying Helios to breast cancer data 
identified a set of candidate drivers highly enriched with known drivers (p-value < e-14). In vitro 
 
validation of 12 novel candidates predicted by Helios found 10 conferred enhanced anchorage 
independent growth, demonstrating Helios’s exquisite sensitivity and specificity. I further provide 
an extensive characterization of RSF-1, a driver identified by Helios whose amplification correlates 
with poor prognosis, which displayed increased tumorigenesis and metastasis in mouse models.  
The second part of this dissertation addresses the problem of identifying tumor vulnerabilities 
using genome-wide shRNA screens across tumor cell lines. I approach this endeavor using a novel 
integrative method that employs different biomarkers of cellular state to facilitate the identification 
of clusters of hairpins with similar phenotype. When applied to breast cancer data, the method not 
only recapitulates the main subtypes and lethalities associated to this malignancy, but also 
identifies several novel putative lethalities. 
Taken together, this research demonstrates the importance of the computational integration of 
genome-wide functional and observational data in cancer research, providing novel approaches 
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Chapter I - Introduction 
 
“Science is limited by the tools we possess and by the imagination we exercise 
to interpret those measurements.” 
Harold Varmus 
The arts and politics of Science (2009) 
 
On December 23, 1971, President Richard Nixon signed the National Cancer Act, officially 
declaring the War on Cancer (National Cancer Institute, 1971). More than 40 years later, we are 
still far from winning this war. In 2014, about 1,660,290 new cancer cases are expected to be 
diagnosed in the US and about 580,350 patients are estimated to die of cancer, almost 1,600 
people per day. It is estimated that 1 in 2 men and a little more than 1 in 3 women will develop 
cancer over the course of a lifetime. The National Institutes of Health (NIH) estimates that the 
overall national costs of cancer in 2008 were $201.5 billion (American Cancer Society, 2013). 
Annual direct costs for cancer care in the US are projected to rise from $104 billion in 2006 to over 
$173 billion in 2020 and beyond (Smith and Hillner, 2011).  
Despite these alarming figures, scientific understanding of Cancer has increased dramatically 
in the last decades, and in just the past few years, new technologies have emerged to help further 
disentangle the complexities of the disease. It took 13 years and $3 billion to sequence the first 
genome; today a single technician can sequence a full genome within a few hours for just $1000 
(Sheridan, 2014). The emergence of high throughput technologies is allowing us to characterize 
cancer genomes at unprecedented resolution and scale. Projects like The Cancer Genome Atlas 
(TCGA) and the International Cancer Genome Consortium (ICGC) are collecting genetic and 
genomic data from hundreds of tumors for more than 40 different tumor types.  
We now understand that Cancer is not a single disease but a complex heterogeneous collection 
of diseases with common traits. These common traits, the hallmarks of cancers, include self-
sustained chronic proliferation, replicative immortality and the capability to invade other tissues and 




initially it was thought that cancer had a viral cause, it is now clear that cancer is a disease of the 
genome and that most tumors are caused by genetic and epigenetic alterations (Weinberg, 2007). 
On one hand, gain of function mutations activate genes that promote the disease, known as 
oncogenes. On the other hand, inactivating mutations in genes that inhibit oncogenic hallmarks, 
known as tumor suppressors, prevent those genes from performing their role. In other words, 
alterations in oncogenes “jam the accelerator pedal” while those in tumor suppressors “eliminate 
the brakes” (Garraway and Lander, 2013). 
There is a surprising variety of mechanisms by which oncogenes and tumor suppressors are 
altered, including somatic copy number alterations (SCNAs), i.e. amplification and deletion of DNA 
segments, chromosomal translocations, inversions and point mutations (Figure I-1)  (Ashworth et 
al., 2011). The nature, number and distribution of these mutations changes significantly across 
different tumor types (Yates and Campbell, 2012). 
 
 
Figure I-1 – Type of genetic alterations 
Graphical representation of some of the most frequent types of genetic alterations. Copy number alterations 
comprise both gains and losses of regions of the DNA, which are known as amplifications and deletions 
respectively. Translocations occur when segments of a chromosome break off and fuse to a different 
chromosome, without any loss of genetic material. Chromosomal inversions are alterations that arise when 
two breaks occur in a chromosome and the piece is reinserted in reversed order. Point mutations, also known 





These alterations are acquired in a multi-step process of clonal expansion that resembles 
Darwinian evolution, where the changes that provide clonal advantage are selected (Yates and 
Campbell, 2012). There are however some striking exceptions to this model, such as 
chromothripsis, a phenomenon of “mutagenic explosions”  observed in some tumors in which 
hundreds of clustered genome rearrangements are produced at once (Stephens et al., 2011).  
Most oncogenic alterations are somatic, acquired throughout life through errors in endogenous 
cellular processes such as replication or through exposure to exogenous agents, such as chemicals 
in tobacco or UV-light (Luch, 2005). Indeed, in most cases (~95%) cancer is a non-hereditary 
disease (Weinberg, 2007). 
Tumor cells harbor a large number of genetic alterations (104–105) compared to normal cells 
(Ashworth et al., 2011).  Most of these alterations (>99.9%) are called passenger mutations, as 
they do not confer any type of advantage to tumors (Vogelstein et al., 2013). Only a small number 
of alterations, known as driver alterations, contribute to tumor fitness and progression. The cause 
of this complex landscape of alterations is fairly simple. Normal cells have an extraordinary 
capability to identify and resolve problems with DNA integrity. To acquire the driver mutations 
required to achieve tumorigenesis, tumors often increase the mutation rate, resulting in a large 
number of random alterations (Hanahan and Weinberg, 2000).  
The omics era  
The data collected by large-scale projects such as TCGA or ICGC are helping us to understand 
the complexity of the landscape of alterations in cancer. The analysis of these data has revealed a 
staggering heterogeneity in alterations both within and across tissues, all of which lead to 
converging oncogenic phenotypes. The heterogeneity in alterations has major clinical 
consequences. No two patients have identical clinical courses even if they follow the same 
treatment. Even in vitro experiments within a tumor lineage reveal remarkable heterogeneity in drug 
response (Barretina et al., 2012a; Garnett et al., 2012; Heiser et al., 2011). Although ~140 driver 
genes involved in tumor development have been identified, more remain to be discovered and 




Because the vast amounts of data generated by high-throughput technologies largely exceed 
the human capabilities of understanding, new computational methods are required to digest and 
summarize these data. Furthermore, the availability of data has caused a paradigm shift in the field. 
The last century of life sciences research focused on reductionist approaches that aim at 
understanding complex biological systems by studying their constituent parts (genes, proteins …) 
in isolation. The availability of high-throughput data across different levels (genetic, transcriptional, 
proteomic, epigenetic,…) has enabled researchers to pursue system-level integrative approaches, 
leading to the emergence of the field of ‘systems biology’ (Aderem, 2005).  
The high-throughput data provided by these large-scale tumor characterization projects 
constitute a valuable resource for cancer research but share the limitations typical of observational 
studies of complex systems, where in many cases it is impossible to differentiate between causality 
and correlation. These problems become even more acute in the context of cancer research due 
to several reasons. First, cancer researchers frequently face problems where the number of 
measurements vastly exceeds the number of samples, such as the analysis of genome-wide data 
(~20k genes) for tens or hundreds of tumors. Second, omics data usually have a strong correlation 
structure. For example, at the transcriptomic level, there is high coordination of the activity of genes 
and biological processes, while at the genetic level, some alterations such as SCNAs disrupt 
several genes simultaneously, causing proximal genes to have almost identical alteration profiles.  
We could try to establish causality of events within the correlation structure of the data if the 
genome was functionally annotated, but it is estimated that >40% of the genome has not yet been 
assigned a single function (Grimm, 2004) and moreover many genes are pleotropic. We know a lot 
about a few genes and practically nothing about most, and it is likely that many of the key players 
in oncogenesis will turn out to be among those uncharacterized genes (Ashworth and Bernards, 
2010).  
The RNAi revolution 
Considering the shortcomings of the analysis of primary tumor cohorts described above, a 




the cancer genome. The scientific method proposes to use controlled experiments to determine 
causality of events occurring in complex systems. By performing functional assays, we can 
interrogate genes for their function, therefore providing evidence that can help to disentangle the 
correlation of alterations and biological processes observed in primary tumors. 
Functional work in cancer research is usually performed using immortalized cell lines. An 
immortalized cell line is a population of cells from a multicellular organism which has been 
manipulated to achieve unlimited growth in vitro (Masters, 2000). The first cancer cell line, HeLa, 
was developed in 1951 by George Gey using a cancer sample that came from the cervix of 
Henrietta Lacks, a 30-year-old mother of five living on New Pittsburgh Avenue in Baltimore 
(Masters, 2002). It is important to note that although cancer cell lines provide better models of 
tumors than model organisms like yeast (which does not have counterparts to key processes in 
cancer such as apoptosis or senescence), they are not fully representative of the biology of primary 
tumors. For example, they lack the tissue structure and microenvironment, which are key to cellular 
behavior (Grimm, 2004).  
Despite their limitations, cancer cell lines have been the workhorses of cancer research for the 
last 60 years (Masters, 2002). Until recently, silencing a gene was a tedious and laborious process. 
In 1998 Fire, Mello and colleagues discovered a mechanism by which genes can be silenced in a 
sequence-specific manner in the nematode worm Caenorhabditis Elegans ( (Fire et al., 1998). This 
mechanism, known as RNA interference (RNAi) (Figure I-2), is used by cells to defend against 
viruses and other parasitic nucleotide sequences. The discovery in 2001 that RNAi can also be 
used to silence genes in mammalian cells revolutionized the field (Elbashir et al., 2001). RNAi can 
be used to silence almost any gene with unprecedented easiness and quickly became one of the 
most frequently used tools for functional analysis of mammalian genomes. The discovery of RNAi, 
recognized with a Nobel Prize in Medicine to Fire and Mello, is a fine example of the importance of 







Gene silencing by RNAi can be performed in mammalian cell lines by two different methods: 
small interfering RNA (siRNA) and short hairpin RNA (shRNA). siRNAs are easily synthesized in 
vitro and when transfected into a cell line cause a transient knockdown of the target gene. shRNAs 
are vector-based and are usually delivered through viral infection, producing long-term silencing of 
target genes (Rao et al., 2009).   
 
Figure I-2 – shRNA mechanism 
This cartoon represents the ideal process of RNAi silencing for a lentiviral shRNA hairpin. The virus 
containing the hairpin infects the cell and integrates the shRNA sequence into the DNA. This sequence is 
used as a template to produce shRNA hairpins, being first transcribed by the cellular transcription 
machinery and then processed by the Drosha complex and finally exported to the cytoplasm. Once the 
hairpin is outside the nucleus, it is processed by Dicer and loaded into the RISC complex, where it is used 




Despite how straightforward and effortless gene silencing became thanks to the development 
of RNAi assays, these experiments could only be performed one gene at a time. The development 
of pooled shRNA screens finally combined the power of RNAi with high–throughput screening 
techniques, opening the field of genome-wide functional screens in human cells (Grimm, 2004). 
These assays facilitate the systematic assessment of essentiality of genes across cancer genomes 
in one experiment, promising the fast discovery of novel drug targets.   
Recently, several large-scale genome-wide shRNA datasets across several cancer cell lines 
have become available (Cheung et al., 2011), (Marcotte et al., 2012). Although genome-wide 
shRNA screens potentially provide a powerful tool for detecting tumor vulnerabilities, in practice 
they have failed to fulfill the expectations. The analysis of the data obtained from these 
experimental tools pose several challenges that are difficult to tackle, including the small number 
of genetic backgrounds assayed, the large noise to signal ratio (due to the stochastic nature of the 
experiment) and the discrepancies between clinical tumors with in-vitro model systems (Kaelin, 
2012).  
In addition, the lack a good understanding of shRNA hairpin design results in a large percentage 
of hairpins having extremely low or even void efficiency. For that reason there is a large number of 
false negative results in these assays, which prevents us from using negative results to draw 
biological conclusions (Willingham et al., 2004). In this type of assay, absence of evidence is no 
evidence for absence. 
The key limitation of the RNAi technology is, however, not related to the large number of false 
negative predictions but to the large percentage of false positive results. shRNA hairpins are 
designed to silence a specific target gene, but in practice many hairpins simultaneously silence 
numerous unintended genes through miRNA-like mechanisms, resulting in a large percentage of 
false positive results. These off-target effects are ubiquitous and can be caused by as few as 6–7 
nucleotides of sequence complementarity, making the computational prediction of likely off-target 
effects unfeasible (Sigoillot et al., 2012).   
Theoretically, the introduction of redundancy through the use of several different shRNA 




efficient off-target-free hairpins is small and the analysis of these datasets still proves extremely 
challenging.  
Integrative approaches 
The TCGA project finished collecting samples in December, 2014 and ICGC has recently 
stopped accepting proposals (Nature, 2014). Although these projects have provided some valuable 
insights into the disease, many - if not most - vital questions still remain unanswered. Despite the 
large availability of high-throughput data, we lack the computational tools that would enable us to 
harness the knowledge that these data encode. The field of computational analysis of high 
throughput cancer data is still in its infancy and statistical methods are frustratingly underdeveloped 
(Weinberg, 2014). More computational efforts should aim to develop original methods to analyze 
these data in completely novel ways instead of focusing on providing incremental performance 
improvements for established methods.  
A promising avenue of research is the development of methods that integrate heterogeneous 
data types (Kristensen et al., 2014). By merging the complementary views of the disease provided 
each data type we hope to achieve a better understanding of the complex biological system. 
However, developing sound integrative methods that produce biologically interesting results for 
data with such disparate semantics and distributions is a difficult endeavor. Data integration in 
computational biology of cancer poses both conceptual and computational challenges.  
Conceptually, it is difficult to define integrative models that appropriately capture and connect 
the semantics of the different data types. There are several generic methods to perform data 
integration without modeling the semantics of the data, such as those to combine p-value obtained 
from the analysis of each data source in isolation (Zwet and Oosterhoff, 1967). Those methods are, 
however, unlikely to harness the full potential of the data.   
Methodological, many crucial biological problems are of a semi-supervised or even 
unsupervised nature, as there is an inherent lack of labeled samples that would help answer these 
questions. Given the lack of labeled data, even the definition of the mathematical function that 




paradigms that are capable of succeeding using limited or no amounts of labeled information such 
as transfer learning (Ratsch, 2011) and co-training (Blum and Mitchell, 1998).  
Given the largely orthogonal strengths and weaknesses of descriptive analysis of genetic and 
genomic observational data from cancer genomes and in-vitro genome-wide functional screening, 
I hypothesized that integrating the two data types into unified models would significantly increase 
the power of the biological analysis. In this thesis, I will tackle two key problems in cancer biology 
using integrative approaches that combine functional and genomics data. In the first part of this 
thesis I will focus on the problem of identifying driver genes. In the latter part I will approach the 
challenge of identifying tumor specific vulnerabilities. In the next two sections I will elaborate the 
description of these two problems. 
Identifying driver alterations  
In the first part of this thesis, I will tackle the problem of identifying driver genes, which has been 
a central challenge in cancer research defined as a grand challenge by the National Cancer 
Institute (NCI). The identification of novel drivers can both accelerate our understanding of 
biological processes known to be involved in cancer and reveal processes previously not known to 
play a role in the disease. The efforts to identify drivers in  large-scale cohorts during the last few 
years have revealed some surprising new categories of drivers, such as regulators of chromatin 
biology (CREBP, EP300, MLL2) , metabolism (IDH1, IDH2) and splicing (SF3B1, U2AF1) 
(Garraway and Lander, 2013). For example, the identification of IDH1 as a driver in a major subset 
of primary human brain cancers has revolutionized the field of tumor metabolism (Dang et al., 
2009). Genes such as IDH1 and SF3B1 would not have been identified without an unbiased, 
genome-wide approach.  
Tumor cells can spread from the original site to other organs, establishing secondary tumors in 
a process called metastasis. Metastasis is responsible for 90% of cancer mortality, because once 
a tumor metastasizes there is no effective treatment (Chaffer and Weinberg, 2011). Unfortunately, 




understood hallmarks of cancer. The identification of drivers involved in metastasis could prove 
vital for estimating patient survival prognosis, and for developing new therapeutic options.    
Ultimately, learning the role of driver genes transcends the context of the disease and brings us 
closer to understanding fundamental processes in cellular biology. As Nobel laureate David 
Baltimore said: “In biology often the only way to know what’s right with something is to see what 
happens when it goes wrong”. By studying the disruption produced by cancer we are beginning to 
comprehend key biological processes such as cell differentiation, apoptosis and cell proliferation.  
The discovery of novel drivers, specifically the identification of oncogenes, potentially has direct 
actionable clinical utility. Cancer cells often become dependent on the aberrant function of their 
activated oncogenes, and blocking these aberrant signals compromises their viability—a 
phenomenon termed “oncogene addiction” (Weinstein and Joe, 2008). Targeting drive genes that 
display oncogene addiction establishes a therapeutic window to selectively kill cancer cells without 
damaging normal cells. Although the underlying mechanism of how tumors remain dependent on 
oncogenic alterations is not fully understood, this phenomenon is the basis of some of the most 
effective therapies, such as those targeting ERBB2 amplification, BRAF V600E mutation or BCR-
ABL fusion (Ashworth et al., 2011). The development of such therapies is allowing us to shift from 
cytotoxic drugs to highly selective, targeted therapeutic agents. 
Unfortunately, the successful initial response to treatment with selective drugs is, in most cases, 
transient and is almost inevitably followed by the development of drug resistance and relapse 
(Pisco et al., 2013) . For example, the use of BRAF inhibitors in BRAF mutant melanomas leads to 
spectacular responses, but practically all patients relapse within a year (Flaherty et al., 2010). 
In order to minimize the probability of developing resistance in a heterogeneous population of 
cells, the best course of action is to apply combinatorial therapies (MacLean et al., 2010). If the 
probability of encountering a subpopulation of the tumor that is resistant to treatment is p, the 
probability of the tumor challenging a combinatorial therapy of n different independent drugs is pn. 
This concept has been successfully applied to HIV treatment by doctors using combinations of 




There is, however, a major obstacle to the application of combinatorial therapies in cancer: the 
striking lack of druggable targets. Indeed, the majority of drug approvals target a very small set of 
proteins (Collins and Workman, 2006). The identification of novel druggable targets would pave the 
way to combinatorial therapies for cancer patients and, with it, to the longed dream of personalized 
treatment with low chances of relapse (Bernards, 2012) (Garraway and Jänne, 2012).  
Analyzing datasets of genetic alterations in primary cohorts is not a simple endeavor. Tumors 
harbor a great number of alterations and it is difficult to distinguish between driver and passenger 
aberrations.  Several approaches have been designed to identify oncogenic drivers using data from 
large cohorts of cancer patients. Typical approaches detect genes harboring alterations at a higher 
frequency than the background mutation rate, which is what we would expect for driver genes as 
they are preferentially selected due to the advantage they provide to tumors. This strategy has 
been used to analyze both SCNAs (Mermel et al., 2011) and sequence mutations  (Banerji et al., 
2012). The assumption of higher frequency of driver mutations is obvious for tumor initiating 
mutations, as those are expected to be present in tumors by definition. There are, however, many 
 
Figure I-3 – Copy number profile for chromosome 11 in breast tumors 
IGV plot of the copy number of chromosome 11 of 785 samples of the TCGA Breast Cancer cohort. The 
horizontal axis represents chromosomal positions while the vertical axis displays different samples. Copy 
number amplifications are displayed in red while copy number deletions are represented in blue. Wild type 





driver mutations that increase tumor fitness without having the capability to promote transformation. 
The process of clonal evolution of tumors follows the laws of Darwinian evolution and while most 
random alterations will be lost, the persistence of these driver alterations will be also favored due 
to the fitness advantage they provide.  
Although the study of sequence mutations has led to a few novel drug targets such as IDH1, 
the majority of sequence mutated genes display low population frequencies, with only a handful of 
genes displaying alteration in more than 5% of patients (Stephens et al., 2012a). This long tail of 
point mutations is common across cancers in different tissues (Garraway and Lander, 2013). Even 
if larger cohorts facilitate the identification of driver alterations, the low frequency of mutations 
Figure I-4 – Frequency of mutation in breast cancer 
Frequency of alteration in 507 samples of the TCGA breast cancer dataset of (A) genes with recurrent 
point mutations and (B) regions of recurrent copy number alteration.Significant genes and regions were 
obtained from the DBroad Genome Data Analysis Center Firehose Analytics Platform 
(https://confluence.broadinstitute.org/display/GDAC/Home), selecting the TCGA pipeline algorithms 




raises questions about the feasibility of clinical applications. In addition, studies of new cohorts 
across tumor types are “rediscovering” the same driver genes again and again, suggesting that 
most frequently mutated drivers have already been discovered. Additional novel drivers will likely 
be discovered, but those drivers will probably emerge in uncommon tumor types that remain 
understudied (Vogelstein et al., 2013). 
On the other hand, SCNAs tend to be prevalent in many cancers. An average tumor harbors 
amplifications in 17% of the genome and deletions in 16%, compared to 0.35% and 0.1% in healthy 
samples. (Beroukhim et al., 2010a). For example, in Breast Cancer only 6 significantly altered 
genes harbor sequence mutations in more than 5% of the patients, while 87 SCNA regions are 
recurrently altered above that frequency (Figure I-4). 
While analysis of SCNA profiles has revealed cancer-associated genes in several cases, such 
as MTS1 (Kamb et al., 1994), N-MYC (Shiloh et al., 1986) and MDM2 (Oliner et al., 1992), the lack 
of specificity of these lesions makes it difficult to identify the driver genes that contribute to 
tumorigenesis within altered regions. One recent effort to analyze the copy number landscape 
 
Figure I-5 – Regions of recurrent copy number alteration 
The same chromosome in different tumors, red represents aberrant regions. The highlighted region is 
recurrently altered in multiple tumors and therefore likely to contain a driver gene. However, the region 




across multiple tumor types reported that over 70% (102) of the 140 regions of recurrent alteration 
did not contain a known oncogene or tumor suppressor (Zack et al., 2013). While point mutations 
directly indicate the genes they affect by virtue of their precise location, SCNAs may simultaneously 
affect up thousands of genes.  
The predominant approach to this problem is to define a minimal region of maximal alteration—
called the peak region—and to prioritize genes within this region (Figure I-5).  While useful (Bass, 
Watanabe et al. 2009, Beroukhim, Mermel et al. 2010), this approach is insufficient because the 
minimal region is often still very large and may span an intractable number of genes. Additionally, 
in many cases the targeted oncogene does not reside within this minimal region. SCNA studies 
identify hundreds of candidates across the genome and systematic validation of candidates 
indicated by SCNA has not been possible. As a result, substantial work remains in elucidating the 
biological consequences of recurrent SCNA events.  
The problem of identifying driver SCNA-altered genes is therefore twofold, requiring 1) the 
identification of significantly altered regions and 2) the determination of drivers within these regions, 
which are often large and contain numerous “passenger” genes that likely do not contribute to 
oncogenesis. Pinpointing the driver or drivers within regions of recurrent copy-number alterations 
remains a crucial bottleneck in cancer genomics (Albertson et al., 2003). 
Chapter II tackles the problem of identifying recurrent regions of copy number alterations by 
developing ISAR, a novel approach that models the distribution of SCNA locally.  
In Chapter III I address the problem of identifying driver genes within SCNA regions. I use the 
concept of oncogene addiction to connect functional screens to this problem. I further develop an 
unsupervised Bayesian hierarchical method that integrates this and other signals with SCNA data 
from primary tumors to provide a probabilistic score to pinpoint drivers. I apply this method to 
analyze the landscape of amplifications in breast cancer in Chapter IV. In addition, RSF-1, one of 
the novel validated candidates from our analysis in Chapter IV, is further characterized as a novel 
driver of metastasis in Chapter V.  
Chapter VI describes the computational analysis of the landscape of deletions in breast cancer, 




the results of a functional screen for anoikis. As a result of this analysis, I discovered the novel 
tumor suppressor BIN3, which is characterized in Chapter VII. 
Non-oncogenic addictions 
Current cancer therapies based on oncogene addiction have serious limitations: not all 
oncogenes exhibit oncogene addiction and only a minority of the oncogenes that do are currently 
druggable (Workman and Al-Lazikani, 2013). Relying solely on therapies that target oncogenes 
leaves patients with alterations in tumor suppressors and in non-addictive or non-druggable 
oncogenes without any option beyond traditional chemotherapy. Therefore, in order to successfully 
treat this disease, oncogene addiction must not be the only clinical avenue. Fortunately, directly 
targeting oncogenes is only the tip of the iceberg of cancer vulnerabilities. I dedicate the second 
half of the thesis to methods for identifying lethalities beyond oncogene addiction. 
The search for druggable targets can be extended from oncogenes to signaling partners, some 
of whom may also display essentiality under activation of the oncogene, such as BRD4 in tumors 
with MYC amplification (Toyoshima et al., 2012). Interestingly, some of these genes may prove to 
be more essential to a significantly larger array of tumors than any related altered genes. These 
genes become ‘tumor bottlenecks’, like the transcription factors Stat3 and C/EBPb, which are active 
in 60% of Glioblastoma Multiforme (Carro et al., 2010).  
The group of direct signaling partners can be extended to define a set of genes involved in 
responding to each external or internal event, a concept known as biological pathway (Ramanan 
et al., 2012).   Although it has been observed in many tumor types that genetic alterations are 
sparsely distributed across the genome, the function of targeted genes converge in a few key 
oncogene pathways (The Cancer Genome Atlas Research et al., 2013). Identifying essential 
pathways in cancer, biomarkers associated with their oncogenic activity and essential druggable 
genes within those pathways is therefore one of the most promising avenues of research (Collisson 
et al., 2012; Jones, 2008; Majewski and Bernards, 2011).      
Tumor cells may also display enhanced sensitivity to particular agents without directly targeting 




therefore a cost that cancer pays for transformation. For example, the hallmarks of genome 
instability and high proliferation cause tumor cells to be more sensitive to DNA damage agents, 
which is currently exploited in chemotherapy. Some of the most common cancer stress phenotypes 
are DNA damage/replication stress, proteotoxic stress, mitotic stress, metabolic stress, and 
oxidative stress (Luo et al., 2009).  
In addition to treatment with external agents, these vulnerabilities can potentially be exploited 
by targeting genes involved in the pathways that orchestrate the stress response. For example, 
many cancers that have sensitivity to DNA damage due to inactivation of the tumor suppressors 
BRCA1/2 can be effectively treated with PARP-inhibitors. These drugs target PARP1, a gene 
involved in an alternative mechanism to BRCA1/2 for repairing double strand breaks (Ashworth, 
2008). Identifying and targeting these vulnerabilities is a promising avenue for therapeutic 
intervention. 
Although genome-wide shRNA screens pose promising technology to identify lethalities in a 
systematic fashion, computational methods that overcome the challenges posed by this technology 
are underdeveloped. There are two main approaches to harness information from shRNA screens 
and both of them seem to have serious shortcomings.    
The first and most commonly used computational approach to identify vulnerabilities in genome-
wide shRNA screens is to assess the association of lethality with a binary qualifier of the cell lines, 
such as classification as a specific tumor type or presence of a specific genetic alteration (Cheung 
et al., 2011). This approach requires the characterization of tumors both in terms of subtypes and 
driver alterations and, unfortunately, those are still great challenges in the field. Also, the search of 
lethalities associated with combinations of subtypes and alterations poses serious concerns 
regarding the statistical significance of the results considering the large number of tests that would 
be performed.  
The other alternative approach proposed so far aims at creating a shRNA profile for those genes 
that display several correlated shRNA (Shao et al., 2013). Although the presence of two or more 




this type approach is too restrictive as for most genes we are not expecting to find more than a 
single on-target efficient hairpin.  
Chapter VIII describes the dataset used for this analysis and gives an overview of the analytic 
pipeline. Chapter VIII describes the method develop to model and score hairpin dropout. 0 
describes a novel method that identifies signatures of lethality in shRNA assays through the 
integration of genetic and genomic data. Chapter XI analyzes the results of applying this method 
to the breast cancer dataset described in Chapter VIII. Finally, Chapter XII provides the conclusions 




Chapter II – Detection of regions of 
copy number alterations 
Introduction 
Technological advances such as array comparative genomic hybridization (aCGH) and single 
nucleotide polymorphism (SNP) arrays have enabled the detection of chromosomal regions of 
amplifications and deletions genome-wide and at high resolution, interrogating up to a million 
markers around the genome for DNA dosage (Engle et al., 2006; Koboldt et al., 2012; Michels et 
al., 2007; Rusk, 2008; Xi et al., 2011). Datasets measuring such aberrations in patient tumors are 
accumulating at a staggering rate for multiple types of cancer (Beroukhim et al., 2010b; Northcott 
et al., 2009; Pollack et al., 2002; Weir et al., 2007a). 
However, analyzing such datasets is not a simple endeavor. Tumors harbor a great number of 
copy number alterations, some of which may simultaneously affect up thousands of genes, and it 
is difficult to distinguish between driver aberrations (functional changes vital for cancer progression) 
and passenger aberrations (random and with no selective advantage).  Thus, the distinction 
between driver and passenger mutations has become one of the key challenges in cancer 
genomics.  
The key property used to identify driver alterations is the following: if a mutation provides a 
fitness advantage in a given tumor type, its persistence will be favored, and therefore it is likely to 
be found at a higher frequency that would be expected by chance. The identification of regions that 
are recurrently altered across many patients is the first step in the identification of driver genes. 
Overview of computational approaches  
There is an increasingly large number of methods for the identification of regions of copy number 
alterations in cancer, including STAC (Diskin et al., 2006) , pREC (Rueda and Diaz-Uriarte, 2009), 
GISTIC (Beroukhim et al., 2007), MSA (Guttman et al., 2007) , RAE (Taylor et al., 2008), GEAR 
(Kim et al., 2008), KC-MART (de Ronde et al., 2010) , Rapaport’s method (Rapaport and Leslie, 




2011), GISTIC2 (Mermel et al., 2011),STAC (Diskin et al., 2006), SAIC (Yuan et al., 2012a) , 
TAGCNA (Yuan et al., 2012b), ADMIRE (van Dyk et al., 2013), GAIA (Morganella et al., 2011) and 
MUTConFocal (Trifonov et al., 2013). Given the fertility of the field, a comprehensive review of the 
characteristics and performance of all methods is out of the scope of this thesis. A performance 
assessment of some of these methods in synthetic and experimental data has recently been 
published (Yuan et al., 2012c). The authors observed very similar performance in experimental 
datasets and conclude that the most critical challenge in the field is not the identification of SCNA 
regions, for which several methods obtain reasonable performance, but the identification of driver 
genes within those regions. 
Input data 
Marker reads obtained from aCGH and SNP arrays suffer from the high noise characteristic of 
these technologies. Fortunately, this problem can be ameliorated by smoothing the signal across 
contiguous markers. Several algorithms for performing such segmentation are available, such as 
GLAD (Hupe et al., 2004) and CBS (Olshen et al., 2004). For a comprehensive review of algorithms 
for this task see (Dellinger et al., 2010). Some algorithms take segmented data as input while others 
prefer to use the raw data so that they can take into account the uncertainty about the probe 
measure in the analysis of regions of alteration.  
Both aCGH and SNP technologies measure units of genomes (DNA mass). One would naively 
expect to easily associate these calls to discrete numbers: 2 for non-aberrant regions, 1 and 0 for 
losses of 1 and both alleles respectively and 3,4,.. for copy number amplifications. However, the 
actual measure is continuous due to several biological and technical factors that I will briefly 
describe.  
First, there is the issue of cellularity. Tumor are not homogeneous masses but organ-like 
structures that contain different cell types that support tumor growth (Hanahan and Coussens, 
2012). Some of those cell do not harbor any genetic alterations as they are not the result of the 
clonal expansion of the malignancy but genetically normal cells recruited by the tumor. These 




Second, we need to consider the multiclonality of tumors. Even if recruited cells where 
segregated - which is possible by a large extend by costly and rarely used methods such as laser-
capture microdissection (Ma et al., 2009) – the clonal evolution of tumors can produce significant 
intra-tumor heterogeneity of genetic alterations (Navin et al., 2011; Pleasance et al., 2010).  
Third, the DNA mass has to be normalized to the DNA content of each cell, known as ploidity. 
This is usually performed by assuming that cells have on average two copies of each chromosome. 
However, this assumption does not necessarily hold in the case of tumor cells,  as polyploidity is a 
frequent phenomenon in cancer genomes (Storchova and Pellman, 2004).  
Although several algorithms have been proposed to estimate cellularity and ploidity (Carter et 
al., 2012; Greenman et al., 2010; Li et al., 2011; Van Loo et al., 2010; Yau et al., 2010; Yu et al., 
2011), their predictions differ strongly for many samples and none of them has been consolidated 
as a standard. Most research is performed without considering cellularity and ploidity and only 
samples with extremely low cellularity are discarded. The input for those algorithms is usually a 
log2 ratio of the measure to the median ploidity of the sample.  
Some algorithms perform a significantly rougher simplification and discretizing the data in three 
possible states: copy number neutral, amplified or deleted. Such simplification removes vital 
information from the data as it, for example, disregards focal (small) amplifications within larger 
(broad) ones. The information in such focal events is key to narrow down SCNA region and 
therefore I strongly advocate against such simplifications.  
Modeling approaches 
Several modeling approaches have been used for the problem of identifying regions of SCNA. 
Most methods follow a permutation test strategy to compute the p-value for a statistic of interest 
(Beroukhim et al., 2007; de Ronde et al., 2010; Diskin et al., 2006; Guttman et al., 2007; Morganella 
et al., 2011; Walter et al., 2011; Yuan et al., 2012a; Yuan et al., 2012b). These algorithms usually 
perform the permutation test across markers while the differences among methods reside both on 
the statistic they use and the null model they employ to compute the statistical significance of the 




across samples as a metric that takes into consideration both the amplitude and the frequency of 
each alteration while CMDS (Zhang et al., 2010) scores the correlation of each marker with its 
neighbors. GISTIC calculates a semi-exact null distribution of permuting markers within samples 
across the whole genome while STAC (Diskin et al., 2006) and MSA (Guttman et al., 2007) perform 
the permutations of markers within each chromosome. DiNAMIC (Walter et al., 2011), on the other 
hand, performs a cyclic permutation strategy.  
However, permutation testing is not the only possible approach. I will further describe three 
alterative options in the following paragraphs. These are indeed not the only options and some 
authors have considered different models.  
GISTIC2 (Mermel et al., 2011) instead of working with markers, decomposes the segmented 
data into the most likely set of genetic events, disregarding very large events and using the focal 
events to compute the distribution of alterations used to evaluate the significance of the SCNA 
profile for each marker.  
pREC (Rueda and Diaz-Uriarte, 2009) uses first a Hidden Markov Model (HMM) on the raw data 
to segment the profiles and define the number of states of alteration (Rueda and Díaz-Uriarte, 
2007). Then the method uses the resulting HMMs to identify recurrent regions above a selected 
probability threshold.   
KC-MART (de Ronde et al., 2010) and Rapaport’s method (Rapaport and Leslie, 2010) use 
unsegmented data directly, avoiding the loss of information produced during segmentation. The 
former uses a kernel function method while the latter employs regularized regression.  
From SCNA regions to driver genes 
Since the final objective of most authors is to identify driver regulatory elements, the methods 
usually try to further use copy number to refine large regions, which may contain hundreds of genes. 
The objective is to reach minimal regions of maximal alterations, known as peaks, which would 
hopefully contain a very small number of regulatory elements that could be assayed. Unfortunately, 
despite the variety of approaches employed, no method has been successful at systematically 




In many cases, these methods fail because SCNA data does not contain enough information to 
succeed at this task. Further information should be employed to tackle this problem. For example, 
MutConFocal (Trifonov et al., 2013) combines information of copy number alterations and point 
mutations into a single score. Although conceptually the approach is interesting, in practice very 
few genes harbor point mutations and although the method can help pinpoint drivers in some 
regions, it is likely to miss many driver genes.  
CONEXIC (Akavia et al., 2011) integrates copy number and gene expression to identify drivers 
that display a footprint as transcriptional regulators, associating them with a module of genes whose 
expression corresponds with that of the predicted driver.  
RNAi screens can also be used to identify those cancer drivers that display oncogene addiction 
effect, a phenomenon in which active oncogenes become vulnerabilities of the tumor (Weinstein 
and Joe, 2008).  By simply intersecting regions of SCNA with genes that display lethality in ovarian 
tumors,  PAX8 was identified as key driver of this disease (Cheung et al., 2011). 
Although sequence mutations, gene expression and RNAi screens have been independently 
used to identify drivers, no method has systematically integrated all of them into a single score that 
would not only capture the strongest signals provided by each individual data source, but would 
also use more subtle signals for each data source to achieve more confidence about less obvious 
candidates.  
ISAR 
Most algorithms for SCNA analysis aim at identifying regions with high confidence based on a 
distribution computed across a chromosome or even the whole genome. By visual inspection of 
SCNA data collected by the TCGA project from 785 primary breast carcinomas, I noted multiple 1-
100 MB regions that appeared recurrently amplified relative to nearby regions of the chromosome 
that were not detected by the state of the art algorithm GISTIC 2.0 (TCGA, 2012). For example, 
although a region of chromosome 18 containing BCL2 is not significantly amplified based on its 
absolute copy-level, its copy-number is nevertheless significantly higher than the adjacent 




My strategy to identify driver genes in SCNA regions follows an integrative approach performed 
two steps. In the first step, I use copy number data to identify regions of recurrent alteration. In the 
second step, I integrate other data sources in order to pinpoint driver genes within those regions.  
 
 
In order to obtain best results with this approach, it would be desirable to employ in the first step 
a less stringent algorithm that detects a larger number of SCNA regions, even if there is less 
confidence in some of those. The reason is two-fold. First, although SCNA data by itself might not 
provide enough evidence for each region, the combination of SCNA with other sources can provide 
high confidence in the identification of driver genes. Second, by having more candidate genes helps 
the learning process for the unsupervised algorithm used in the second step. 
Therefore, I developed ISAR, an algorithm that also detects stretches of relative copy-number 
elevation within local contexts such as these, thereby expanding the list of candidate driver 
alterations.  Most SCNA detection algorithms (e.g. GISTIC2) compute a null distribution across the 
entire genome to estimate the significance of the alterations harbored by each marker. However, 
the alteration rate can strongly differ across different genomic regions, due to features such as DNA 
secondary structure and DNA hypomethylation (De and Michor 2011).  
ISAR accounts for local differences in SCNA rate due to these and other unknown forces by 
scoring statistical significance with respect to a null distribution defined by a sliding window along 
the genome.  By computing the significance locally, the algorithm is capable of identifying subtle 
events, such as a focal amplification within largely deleted regions, which would be missed if the 
background distribution for the whole genome is employed. 
ISAR is based on the G-score metric, a significance measure of the aberration for each marker, 
which was originally defined in GISTIC (Beroukhim et al., 2007). Specifically, the G-score for a 
marker m is the summation of the copy number across samples that surpass an aberration 
threshold θ. Therefore, given the copy number for N samples, the G-score for a marker m in the 
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Figure II-1 – 18q21 copy number region in Breast Cancer.  
Heatmap of the copy number profile of the TCGA Breast cancer cohort (785 samples) for the 18q arm and a 




State of the art algorithms like GISTIC2 compute a null distribution across the entire genome to 
estimate the significance of the alterations harbored by each marker. However, the alteration rate 
can strongly differ cross genomic regions, due to features such as DNA secondary structure and 
DNA hypomethylation (De and Michor, 2011). ISAR accounts for local differences in the alteration 
rate due to these and other unknown forces by scoring the significance of each alteration locally.  
ISAR uses a local sliding window of constant size that moves along the chromosome, 
calculating the null distribution for each window. The use of a window allows the algorithm to 
estimate the local distribution of alterations and assign an accurate q-value to each marker based 
on its local distribution. Once the distribution has been computed in all windows within a 
chromosome, each genomic marker is associated with several overlapping windows. The algorithm 
takes a conservative approach by selecting the least significant q-value among the values 
computed for all overlapping windows containing the marker.  
By computing the significance locally, the algorithm is capable of identifying subtle events, such 
as a significant focal amplification within largely deleted regions, which would be missed if the 
background distribution for the whole genome is employed. For example, the pattern of alterations 
displayed by BCL2 in breast cancer becomes significant when you consider the background 
alteration levels of its region (Figure II-1).  
The algorithm is sensitive to the selection of the window size. Different window sizes are 
adequate for capturing events of different granularity: large windows tend to detect regions 
harboring large aberrations while small windows perform better in regions with small focal 
alterations.  Therefore, ISAR is executed with several window sizes and the final score for each 
marker, denoted S-score, is the most significant q-value among the different window sizes. 
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Where W is the set of window sizes used and qvaluei(m), denotes the qvalue of marker m, using 




Once the S-score has been computed for each marker, it is straightforward to define significantly 
altered regions. Each marker scoring above the user-defined peak threshold TP is considered part 
of a region of alteration. These regions are extended to consecutive markers with score above a 
user-defined region threshold TR. Typical values for TP are selected to match a q-value for the local 
window of 0.01-0.001 (TP=2=-log10(0.01) - TP=3=-log10(0.001)), while TR is usually selected to 
match a slightly higher q-value, in the range of 0.1-0.01 (TR=1=-log10(0.1) – TR=2=-log10(0.01)). 
ISAR-DEL 
I further extended ISAR to better identify driver deletions. ISAR-DEL exploits a key difference 
between gain and losses to identify drivers in deleted regions. Amplifications are generally 
expected to have a functional effect only if they span the whole sequence of a gene. However, this 
is not the case for deletions:  the loss of a fraction of the sequence of a gene is likely to cause its 
inactivation. Therefore, to maximize the selectivity in regions of loss, we should take into account 
the contribution of all deletions harbored by a gene, rather than focusing on each locus 
independently. For example, deletions encompassing portions of BRCA1 and PTEN have 
previously been observed as mechanisms to cause the inactivation of these tumor suppressors in 
different clinical tumors (Abdel-Rahman et al., 2006; van den Ouweland et al., 2009). Indeed, even 
the loss of a single base pair can render a key transcription factor like TP53 disabled(Greenblatt et 
al., 1994).       
Given that inactivating aberrations in tumor suppressing driver genes are selected for in tumors 
and that those do not need to span the whole gene, such genes may display a pattern of non-
overlapping deletions.  For example, Figure II-2 illustrates the recurrently deleted 10q23 region in 
the TCGA breast cancer dataset. The bona fide tumor suppressor PTEN stands out as the 
epicenter of this region due to a striking patter of losses of different parts of the gene: start, end, 
intragenic regions or the whole gene. An approach that considers the most altered marker would 
underestimate the significance of the aberrations harbored by this gene as many of these do not 




accumulation at a specific locus, could aid distinguishing between driver and passenger genes in 
a deleted region. 
 
 
The input data for the algorithm consists of the copy number reads for genetic markers across 
the genome for a cohort of tumors. Each gene spans a set of genetic markers and we assume that 
the alteration of any of those markers would cause the inactivation of the gene in the same way 
that the full deletion of the gene would. Thus, the expected functional effect of the deletions 
harbored by a gene in a sample is determined by the strongest loss across all markers. For a gene 
g, we define the gene deletion G-score as: 
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Figure II-2 – 10q23 region in Breast Cancer.  





That is, the G-score considers for each sample the most significant alteration across the M 
consecutive markers corresponding to the gene location.  
However, in order to calculate the significance of the alterations harbored by a gene one should 
take in consideration not only the strength of the alterations but also the length of the gene. Larger 
genes are more likely to be hit by passenger alterations, resulting in larger gene deletion G-scores. 
I therefore developed ISAR-DEL, a novel method that estimates the significance of the recurrence 
of all deletions accumulated by a gene. 
ISAR calculates de null distribution of G-scores by computing the score for all possible 
permutations of markers belonging to the local window within each sample. Similarly to GISTIC, 
ISAR computes this estimate by performing the convolution of the histogram of values in each 
sample. Note that for a given gene size, the null distribution for the novel gene deletion G-score 
can be computed with the same permutation scheme used in the case of a single marker by simply 
substituting the copy number of each marker m with the minimum copy number across M 
consecutive markers starting in m. Unfortunately, estimating this null distribution for all gene sizes 
is unfeasible due to the high computational cost of this operation.  
ISAR-del avoids the computational burden of calculating the background distribution for all gene 
sizes by disregarding those that can be deemed unnecessary beforehand. I will show how the 
design of the ISAR method - specifically the fact that ISAR computes the background distribution 
in a local window - facilitates the optimization of the computational cost of the algorithm.  
For a given local window, ISAR only needs to consider the gene sizes corresponding to the 
genes located in the window. While this step already shrinks the number of genes sizes 
dramatically, further filtering is needed to reduce the computational cost of the algorithm. 
First, I discard most genes from considerations by using the background distribution as an upper 
bound on the significance of the recurrence of alterations. A simple way to produce such an upper 
bound is to compute the significance of the gene deletion G-score using a background distribution 
developed for genes of smaller marker size. Specifically, in each window ISAR-del calculates the 
background distribution for genes that span a single marker. Most genes will not be deemed 




computational cost of calculating the background distribution for their exact gene size. For example, 
in the TCGA breast cancer data, ~85% of the genes were discarded by this step.   
Second, I make use of the fact that ISAR uses a sliding window that selects for each gene the 
least significant score across overlapping windows. If the alterations harbored by a gene were 
deemed statistically insignificant in a window it is unnecessary to further consider this gene in any 
subsequent window. 
Third, I further improve the computational time by additional approximation. Specifically, we can 
bin similarly sized genes and can consider the same background distribution for this group of 
genes. Taking into account that gene sizes follow an exponential distribution, this can significantly 
reduce the number of required calculations. The user-defined parameter delbin defines a bin size 
for a binning scheme. A conservative approach is employed in this approximation, using the largest 






Chapter III – Identification of driver 
genes in regions of copy number 
alteration 
Introduction 
Pinpointing the driver or drivers within regions of recurrent copy-number alterations remains a 
crucial bottleneck in cancer genomics. The predominant approach to this problem is to define a 
minimal region of maximal alteration—called the peak region—and to prioritize genes within this 
region.  While useful (Bass, Watanabe et al. 2009, Beroukhim, Mermel et al. 2010), this approach 
is insufficient because the minimal region is often still very large and may span an intractable 
number of genes. Moreover, the peak region may be driven by local properties of the chromatin 
and need not necessarily contain the driver. The importance of this problem is demonstrated by a 
recent report that over 70% (102) of the 140 regions of recurrent alteration across multiple tumor 
types do not contain a known oncogene or tumor suppressor (Zack et al., 2013).  
Helios, the approach I proposed to tackle this problem, seeks to exploit the fact that genes 
bearing additional properties of oncogenes—e.g. recurrent domain-specific point mutations or 
enrichment in a lethality shRNA screen—are more likely than others to be the driver targeted by 
the SCNA.  Helios considers the entire significantly altered region, but prioritizes the genes within 
this region by incorporating cues from different genetic and genomic data types to estimate the 
probability that each is a driver (Figure III-1).  It is a statistically rigorous framework for combining 
multiple signals—each of which may not have sufficient power to implicate the driver individually—
into a single score representing the available evidence that each gene’s amplification specifically 
increases the tumor’s fitness. Here, I integrate candidate scores derived from exome-sequencing, 
shRNA screening, and gene-expression profiling data, but these could readily be removed, 





Helios is formulated as a binary classification wherein a set of features is used to classify genes 
as either drivers or passengers, based on inference within a hierarchical Bayesian mixture model 
(see Methods, Figure III-3).  Standard approaches to classification rely on an initial list of positive 
and negative examples—drivers and passengers—to train the model.  Unfortunately, the list of 
known oncogenic drivers is relatively small and strongly biased towards kinases and the extreme 
phenotypes that facilitated their discovery.  Therefore, instead of this usual strategy, Helios begins 
with the assumption that a driver gene is more likely than passenger genes to be near the peak of 
the ISAR region. This is used to initialize the algorithm by providing a list of drivers and passengers 
to start from. From there, Helios iterates between 2 stages until convergence: 
1) Learning the parameters to predict which genes are passengers and which are drivers on 
the basis of their SCNA profile and on the additional genomic data 
 
Figure III-1 –Diagram of the classic and Helios approach 
While the classic approach relies solely on copy number, both to identify significantly altered regions and 
to further narrow down those region to a minimal region of maximal alteration, Helios identifies regions in 
the same fashion, but then integrates features extracted from different data sources to compute the 





2) Re-computing the probability that each gene is a driver using the parameters determined 
in step 1 
The general computational framework employed by Helios is known as transfer learning 
(Widmer and Rätsch, 2011). With this approach, drivers with clearer signal (e.g. at the peak of their 
region) are used to extract informative features to improve performance in cases with less obvious 
signal. Helios automatically learns the weights of features from a training set of driver genes and 
then uses these learned features to search for additional genes that share similar features in an 
iterative fashion.  With each iteration, Helios learns a better classification of drivers and passengers, 
which in turn is used to learn a better set of parameters, until convergence. 
Helios includes several improvements over many common approaches to identifying driver 
genes from SCNA regions. For one, Helios utilizes a mixture of two distributions– one for drivers 
and one for passengers—to model copy-number, thus avoiding the problematic selection of a hard 
threshold for defining aberrant regions (Figure III-4). Additionally, Helios permits final models where 
more than one gene in a region is identified as a high probability driver, or where no probable driver 
genes are identified.  
Finally, Helios can readily incorporate additional features, including complex features generated 
by combinations of multiple data sources. It automatically learns the contribution and importance 
of each such feature directly from the data, making it easily extendable and adaptable to other 
cancer types. For example, here, I integrate data from functional screens based on the concept of 
oncogene addiction (Weinstein and Joe, 2008). Using gene expression as a proxy for the activity 
of an oncogene, I consider overexpressed genes that show lethality when experimentally 
downregulated to be likelier candidates. This idea has recently been used to discover the novel 
oncogene HNF1B (Shao, Tsherniak et al. 2013).   
An important feature of my oncogene addiction score is that it allows for both linear and non-
linear relations between gene expression and lethality (See Figure III-2, Methods). Some features, 
e.g. point mutations within protein coding regions, are based on a single data type (Banerji et al., 
2012), while others, like the score for oncogene addiction, are a function of multiple data types 




from heterogeneous data types into a single score enables Helios to pinpoint the driver gene from 
within the recurrently altered region. 
 
 
Figure III-2 –Oncogene addiction 
(A) My oncogene addiction score uses monotonic regression to measure the association between gene 
dosage (X axis) and shRNA dropout (Y axis), aiming at differentiating the proto-ongonenic state (I) of the 
driver, which is expressed at wild type levels, and the oncobgenic state (II), which is characterized by high 
expression and high dependency on the gene for survival. (B) Monotonic regression of the shRNA dropout 
(Y axis) based on the gene dosage (X axis) for the two top scoring genes for oncogene addiction in the 
17q12 region. (C) Monotonic regression of the shRNA dropout (Y axis) based on the gene dosage (X axis) 





Once the regions of significant SCNA have been detected, Helios uses an integrative Bayesian 
approach to rank which are the most likely driver genes within each region.  Helios uses a 
hierarchical Bayesian mixture model to distinguish drivers from passengers among the genes 
present in significantly altered regions. The unsupervised Bayesian algorithm discriminates driver 
genes (T=1) by integrating the copy number alteration information (SCNA), with cues from different 
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Instead of predicting the classification as driver or passenger directly (T=0 or T=1), the system 
learns by maximizing the likelihood of the observed copy number landscape (P(SCNA)).  The 
graphical model has two components, one formalized as a classification 36 = 7|8 and a second 
that uses this classification to predict copy number. The assumption is that once the status of a 
gene as driver or passenger is given (T=0 or T=1), the frequency of alteration (4) becomes 
independent from other predictive features (X).    
In summary, the model separates the modeling of copy number (34|6 = 7) from other 
sources of information (36 = 7|8) while focused on the predictive task of the observed copy 
number landscape (34).  
The algorithm iteratively fits a model for each part: 34|6 = 7 and 36 = 7|8 and updates 
the estimations (P(T)) for each gene (T), taking both parts into account. The algorithm continues to 
iterate until the model converges into a stable solution, incorporating all the information into a single 




Figure III-3 shows the graphical model 
for Helios, where genes are classified by 
combining the information from different 
data sources X and SCNA. w represents the 
parameters that control the integration of X, 
while λ parameterizes the influence of T on 
SCNA. In this model, when the values Tn for 
the genes are given, the parameters for the 
different sources (W) and copy number (λ) 
are independent. This property makes it 
possible to fit the model efficiently using the 




Modeling copy number  
A widely used approach to pinpoint driver genes within significantly altered copy number regions 
is to define a minimal region of maximal alteration, called the peak region.  While demonstrating 
some utility in the past (Bass et al., 2009; Beroukhim et al., 2010b; Weir et al., 2007b; Zender et 
al., 2006) , this approach is insufficient for a number of reasons: (1) Even with a very stringent 
threshold, the minimal region of alteration can be fairly large and still contain multiple genes.  (2) In 
many cases, the driver is not in the peak region, such as ADAM15 or BCL2 in the TCGA breast 
cancer dataset (3) Each SCNA region is expected to contain one driver gene. However, some 
regions may target several drivers while other regions might not contain a single driver gene 
because they target other regulatory elements (miRNA, lncRNA,…) or simply because they are the 
result of other forces that affect the rate of DNA breakpoints, such as genomic structure.   
 
 
Figure III-3 – Graphical model for the Helios 
Algorithm 
N input genes are classified as either driver gene 
(Tn=1) or passenger gene (Tn=0) by combining the 
information from SCNA and different data sources X. 
The model needs to fit both the parameters that control 
the integration of X (w) and the parameters that 





Helios considers the entire significantly altered region, but prioritizes the genes within each 
region using a Bayesian approach that makes explicit the uncertainty about the actual target/s of 
the SCNA.   To achieve such prioritization, Helios uses additional sources of information to 
distinguish between genes which have equivalent copy number statistics and moreover the highest 
scoring gene need not be in the peak region.  Finally, Helios can give a high score to more than 
one gene per region, or give low scores to all genes in a region.   
I aim to model a distribution of SCNA that reflects the differences between driver and passenger 
genes, independently of the chromosomal region. However, in contrast to the subtle differences in 
SCNA within each altered region, the distribution of alterations differs dramatically between regions. 
Indeed, the median difference in G-score between genes in a region is significantly smaller (172) 
than the difference for genes across different regions (6405). Thus, without appropriate 
normalization, the G-score should not be used to prioritize drivers across regions. Ideally, instead 
of modeling the absolute number of alterations (which is dominated by the strongest alterations in 
the genome), I would like to model whether the gene is among the most altered genes in its own 
region (and therefore more likely to be the driver of that region). I therefore define a relative metric 
that measures the difference in terms of G-score to the highest value in each region. That is, for a 
single gene g, I define the GSDist score as: 
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The most altered gene(s) in a region will have GSDist=0, while any other gene will have a 
positive value that indicates the “delta” in terms of G-score to the most frequently amplified gene in 
the region. Note that traditional approaches would use a threshold on this metric to make a hard 
decision on whether genes in the altered region are peak genes (Figure III-4).  Instead Helios 
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This model is based in the following intuition: the perturbation of driver genes provides a fitness 
advantage to cancer and therefore driver genes are likely to be among the most altered genes of 
their region, which translates into a GSDist distribution that exponentially decreases from zero with 
small variance.  Passenger genes, on the other hand, have no evolutionary pressure to be selected 
for alteration and therefore can be modeled by a uniform distribution, which is approximated by an 
exponential distribution with large variance.  This prior information on the variances of the two 
distributions is encoded into the algorithm through conjugate priors for C9. Considering a Gamma 
function for the prior distribution for C9 , the posterior probability for C9  belongs to the following 
Gamma distribution: 
 3C9|
4 = %%I9 J 	 316 = 71 , I9 ∗ L9 J 	 316 = 7
;<7 1  Eq. 7 
 
 
Figure III-4 – Diagram of the copy number model of the Helios Algorithm 
. Traditional approaches (top) calculate a hard threshold on the delta to the most altered marker (GSDist, 
X axis) to define the peak region (Y axis). Helios (bottom) instead calculates the probability (Y axis) of 





Modeling additional sources of information 
In most cases, the information extracted from copy number alone, is insufficient to pinpoint 
driver genes within altered regions. Helios overcomes this problem by incorporating cues from 
additional data sources that can facilitate the discrimination of driver genes from passenger genes.  
Helios’s strength is its ability to combine multiple weak pieces of evidence from heterogeneous 
data types to provide strong indication of the oncogenic role of a gene. 
The great challenge of data integration is to provide a unified framework to utilize all the data, 
despite the disparate nature of the features involved. In Helios, the information is unified by the 
function 36|8  that combines cues from all data sources into a single score. From the 
computational standpoint, 36|8 is a binary classifier that uses a set of features (X) to estimate 
whether the gene is driver (T=1) or passenger (T=0).  
The features X are extracted from a diversity of data sources such as functional screens, gene 
expression and DNA sequencing. Features do not only help raise confidence in candidates, but 
also help to discard unlikely candidates. Indications like an unexpected frequency of point 
mutations or the oncogene addiction measured in shRNA screens can reinforce our confidence in 
driver candidates. While signals like the absence of variation in gene expression can help the 
algorithm discard passenger genes. I will describe the function 36|8 in greater detail after 
specifying some of the features X.  
Features used in the Helios algorithm 
The datasets are processed to extract features that can facilitate the identification of driver 
genes and distinguish these from passenger genes in SCNA regions. Some features, such as the 
significance of the number and location of point mutations harbored by a gene, are based on a 
single data type (DNA-sequencing), while others, like the score for oncogene addiction, are 
computed based on a combination of data types (gene expression and shRNA screens). In the 
following subsections I describe the features currently used in the Helios algorithms. Note that the 
algorithm provides a general framework where more features can be included as they become 





Driver genes can show a footprint of sequence mutations. This footprint consists on a higher 
recurrence of alterations, which in some cases may focus on specific locations such as certain 
functional domains or even a single base pair. In breast cancer and many other tumor types, the 
frequency of SCNAs for driver genes is significantly higher than the frequency of point mutations, 
with a handful of well-known exceptions such as PIK3CA and TP53.   
I use MutSig (Banerji et al., 2012) to compute the statistical significance of the recurrence of 
point mutations. MutSig tests the null hypothesis that the number of observed mutations in a gene 
can be attributed to a random background mutation processes, taking into account the bases 
covered, the length and composition of the gene.  The computed p-value was log transformed to 
be used a feature for Helios. 
Expression 
Helios uses features extracted from RNA-Seq based gene expression to identify genes that are 
not expressed and those that, although expressed, do not seem to be driven by SCNA. 
Expressed genes 
 
Helios first uses RNA-Seq data to identify genes that are unlikely to be expressed in the tumors. 
Ramskold et al. (Ramsköld et al., 2009) concluded that RPKM measures can be employed to 
estimate whether a gene is expressed and estimated the percentage of genes that are expressed 
in different tissues. I compute the percentage of samples in which each gene is above this 
percentile and use it as a feature for Helios.  
Association with alteration 
 
The oncogenic activity of an amplified driver gene is expected to be reflected in the gene’s 
mRNA dosage (Akavia et al., 2011; Santarius et al., 2010). I therefore anticipate the expression of 
the gene to be significantly higher in samples where the gene is amplified. I split the cohort into two 
groups, those samples in which the gene is amplified and those in which the gene is diploid and 




Wilcoxon rank sum test between these groups. As the driver mutation may only be operating in one 
subtype, this score is also computed for each subtype independently.  
 
Genes that contribute to tumor development can also be overexpressed by different 
mechanisms in the absence of amplification. If those mechanisms prevail over copy number 
amplification, the gene can present a lack of correlation between overexpression and amplification. 
I considered that those genes may show significant difference in expression between tumor types 
and therefore I measure the significance of gene the difference in expression differences between 
subtypes, using the same test performed for association of amplification.  Genes that do not show 
any significance in any of these two tests (p-value<0.05) are discarded and not scored.  
shRNA 
Although loss-of-function shRNA screens on tumor cell-lines are rapidly accumulating (Marcotte 
et al., 2012), (Cheung et al., 2011), these assays have not yet fully unleashed their terrific potential 
as an unbiased genetic approach for the identification of tumor dependencies. The main reason 
being that these screens pose difficult challenges such as off-target effects, low hairpin efficiency 
and, last but not least, the noise introduced by the stochastic nature of the pooled experiment 
(Kaelin, 2012).  
Oncogene addiction score 
The lack of reliable information about hairpin efficiency hinders the estimation of a ranking of 
gene lethality based on a single cell line.  Therefore, to identify vulnerabilities, binary comparisons 
of hairpin dropout rates across several cell lines are usually performed. These comparisons are 
typically based on the classification of cell lines in tumor types or subtypes.  Instead, I take a 
different approach based on the concept of oncogene addiction (Weinstein and Joe, 2008): the 
perturbation of an oncogene produces dramatic changes in the cell, making it dependent on 
oncogene activity. Using gene expression as a proxy for the activity of an oncogene, I consider 
genes that show increased lethality when overexpressed to be likelier candidates. This idea has 




I score oncogene addiction by building a composite statistic reflecting the extent to which 
shRNA-depletion in a genome-wide screen is correlated with over-expression of the gene at 
baseline. The oncogene addiction score for a hairpin h with shRNA dropout 
M that targets a gene 
with expression profile NOP9,-1/9M is the negative log likelihood of 
M given NOP9,-1/9M: 
 Q4M = − log U3V
M  W NOP9,-1/9MXY = −log 3Z Eq. 8 
 
Where Z is the residual error vector of the shRNA dropout prediction vector 
M[:  
 Z = 
M − 
M[ = 
M − \NOP9,-1/9M Eq. 9 
 
It is important to use a nonlinear regression for the prediction due to the strongly non-linear 
relationships observed in several bona fide cases, such as ERBB2 or FOXA1 (see Figure III-2). 
Therefore I decided to model \NOP9,-1/9M using a linear ordering isotonic regression (Barlow et 
al., 1972). I use the PAVA algorithm (Brunk, 1955) to estimate the best fit for this regression. 
I assume a Gaussian error Z ~ 0, ^_. Considering  Z the error for cell line i, the oncogene 
addiction score for a hairpin can be computed as: 
 
 Q4M = − logV3ZX = 	 −log ̀ 1√2c^ exp − 12 Z^_Zf  Eq. 10 
 
The variance for the error distribution ^_ was estimated from each hairpin independently. Note 
that many hairpins have extremely low variance, as there are a large number of inert shRNA 
hairpins and many other that target genes that are nonessential across all cell lines. To handle this 
situation, in instances where the hairpin’s variance was smaller than the shRNA population 
variance, the latter was used as estimation of the variance for the error distribution.  
While the previous score is defined for a single hairpin, each gene is usually targeted by several 
hairpins. The final score for each gene is computed as the average of the best two scoring shRNA 




Subtype lethality score 
For cancer types for which a molecular sub-classification is available, Helios includes a feature 
that scores the association between lethality and tumor subtype. I employ the same scoring scheme 
used for the oncogene addiction score, but in this case the predictor is a binary variable indicating 
the tumor subtype. 
The oncogene addiction score and the subtype lethality score are not independent as in many 
cases (for example FOXA1, ESR1 and GATA3 in luminal breast cancer) overexpression and 
lethality are dominant across a whole subtype. I encode this dependency in the structure of the 
Bayesian network. I introduce an additional intermediary node in the network that represents the 
overall lethality score for the gene and connects the two scores to the final node (Figure III-5). 
Combining the features into a unified framework 
The function 36|8 should be flexible enough to accommodate very diverse data types. At the 
same time, it should be bound to avoid over-fitting.  The key challenge is how to combine these 
different features and weigh the relative contribution of each.  Multivariate logistic regression is a 
common choice for classification problems with continuous features where over-fitting is a concern 
(Bishop, 2006). However, the use of a simple logistic regression model is not well suited for this 
domain due to the strong non-linear nature of some of the features and existence of dependencies 
between features. For example, clear dependencies between the different features that reflect 
oncogene addiction.  
Instead, I extended the logistic regression model by introducing additional layers of sigmoid 
functions (Figure III-5): each individual feature connects to a node representing a single sigmoid 
function and these are either combined into intermediary nodes and/or connected directly to a final 
node. The resulting classification is based on a final sigmoid function computed in this top node. 
For example, as we can see in Figure III-5, the network contains two nodes related to shRNA which 
are joined into a single node that summarizes the lethality information for the gene. To avoid over-
fitting, Helios uses Gaussian priors  (Dan Foresee and Hagan, 1997) for the parameters of this 
Bayesian network (W). These parameters serve multiple roles in determining how the signal is 




on the importance of their contribution.  Higher/lower W give their respective feature more/less 
weight in the final score. But, due to the structure of the Bayesian Network, they do much more 
than that, each feature goes through sigmoid nodes to adapt their input signal and the W 
parameters fit those as well, determining not only how much a feature contributes, but also 
thresholds defining when and how this contribution occurs.   
Model learning 
To classify genes as drivers (T=1) or passengers (T=0), the model (Figure III-3) requires fitting 
two sets of parameters: the parameters C9 for the mixture of exponential functions that model the 
SCNA data and the parameters W of the Bayesian network that weigh and integrate other data 
sources. These sets of parameters are learned using the Expectation Maximization algorithm (EM) 
(Dempster et al., 1977), which iterates between two steps, optimizing the likelihood of the model in 
each step, until convergence. Note that when the classification T for the genes is given, the two 
sets of parameters become independent and they can therefore be learned independently. EM 
 
Figure III-5 – Bayesian Network for data integration in the Helios Algorithm 
Helios uses a Bayesian network with sigmoid nodes to integrate different data sources. The current version 
of Helios contains two input nodes (shRNA-addiction and shRNA-subtype) that integrate genome-wide 
vulnerability assays and that are merged into a single node (shRNA-node), an input node for sequence 
mutations (DNASeq) and an input node for gene expression (RNASeq). The output of this network gives 
the expected classification of a gene as target (T=1) or passenger (T=0) when SCNA information is not 




iterates between two stages that compute the estimates for T and the two sets of parameters 
respectively.   
In the E-step the posterior odds for T are updated based on the prior odds 36 = 7|8, g 
(computed by the Bayesian network that constitutes the integrative prior, Figure III-5) and the 
likelihood ratio 3
4|6 = 7, C9 (computed by Eq. 7, which models the SCNA distributions): 
 36 = 11 − 36 = 1 = 3
4|C3
4|C: × 3
6 = 1|8, g1 − 36 = 1|8, g Eq. 11 
 
 
In the M-step the parameters C9  and W are re-estimated using the updated values of P(T) 
computed in the previous E-step. Specifically: 
The parameters C9  are recomputed as the expected value of their posterior Gamma distribution 
described in Eq. 7. Therefore the updated estimation is:  
 
 C9  = I9 ∗ L9 J ∑ 316 = 7
;<7 1I9 J ∑ 316 = 71  Eq. 12 
 
 
The estimation of the optimal solution for the parameters W for the Bayesian network requires 
the computation of the Hessian matrix.  To avoid the computational overhead, I use the Gauss-
Newton approximation (Dan Foresee and Hagan, 1997). I employ the implementation provided by 
the function trainbr in Matlab’s Neural Network Toolbox. 
Initializing a starting point  
The EM algorithm does not guarantee to converge to the global optimum, but rather only to a 
local optimum.  Therefore, a reasonably close initial point is key to achieve a good solution 
(McLachlan and Krishnan, 2007). Helios needs to initialize the parameters for both the mixture of 




information.  Note that given the assignments of T, the two parts of the system are independent 
and all the parameters of each part can be learnt efficiently.   
The initialization of the Bayesian network is based on the SCNA data. By selecting the most 
frequently altered gene in each region I can provide a good “first guess” for which genes are drivers. 
In practice, to initialize the parameters W for the Bayesian network that models ij|k, I use a 
rough labeling of the subset of genes based on SCNA and point mutations. Genes that are 
significantly less aberrant than the top of their region (GSDist>150) are labeled passenger genes 
for the initialization process. While the most altered genes in each region (GSDist=0) and as well 
as those that are significantly mutated in sequence according to MusSig (p-value<0.01) are labeled 
driver genes. Using this binary assignments for P(T) Helios can learn the parameters for the 
network in the same way it would in an iteration of the M step. I therefore achieve an initial fitting of 
the parameters W and an initialization of ij|k. 
Helios then needs to initialize the parameters for the second part of the system, the mixture 
model that represents the SCNA information. As in the previous case, an assignment for P(T) would 
allow to fit the parameters of the model (lm and ln) using the same procedure performed in the M 
step of the EM algorithm.  In this case, I use the current estimate of ij|k (obtained after the initial 






Chapter IV – Computational analysis of 
the landscape of amplifications in 
Breast Cancer 
Introduction 
Enabled by high-throughput, massively parallel technologies, several large-scale catalogues of 
genomic alterations in breast cancer cohorts have recently been published, creating a unique 
opportunity for the identification of driver genes (Curtis et al., 2012; TCGA, 2012). Exome 
sequencing studies have identified putative driver genes, in several cases associating them with 
specific molecular subtypes (Curtis et al., 2012; Stephens et al., 2012).  However, only 3 genes—
TP53, PIK3CA and GATA3—have point mutations in >10% of samples (TCGA, 2012). The 
predominant type of genetic lesion in breast cancer is somatic copy number alteration (SCNA), 
often driven by inactivation of DNA repair genes such as BRCA1/2.  Indeed, HER2, one of the most 
clinically actionable drivers in breast cancer, is primarily dysregulated by copy-number 
amplification.   
While analysis of SCNA profiles has revealed cancer-associated genes in several cases 
(Albertson et al., 2003; Kamb et al., 1994; Oliner et al., 1992; Shiloh et al., 1986), the lack of 
specificity of these lesions makes it difficult to identify the driver genes that contribute to 
tumorigenesis within altered regions. A recent effort to analyze the copy number landscape across 
multiple tumor types reported that over 70% (102) of the 140 regions of recurrent alteration did not 
contain a known oncogene or tumor suppressor (Zack et al., 2013). While point mutations directly 
indicate the genes they affect by virtue of their precise location, SCNA studies identify hundreds of 
candidates across the genome and systematic validation of candidates indicated by SCNA has not 






I applied ISAR to 785 breast cancer samples collected by the TCGA project (TCGA, 2012) and 
identified 83 significantly amplified regions (see Supplementary Table 1), compared to the 30 
regions originally reported by the TCGA consortium.  Among the new regions identified by ISAR, I 
find many bona-fide or likely oncogenes, including MYB, BCL2, CDK4, ESR1, FGFR2, FGFR3 and 
FGFR4.  Identified regions contained an average of 14 genes with a total of 1226 genes across all 
83 regions.  
I used Helios to integrate data from 785 primary breast cancer tumors, including DNA copy 
number, gene expression and sequence mutations from the TCGA (TCGA, 2012), with data from 
27 breast cancer cell lines including gene expression, copy number and shRNA depletion in a 
genome-wide shRNA screen (Barretina et al., 2012b; Marcotte et al., 2012).  
I arrived at 64 candidate drivers by selecting only the top gene in each region and applying a 
threshold to the Helios score of 0.5 (see Supplementary Table 2).  Some significant SCNA regions 
did not contain a high scoring protein-coding gene; these amplifications potentially target non-
coding RNA or other genomic features.  For example, all protein-coding genes were low-scoring in 
an amplified region containing the known oncomir mir21 (O'Day and Lal, 2010).   
To evaluate the sensitivity of the approach, I combined several publically available resources to 
create a comprehensive set of oncogenes that have been implicated in breast cancer ((Beroukhim 
et al., 2010b; Consortium, 2013; Frankild and Jensen), see Methods section).  9 out of the 10 genes 
scored highest by Helios were included in this list (FOXA1, PIK3CA, CCND1, CDK4, MYB, ERBB2, 
IGF1R, BCL2, ESR1) (Figure IV-1). Moreover, the entire list of 64 Helios candidates was 
significantly enriched for the compiled set of breast cancer drivers (16/64, p-value < 4e-15), a large 
improvement over the set of all genes in amplified regions reported by GISTIC2 (TCGA, 2012) 
(17/452, p-value > e-3) (Table IV-1). The performance of the method was also compared against 
two other recently developed algorithms, GAIA (Morganella et al., 2011) and DiNAMIC (Walter et 
al., 2011), outperforming both of them (18/768,p-value > e-3 and 185/10651, p-value > e-3 
respectively), confirming the vast improvement of the novel integrative approach over the state of 






Figure IV-1 – Chromosome view of Helios analysis on breast cancer data 
Each point represents a candidate gene, the X axis shows the Helios score and the Y axis the chromosomal 
location. The color of the gene indicates the ISAR score (truncated to 5). The top ten Helios scoring genes are 




Data integration empowers sensitivity and specificity 
Helios’s integration across multiple data sources is key to its ability to be both specific and 
sensitive. Sequence mutations are gene-specific, but only few drivers harbor such mutations 
recurrently. SCNAs typically cover a large number of genes, making it hard to identify the target of 
the amplification based on copy number alone.  For instance, CDK4 shares exactly the same copy 
number profile with its five closest neighbors, but the lethality associated with luminal tumors 
displayed by CDK4 in the shRNA screen raises its Helios score (Figure IV-2A).  More strikingly, 
BCL2 is only the sixth gene in its region in terms of copy number alteration frequency, but its 
dramatic oncogene addiction score raises its Helios score well above all others in the region (Figure 
IV-2B). In many cases (e.g. EGFR or ADAM15, Figure IV-2C,D), it is not any single feature, but a 
combination of features that identifies the top-scoring gene in the region.  Table IV-2 shows how 
Helios outperforms the simple use of the data sources independently to identify drivers within the 
SCNA regions. Even if the candidates obtained by each data source are joined together naively, 
Helios provides significantly better sensitivity (15 versus 9 detected driver genes) and specificity 
(hypergeometric enrichment p-value of driver genes 8.16E-14 versus 4.72E-11). The outstanding 
performance of the integrative approach is due to its capability to automatically learn the optimal 
weight for each feature, harnessing information from subtle signals that otherwise would be 






GISTIC2  452 17 1.2E-3 
Gaia 768 18 7.7E-2 
DiNAMIC 10651 185 9.9E-2 
Helios Top Genes 83 15 4.71E-12 
Helios Top Genes & Score>0.5 64 15 8.16E-14 
 
Table IV-1 – Performance comparison of Helios and other methods.  
64 genes were selected from the Helios analysis of breast cancer by taking the top scoring gene in each 
region and applying a threshold to the Helios score of 0.5. A gold standard set was compiled by 
combining several publically available resources (See methods for details). The table reports the number 
of genes selected by each method, the number of those genes present in the gold standard and the p-





Functional information extracted from genome-wide shRNA vulnerability assays was particularly 
useful. Data from these assays were used to identify lethality associated either with tumor subtype 
or with mRNA expression levels in a composite statistic reflecting the extent to which shRNA-
depletion in a genome-wide screen correlated with over-expression of the gene at baseline 
(Methods).  These scores can capture oncogenes that are active in only a subset of samples, e.g. 
in a subtype-specific manner (e.g. FOXA1 and ESR1), but also in a subtype-independent manner 
(e.g. BCL2 or ERBB2) depending on the expression profile (Figure III-2).    
 
Figure IV-2 – Helios analysis for the 12p14, 18q21, 1q21 and 7p12 regions 
Genes in the ISAR regions are displayed in the X axis and the Helios score is represented by bars colored 
proportionally to the contribution of each feature (a logistic regression approximation is employed to 






Systematic in vitro validation of Helios-predicted genes 
To systematically select a subset of Helios candidates genes for experimental validation, I 
focused on the most significant regions, based on copy number amplification (ISAR>5.5) and used 
Helios to pinpoint the most likely driver within each region. In 7 of the 17 selected regions, the top 
Helios gene was a bona-fide breast cancer oncogene (ERBB2, CCND1, ZNF217, MYC, miR-21, 
FGFR2 and IGF1R) and these oncogenes scored well above the next best scoring gene. For 
example, MYC’s Helios score was 100 times greater than the score of the 2nd best gene in the 
region (Figure IV-3, “Ratio-next” column).  
I selected the top scoring genes in the remaining 10 uncharacterized regions for in vitro 
validation. In 4 of these regions, there was more than one significantly scoring gene or the 
difference between the first and second candidates was below 1%, and so both candidates were 
assayed.  We failed to clone over-expression vectors for three genes, resulting in a final selection 
of 12 predicted oncogenes for validation.  
One of the hallmarks of transformation that is commonly used to investigate putative epithelial 







SNP mutations 3 3 4.25E-06 
shRNA 9 4 8.07E-06 
Copy number 14 5 1.95E-06 
Union individual sources 23 9 4.72E-11 
Helios Top Genes & Score>0.5 64 15 8.16E-14 
 
Table IV-2 – Performance of data integration.  
A comparison between Helios and the results from the analysis of the data sources individually, testing for 





(Hanahan and Weinberg, 2011). This capacity likely reflects the cumulative impact of multiple 
signals such as increased resistance to stress, increased cellular growth rates and changes in 
metabolism (Buchheit et al., 2012; Davison et al., 2013; Guadamillas et al., 2011). As a result, 
many driver alterations in cancer may potentially impact attachment independent growth through 
multiple mechanisms. Therefore, we based the candidate validation strategy on assaying this 
phenotype.  
We evaluated the ability of a non-tumorigenic human mammary epithelial breast cell line (MCF-
10A) to form colonies in semi-solid media when the putative oncogene was experimentally 
upregulated. Although early passages of this cell line do not form colonies in agar, culturing these 
cells selects for clones with the capability to grow independently of attachment. Because low 
passage MCF-10A are very resistant to transformation (only potent oncogenes; ex. RAS-V12, 
mutant ERBB2 induce robust colony formation in agar), to increase the sensitivity of the assay, we 
selected a passage with intrinsic low attachment independent growth ability (10-20 colonies per 
5,000 plated cells) that demonstrated robust higher growth ability when bona-fide breast oncogenes 
were overexpressed. These cells were transduced with lentiviral vectors expressing the putative 
driver to increase the level of the selected genes and we subsequently evaluated their anchorage 
independent growth in soft agar. We selected CCND1 and MYC as positive controls, as both were 
selected by Helios at the top of their respective region.  As negative controls we selected 5 genes 
from significantly amplified ISAR regions (ISAR > 5.5), but that did not have a high Helios score 
(score < 0.3). 
10/12 tested genes (C6ORF23, BEND3, YEATS4, RSF-1, PRKCZ, GNB1, ZNF652, NIT1, 
PVRL4 and TRPS1) were able to significantly increase MCF10A anchorage independent activity 
with a p-value of 0.005 or below (Figure IV-3). None of the negative controls demonstrated an 
increase in colony formation. This provides in vitro evidence that Helios candidates provide a 
selective advantage for breast cancer cells. Note that a negative result for PRKCZ in this assay 
does not conclusively rule it out as a driver gene for two main reasons. First, attachment 
independent growth is not the only hallmark of cancer and, second, the assays were performed in 




in the context of specific alterations not present in MCF10A. In summary, a systematic validation 




promote oncogenic capabilities in vitro. 
 
 
Figure IV-3 – Helios validations 
Results of the systematic in-vitro validation of Helios candidates including the selected genes and 5 genes 
selected as negative controls (highlighted in grey). The ‘Ratio Next’ column indicates the ratio between the 
Helios score of the candidate gene and the score of the next best scoring gene in the region. The 
‘Validation p-value’ displays the statistical significance of the change in colony size between the 6 empty 
vector controls and the 6 repeats of the cDNA overexpressing the candidate driver gene. This p-value was 
computed using a right-tailed unpaired two-sample t-test. The ‘Supported Driver’ column indicates if the 
gene has been positively validated by the in-vitro assay or a known driver based on previous literature. 
The rightmost panel shows the box plots of the colony numbers for each gene in the validation experiment, 
where grey indicates the control and green the cDNA overexpressing the candidate driver gene. The 
colony assay was not performed for several genes that we failed to clone (MYO18A, SKI), or were bona 
fide drivers at the top of their peak (ERBB2, ZNF217,  FGFR2, ANKRD17, IGF1R). Additionally, no gene 
scored above 0.3 in the 17q23 region, suggesting that the target was another regulatory element, in this 
case the bona fide onco-microRNA MIR21. The three green boxes highlight amplified regions in which we 





   Overall, Helios demonstrated unprecedented accuracy in identifying genes that promote 
oncogenic capabilities. Helios correctly scored 13/14 drivers at the top of their respected region 
(93%). Moreover, 10/12 empirically tested genes validated (83%), thus we identified 9 new genes 
that promote tumorigenic capabilities in breast cancer (excluding PVRL4 which was recently 
published (Pavlova et al., 2013)).  
Additionally, since the genes were selected based on the region’s significance, rather than their 
Helios score, a wide range of Helios scores were tested (between 0.36 to 0.79), increasing our 
confidence in the candidates identified in other regions. Based on this performance, we expanded 
our list of likely drivers based on Helios predictions with more permissive criteria (Supplementary 
Table 2).  
Importantly, Helios identified multiple high scoring (likelihood>0.5) genes for over 20% of the 
regions. Indeed, we validated three regions with multiple genes and each gene independently 
induced colony formation in vitro (Figure IV-3, green boxes), indicating that an amplicon often 
targets more than one gene. In summary, while previously only 7/17 of the most frequently altered 
regions in breast cancer harbored a known oncogene, following our validation 14/17 regions can 
be assigned a driver with substantial confidence. 
Here, I have presented a major advance in addressing this challenge, using a method that 
integrates data from primary tumors with functional assays on cell lines to prioritize candidate 
drivers. The unparalleled sensitivity and specificity of Helios enabled us to execute the first reported 
systematic validation of an algorithm designed to identify tumor dependencies.  
Helios’s performance was confirmed by a success rate of 10/12 candidates in an anchorage 
independent growth assay, successfully characterizing several regions for which there was no 
previously implicated driver. Importantly, because I selected the genes for validation based on their 
amplification significance (ISAR score), rather than their Helios score, I expect that this success 
rate will extend to additional regions that have equally strong Helios scores. Moreover, many of 
these genes are amplified in additional epithelial cancers (e.g. C6orf203, NIT1, ZNF652) 





Using Helios, I have significantly expanded the landscape of high-confidence breast cancer 
drivers by more than two fold (Figure IV-4). Previous analyses of breast cancer cohorts (Stephens 
et al., 2012; TCGA, 2012) had identified 15 driver genes amplified in at least 5% of breast cancer 
tumors (both SCNA and sequence mutations). This analysis has doubled this number to 29, 
substantially expanding the list of potential drug targets. Even more importantly, it has increased 
the number of drivers identified in each tumor, thus raising the possibility that at least one might be 
actionable in a given patient. A previous study (Figure IV-4, grey boxes (Stephens et al., 2012) ), 
could assign each tumor a median of 2 established drivers. Adding the Helios validated genes 
increases this number to a median of 3 drivers per tumor (Figure IV-4B, green boxes). Adding all 
predicted drivers with a high Helios score further expands this number to a median of 5 drivers in 
each tumor (Figure IV-4B, yellow boxes). Thus Helios has substantially expanded the set of high-
confidence drivers in breast cancer. 
Genetic, genomic and functional data on cancers will continue to accumulate from large-scale 
projects in the coming years (Cheung et al., 2011; TCGA, 2008). Such datasets continue to 
accelerate drug development and to yield deep insights into oncogenesis. However, they also 
create new analytical challenges such as the need to pinpoint the alterations that promote cancer.  
Helios can be viewed as an accurate in silico screen for drivers. As such, it can be applied to 






Figure IV-4 – The landscape of driver mutations in breast cancer 
For the driver genes described in (Stephens et al., 2012) (grey), Helios validated genes (green) and other 
Helios genes scoring > 5.5 (yellow) we compute (A) the number of tumors altered (copy number or 
sequence mutation) for each driver gene and (B) the number of driver genes altered (copy number or 
sequence mutation) per tumor. For this Figure we consider the 485 primary tumors in TCGA for which both 





Datasets used  
I used the following public datasets: 
Primary tumor data from the TCGA Project (TCGA, 2012): copy number Affymetrix 6.0 SNP 
arrays (n=785), Illumina HiSeq RNA sequencing (n=732) and whole-exome sequencing (n=507). 
Cell line shRNA screens (n=29) collected by Marcotte et al. (Marcotte et al., 2012).  
Cell line data from the Cancer Cell Line Encyclopedia (Barretina et al., 2012a) for the cell lines 
screened with shRNA:  copy number Affymetrix 6.0 SNP arrays (n=27) and messenger RNA 
Affymetrix U133 plus 2.0 arrays (n=27) 
ISAR Analysis 
We applied the method to analyze the amplification landscape of 785 breast cancer samples 
collected by the TCGA project using Affymetrix 6.0 SNP arrays  (TCGA, 2012). The segmented 
data was preprocessed to remove common CNVs and obvious technical artifacts. The total 
execution time was 4 hours in a laptop equipped with an Intel i7-2620M 2.7GHz processor and 8 
GB of RAM. For this analysis, windows sizes of 4000, 5000, 6000 and 7000 markers were used 
and the window shift was set to 1/8 of the window size.  TP was set to 2 and TR was set to 1. We 
used default values for the parameters shared with GISTIC (aberration thresholds=[0.15,-0.15], 
aberration caps=[2.0,-2.0], bin size=0.01). 
A few post-processing steps are performed to ensure the quality of the detected regions. 
Adjacent regions closer than 250k base pairs were merged. Extremely small regions (size<10bp) 
were filtered out, as those are possibly due to artifacts. Regions that include the edges of the 
chromosomal arms were also discarded, as the statistical significance of the alteration in those 
regions is usually overestimated due to the difficulty of creating a null distribution for these locations 
of the genome 
ISAR obtained 83 regions of significant SCNA (Supplementary Table 1). On average these regions 





Helios uses as candidate drivers the 1226 genes belonging to the 83 regions of significant 
SCNA identified by ISAR. The parameters for the Gamma priors for the copy number model are 
set to L = 125 and I = 1000 for driver genes and L: = 300  and I: = 4000 for passenger genes, 
which emphasizes a smaller GSDist for drivers, while setting both to coherent values within the 
range of the observed data. Different values were also tested for these parameters without 
displaying any significant impact in the results of the analysis.  
Subtype Classification 
Breast cancer is a heterogeneous disease with different molecular subtypes. Despite the 
discrepancies between different molecular classifications that have been proposed in the literature 
(Perou et al., 2000),(Prat and Perou, 2011), (Curtis et al., 2012), all authors agree on the existence 
of two main molecular subtypes of breast cancer:  luminal and basal. Therefore I considered these 
two subtypes in my analysis.  The subtypes for the cell lines were obtained from Marcotte et al. 
(Marcotte et al., 2012). The primary tumors are classified into subtypes using receptor status 
recorded in the clinical annotations, where estrogen and progesterone negative tumors are 
considered basal and any other tumor is considered luminal. 
The association of alteration with each subtype was estimated using the G-score. The G-score 
for the samples in each subtype was calculated and the significance of this score was estimated 
by permutation testing: 10000 random permutations of the data are generated and the G-score for 
the subtype in each permutation was compared against the subtype G-score. Genes that displayed 
a significant p-value for this score (<0.01) were deemed subtype-specific. 
Features for Helios were computed for the whole cohort and for each subtype independently. 
For alterations that are subtype-specific the value of the feature computed for the subtype 
associated to the alteration was employed.  For alterations that do not display association with 







I use MutSig (Banerji et al., 2012) to compute the statistical significance of the recurrence of 
point mutations in the 507 samples sequenced by TCGA. The MutSig analysis was obtained from 
the GDAC TCGA pipeline. Specifically, version 2011112800.0.0 (MutSig v1.5) was employed.   
Expression 
Helios uses several features extracted from RNA-Seq based gene expression from 732 patients 
collected by the TCGA.  The RPKM processed data was obtained from the GDAC pipeline. 
I use the procedure described in Section 0 to compute the feature that estimates whether a 
gene is expressed. The distribution for this feature displayed strongly bimodality and based on this 
bimodality I decided not only to use it as a feature for Helios in this case, but instead to filter out 
genes based on this criteria. Genes that had RPKM values above the threshold in less than 30% 
of the samples were filtered out and removed from consideration.  
shRNA 
For the analysis I use the Breast cancer cell lines from the shRNA screen collected by Marcotte 
et al. (Marcotte et al., 2012). I use the computed shARP score as defined by the authors as a 
measure of lethality for each cell line. The shARP score was median normalized and then 
standardized using the deviation of the positive values. Because RNA-seq data was not available, 
considering the inherent noise of mRNA microarrays and that part of the genome was not measured 
by the array, I also computed the score using copy number instead of mRNA and the most 
significant score between the two was selected.  For genes not assayed in the shRNA screen I 





I executed Helios on the dataset following the initialization described in Section 0. The algorithm 
converged to a stable solution after 25 iterations as we can see in Figure IV-6. 
 
Figure IV-5 – Expression call feature histogram 
Histogram of values for all genes of the expression feature for described in the text  
 
Figure IV-6 – Convergence of the Helios algorithm 
(A) Likelihood of the Helios model for each iteration of the algorithm (B) Parameters for the GSDist 





Stability of Helios 
I performed 100 runs randomly and uniformly sub-sampling 95% of the samples in each 
execution. The percentage of runs in which a region is called by ISAR depends clearly on the ISAR 
score (Figure IV-7A). Peaks with S-score above 3 were called on average in 98.30% of the 
executions. I observed that although displaying more private focal mutations, several regions with 
scores below 3 contained known driver genes such as FOXA1, PIK3CA, GAB1, MYB or NOTCH3. 
I decided to lower the threshold to 2 considering that the integration of other types of data performed 
by Helios would increase the confidence in the presence or absence of driver genes in these 
regions. 
I tested Helios’ stability by comparing gene rakings across sub-sampled runs using Pearson 
correlation. Figure IV-7B shows the histogram of pairwise correlations across runs. Helios 
 
Figure IV-7 – Stability analysis 
(A) ISAR peak stability versus S-score. The percentage of runs in which a peak was called across 
subsample runs is plotted against the S-score. (B) Histogram of Pearson correlation of Helios scores 
across subsample runs of the algorithm. The average correlation between Helios scores across executions 




demonstrated exceptional robustness, displaying an average correlation between Helios scores 
across executions of 0.96 and with the lowest correlation being 0.81.   
 
 
Performance of data integration 
To assess performance, a gold standard set of 330 genes was compiled from the following 
sources: 
• The set of known amplified oncogenes from Beroukhim et al. (Beroukhim et al., 2010a) 
• The set of genes related to Breast cancer according to the University of Copenhagen 
DISEASES database (Frankild and Jensen) with score greater than 2.5. This lists 
includes both oncogenes and tumor suppressors. I filtered out genes categorized as 
tumor suppressors according to Uniprot (Consortium, 2013). 
The different methods and set-ups are compared both in terms of the number of gold standard 
genes captured and the p-value of the hypergeometric enrichment of gold standard genes in the 
predicted set.    
I first compared the performance of Helios against the simple criteria of selecting the top altered 
gene per region. Out of the 118 genes that were top of their region (some regions have more than 
a single gene at the top), 15 are annotated in the gold standard. Helios identifies the same number 
of annotated genes but achieved this with only 64 genes that had score greater than 0.5 selected.  
Thus, it achieves the same sensitivity but significantly increases the specificity, increasing the 
enrichment p-value from 8.40E-10 to 8.16E-14. 
I then compared the performance of the integrative approach against the simple selection of 
candidates within SCNA regions based on each data source individually. I also compared selecting 
genes solely based on SCNA, choosing those that were clearly more altered than any other gene 
in the region. I selected top altered genes in their region where the second altered gene had a 
GSDist>150. Similar results were obtained with threshold between 100 and 200. Table IV-2 shows 




union of genes captured by all independent data sources. Helios clearly outperformed each 
individual data source and the union of all data sources both in terms of sensitivity and specificity. 
This result exemplifies the power and benefits of data integration, in which all the information is 
considered simultaneously in a unified model that leverages subtle signals to achieve better 
performance than what would be obtained by analyzing each data source independently. 
To assess the contribution of each data source to the performance of Helios, the algorithm was 
executed excluding each of the data sources (shRNA,expression and sequence mutations) and 
the enrichment of the genes in the gold standard was assessed with GSEA (Subramanian et al., 
2005b). As we can see in Figure IV-8, the contribution of functional screens is greater than the one 
of any other feature, but all features contribute to the performance.  
 
 
Performance comparison with other methods  
I compared the capabilities of Helios against the state of the art algorithms GISTIC2 (Mermel et 
al., 2011) , Gaia (Morganella et al., 2011) and DiNAMIC (Walter et al., 2011)  (Table IV-1). GISTIC2 
identified 30 peaks containing 452 genes (TCGA, 2012), out of which 17 are annotated in the gold 
 
Figure IV-8 – Contribution of each feature to the Helios score 
GSEA enrichment of gold standard genes both in the final run and in runs where each individual data 




standard, yielding a hypergeometric enrichment of 1.2E-3.  16 of the 83 top Helios genes for each 
of the 83 amplified regions discovered by ISAR are annotated, leading to enrichment p-value of 
4.71E-12. The capability of the Helios score to discriminate drivers becomes even more evident if 
I further select only the 64 genes with a Helios score greater than 0.5, yielding a hypergeometric 
enrichment of 8.16e-14. The other two recently published methods tested, Gaia and DiNAMIC, 
achieved poor specificity compared to Helios, as reflected by their enrichment p-value: 7.7E-2 and 






Chapter V – RSF-1, a novel driver of 
Invasion and Metastasis in Breast 
Cancer 
RSF-1 Promotes Colony Growth In Vitro 
Among the 11 candidates that demonstrated anchorage independent growth in vitro, RSF-1 is 
an especially compelling putative cancer driver because it is recurrently amplified in several 
cancers (Chen et al., 2011; Fang et al., 2011; Hu et al., 2012; Li et al., 2012; Liang et al., 2012; Lin 
et al., 2012; Liu et al., 2012; Shih Ie et al., 2005).  Additionally, an amplicon containing RSF-1 was 
recently associated with a breast cancer subtype bearing one of the worst clinical prognoses (Curtis 
et al., 2012). Although high expression levels of RSF-1 has been associated with poor prognosis 
in several malignancies (Hu et al., 2012; Li et al., 2012; Liu et al., 2012; Tai et al., 2012), its 
involvement in breast cancer pathogenesis and tumorigenic mechanism remain unclear. Therefore, 
we chose to follow-up our analysis of RSF-1 with further in-vitro and in-vivo experiments.  
To extend our studies to different genetic backgrounds in addition to MCF10A , we selected two 
cell lines that were diploid for RSF-1 (MDA-MB-415 and MDA-MB-361) and one with amplified and 
over-expressed RSF-1 (MDA-MB-453).  MDA-MB-415 and MDA-MB-361 cell lines were 
engineered to overexpress RSF-1 and were subsequently tested using the colony formation assay 
in agar. As observed for MCF-10A cells, overexpression of RSF-1 increased the ability to form 
colonies in semisolid media in both MDA-MB-415 and MDA-MB-361 cells (Figure V-1A).  
To assay oncogene addiction with RSF-1, we selected two doxycycline (Dox) inducible shRNA-
mirs that efficiently silenced RSF-1 and assayed colony formation of MDA-MB-453 in agar following 
knockdown of RSF-1.  As expected, silencing of RSF-1 significantly reduced the number of colonies 
formed (Figure V-1B). Notably, only minor effects were observed when RSF-1 was silenced in a 
MCF-10A variant in which the RSF-1 region was not amplified. These experiments provide 





RSF-1 Promotes Growth in Xenograft Models 
Next, we conducted experiments to assay the role of RSF-1 over-expression in breast cancer 
cells in vivo. Three different mammary epithelial cell lines, the human MCF-10A, a MCF-10A variant 
sensitized to transformation called here MCF-10A-TM (MCF-10A-Triple Modified (Pires et al., 
2013)) and the mouse Comma-ID (C-ID), all lacking RSF-1 amplification, were orthotopically 
transplanted in the fat pad of immunocompromised mice (SCID) with and without an RSF-1 over-
expression vector. We then tracked the development of tumors and compared growth between 
controls and those over-expressing RSF-1.   
MCF-10A cells are not tumorigenic, and overexpression of RSF-1 did not transform them. While 
some transplanted MCF-10A-TM cells remained in the fat pad, these did not produce tumor. 
However MCF-10A-TM overexpressing RSF-1 was able to establish small primary tumor 
outgrowths (Figure V-2A). C-ID is a mouse mammary epithelial cell line that has the unique ability 
to regenerate the mammary epithelial tree due to the presence of stem cells (Campbell et al., 1988; 
 
Figure V-1 – RSF1 in vitro validation 
(A) Overexpression of RSF-1 in multiple cell lines enhances it ability to form colonies in agar. (B) 
downregulation of RSF-1 using dox inducible shRNAs in a cell line with amplification of the locus 




Danielson et al., 1989; Jerry et al., 1994). When transplanted in syngenic mice, C-ID cells generate 
hyperplastic lesions that can eventually form tumors. When we transplanted C-ID overexpressing 
RSF-1 cells in SCID mice these cells generated palpable masses as early as 2 weeks after 
transplantation—significantly earlier than control mice, which lacked detectable tumor burden after 
1 month. (P=0.0001)  (Figure V-2B).  
We also transplanted RSF-1 amplified MDA-MB-453 cells and an MDA-MB-453 variant bearing 
a doxycycline inducible RSF-1-ShRNA into the fat pad of our mouse model. As expected, in the 
absence of Dox all MDA-MB-453 variants generated tumors that grew at a comparable rate. 
However, supplementing the mice with Dox rapidly induced regression specifically in the tumors 
carrying the RSF-1 shRNA (Figure V-2C).  This data provides evidence that RSF-1 can contribute 
to tumor progression in vivo. 
 
Figure V-2 – RSF1 in vivo validation 
Overexpression of RSF-1 in (A) MCF10ATM and (B) CID cells enhanced their tumorigenic potential in 
vivo. The MCF10ATM model generated small tumor masses, thus H&E images are also provided. (C) 
Silencing of RSF-1 in MDAMB453 attenuated its tumorigenic potential. In A, B and C cells were 




RSF-1 Promotes invasion in Xenograft Models 
To further characterize the role of RSF-1 in breast cancer, we analyzed the TCGA gene 
expression data and identified gene-expression programs associated with RSF-1 expression levels 
((Akavia et al., 2011; Danussi et al., 2013), (see Methods). Genes associated with RSF-1 in this 
procedure are putative downstream targets of RSF-1 activity.  We identified signatures of genes 
predicted to be up-regulated by RSF-1 activity in the context of both the basal and the luminal 
subtype. To characterize these signatures, we assessed their overlap with previously published 
gene-set annotations in the MSigDB database (Subramanian et al., 2005a). Genes predicted to be 
 
Figure V-3 – RSF1 signature in primary tumors 
The analysis of overexpressed genes related to RSF-1 overexpression in basal (A) and luminal (B) primary 
tumors revealed a signature enriched for invasiveness, migration and dedifferentiation. Interestingly, the 
analysis of downregulated genes was enriched for genes involved in cellular metabolism both in basal (A) 




upregulated by RSF-1 in both the basal and the luminal subtype were enriched for gene sets 
involved in invasion, metastasis, and de-differentiation (Figure V-3).  
Prompted by the above, we hypothesized that overexpression of RSF-1 will promote 
metastases formation in-vivo. To test this, we performed intravenous tail injection of MCF-10A-TM 
cells expressing a luciferase reporter into SCID mice. When breast cancer cells are injected 
intravenously in the tail of recipient mice, the cells travel through the circulatory system and are 
deposited in the lungs, where the majority of the cells die due to the absence of a supportive 
microenvironment (Yang et al., 2012).  Both control and RSF-1 overexpressing cells were rapidly 
cleared and no signal was detected one week after the injection. Importantly, while the luciferase 
signal was never recovered in mice injected with control cells, mice injected with cells 
overexpressing RSF-1 showed luciferase signal located in the lungs 4-5 weeks after the injection 
of the cells. For over 7 weeks following injection, all the mice injected with cells overexpressing 
 
 
Figure V-4 – RSF1 metastasis assay 
MCF10ATM cells expressing a luciferase reporter were injected intravenously in the tail of recipient mice. 
These cells travel through the circulatory system and are deposited in the lungs and quickly cleared. 
Overexpression of RSF-1 allows them to survive and established metastases. H&E of sectioned lungs 
from mice injected with control and RSF-1 overxpressing cells is also shown. The arrows indicate the 




RSF-1 showed luciferase signal in the lungs indicating the formation of lung metastases (Figure 
V-4). This demonstrates that RSF-1 over-expression promotes increased invasive capacity in the 
lungs and therefore a pro-metastatic state in breast cancer cells. 
RSF-1 and CCND1 significantly co-occur and are independent 
predictors of survival  
The association with the pro-metastatic phenotype and the tail injection assay can help shed 
additional light on iCluster2, a novel molecular subtype identified by Curtis et. al (Curtis et al., 2012) 
bearing significantly worse long term prognosis than all of the other subtypes (overall 5-year 
survival probability below 0.4). This subtype is characterized by the alteration of 2 genomic regions, 
one containing RSF-1 and one containing CCND1, a well-known oncogene known to be associated 
with poor survival in ER+ tumors (Elsheikh et al., 2008) .  
Interestingly, RSF-1 resides on chromosome 11, only 7.9 Mb away from CCND1 and we thought 
these might be co-amplified in a single event, simply due to their proximity. . We visually inspected 
this region and found a very striking pattern: CCND1 and RSF-1 were consistently located in distinct 
amplicons (See Figure V-5). However, these amplifications tended to co-occur in the same samples 
more often than would be expected by chance (Fisher Exact Test P = 2.2e-16), or any other pair 
of amplicons in the genome (Figure V-7). Analysis of allelic copy ratios of these two alterations 
failed to suggest one event as a precursor to the other. Rather, the two events are statistically more 
likely to be subclonal in the same patients than expected by chance (see Methods section,Table 
V-1).   
Although other subtypes were also characterized by CCND1 alteration (iCluster6 and iCluster7), 
iCluster2 in which both the RSF1 and CCND1 loci were amplified displayed significantly worse 
prognosis (Curtis et al., 2012). The identification of RSF-1 as an oncogene in this region that 
confers anchorage-independent growth and metastasis capabilities provides an explanation for the 















































































































































































We used a modified version of Multi-Reg (Danussi, Akavia et al, Cancer Research 2013) to 
identify potential targets of RSF1. We ran Multi-Reg once on the Basal samples and once on the 
Luminal samples. For each sample type, we unified all modules generated by Multi-Reg that were 
associated with RSF1 into two modules - genes induced and genes repressed by RSF1 (Figure 
V-6). All other parameters of Multi-Reg were as described in the original article. 
We downloaded the C2 subcomponent of the MSigDB signature database version 3.1 from 
http://www.broadinstitute.org/gsea/msigdb/index.jsp on May 9th, 2013 (Subramanian, Tamayo, et 
 
Figure V-6 – RSF1 expression signatures 
 (A) The analysis of the overexpression changes related to RSF1 overexpression in luminal primary tumors 
revealed a signature enriched for invasiveness, migration, EMT and stem cell. (B-C) The analysis of the 
underexpression related to RSF1 overexpression in luminal (B) and basal (C) primary tumors reveals 




al. 2005, PNAS 102, 15545-15550). We ran hypergeometric enrichment using the Genatomy 
software (see Figure V-3,Figure V-6). 
Alteration co-occurrence 
To identify epistatic interactions we computed the statistical significance of the co-occurrence 
of alterations among detected regions. Copy number data was binarized (copy number threshold 
0.5) and the p-value of the co-occurrence of alterations was assessed using the hypergeometric 
function.  The computed p-value was corrected for multiple testing using Bonferroni. 
If two regions are located in the same chromosome, the existence of single alterations that span 
both regions needs to be taken into account for the analysis. These alterations can induce high 
correlation between copy number profiles of the regions just due to the genomic structure instead 
of the biological association of the mutations. We use the Ziggurat Deconstruction algorithm 
implemented by GISTIC2 (Mermel et al., 2011) to decompose the copy number profile of each 
sample into the most likely set of events. Once the genomic events are defined, we discard samples 
where both regions are altered due to a single event as this would strongly bias the results. Figure 
V-7 shows the results of this analysis.  
Clonality analysis of RSF1 and CCND1 
We downloaded level 2 (allelic copy-number levels) and level 3 (segmentation files) data from 
SNP6 array measurements of the 58 TCGA samples  with log transformed copy number estimates 
for both CCND1 and RSF1 above 0.5. We ran HapSeg (Carter et al., 2011) using phased 
haplotypes from downloaded from the BEAGLE website 
(http://bochet.gcc.biostat.washington.edu/beagle/1000_Genomes.phase1_release_v3) on 
6/4/2013 with the parameters: 
genome.build <- 'hg19', platform <-  'SNP_6.0', use.pop <- 'CEPH', impute.gt<-F, plot.segfit<-T, 
merge.small <- TRUE, merge.close <- TRUE, min.seg.size <- 5, normal <- FALSE, out.p <- 0.001, 





and obtained results consistent with amplification of both CCND1 and RSF1 in 35 of these 
samples. We then ran ABSOLUTE (Carter et al., 2012)  on these 35 samples with the parameter 
settings: 
genome <- "hg19", platform <- "SNP_6.0",  primary.disease <- 'BRCA', sigma.p <- 0, 
max.sigma.h <- 0.02, min.ploidy <- 0.95, max.ploidy <- 6, max.as.seg.count <- 1500, 
max.non.clonal <- 0, max.neg.genome <- 0, copy_num_type <- "allelic"  
 
Following manual curation of the solution space as described 
(http://www.broadinstitute.org/cancer/cga/sites/default/files/data/tools/absolute/ABSOLUTE%20tr
aining.pptx) we obtained inferences of the clonality of the 2 amplifications in each sample. We 
obtained the contingency table for the clonality status of RSF1 and CCND1 shown in Table V-1 
consistent with a 2-tailed fisher exact test P-value of .012 for the hypothesis that the clonality status 








RSF1 Subclonal 9 5 
RSF1 Clonal 4 17 
 
Table V-1 – Clonality analysis of RSF1 and CCND1.  






































































































Chapter VI – Computational analysis of 
the landscape of deletions of Breast 
Cancer for the identification of drivers 
of resistance to anoikis 
 
To successfully metastasize, cancer cells must be able to survive detachment and thrive in 
inappropriate ECM environments (Gilmore, 2005; Kim et al., 2012; Taddei et al., 2012). Thus, 
elucidating genes that modulate the anoikis response are critical to understanding cancer 
progression. This chapter focuses on the analysis of the landscape of copy number alterations of 
breast cancer for the identification of drivers of resistance to anoikis. 
I tackle this challenge by combining a genome-wide RNAi screen designed to uncover genes 
that positively modulate anoikis with the analysis of the deletion landscape of a large cohort of 




Figure VI-1 –Genetics-genomics strategy 
Graphic representation of the genetics-genomics strategy described in the text. SCNA data from primary 
tumors is used to identify regions of recurrent deletions. Within those regions we select those genes whose 




The success of this simple strategy exemplifies the power of integrating observational and 
perturbational data in cancer research. The benefits of integrating functional screens with primary 
tumor data are three-fold. First, by imposing an additional filter to the RNAi assay I ameliorate the 
false positive rate that characterizes pooled genome-wide functional screens. Second, by selecting 
candidates from primary tumors I prioritize genes that have clinical relevance. Third, the functional 
data allows me to associate a phenotype, in this case aniokis, with the genetic data.  
ISAR-DEL analysis 
I used ISAR-DEL to analyze the deletion landscape of 785 breast cancer samples collected by 
the TCGA project using Affymetrix 6.0 SNP arrays(TCGA, 2012). ISAR-DEL was executed using 
the same parameters as in Chapter IV and delbin=1 (no approximation for gene size). ISAR-DEL 
identified 52 regions of alteration (Supplementary Table 3), containing 635 genes with an average 
of 12.21 genes per region. Several bona-fide tumor suppressors such as CDK2NA, PTEN, BRCA1, 
CREBBP, FOXO3, RB1 and MAPK4K were located in these regions. Compared to the 4 hours that 
ISAR needed to analyze the data, ISAR-DEL had a total execution time of 11 hours in a laptop 
equipped with an Intel i7-2620M 2.7GHz processor and 8 GB of RAM. 
To assess the performance improvement of ISAR-DEL over ISAR we selected those genes 
whose enhanced gene S-score was both larger than the threshold and the ISAR’s marker-based 
S-score. Surprisingly, only four genes that comply with these criteria (Table VI-1). Even more 
surprisingly, three of these genes are bona fide tumor suppressors (MAP2K4, RB1, PTEN) while 









MAP2K4 17 65 21024 21514 14.47 14.65 
RB1 13 198 16029 16997 7.63 11.02 
PTEN 10 209 7674 8527 8.76 10.80 
BIN3 8 35 23289 23518 7.30 8.07 
 
Table VI-1 – ISAR-DEL improvement.  






the fourth gene, BIN3, was confirmed as a novel epithelial tumor suppressor gene as I will describe 
in Chapter VII.  
All of these four genes had the most significant S-score in their respective regions once the 
enhanced gene S-score was considered. Figure VI-2 shows the results of applying the algorithm 
to the 10q23 region.  Although considering single markers PTEN is the most altered gene in the 
region, the difference with the second most altered gene, KILLIN, is quite small. Indeed, GISTIC2 
is unable to distinguish which of the two genes is the target of the region and both genes are 
selected in the peak region. However, when all the alterations harbored by each gene are 
considered, the difference between the S-score of the two genes increases dramatically as we can 
see in Figure VI-2.  
 
In the 13q14 region if the best marker is considered RCBTB2 is the top scoring gene but once 
all alterations harbored by each gene are considered, the well-known tumor suppressor RB1 clearly 




Figure VI-2 – ISAR-DEL analysis for the 10q23 region 
ISAR S-score and ISAR-DEL S-score for the genes in the 10q23 SCNA region. The S-score improves 
once all deletions harbored by each gene are considered (gene S-score delta) clearly pinpoints PTEN as 





BIN3 is located on the chromosomal region 8p21.3, one of the most frequently lost regions in 
epithelial cancers and that is thought to contain several tumor suppressors (Cooke et al., 2008; 
Xue et al., 2012). Similarly to the case of RB1, BIN3 only becomes the most significantly altered 
gene once the enhanced gene S-score is considered (Figure VI-4).GISTIC2, the state of the art 
algorithm for the identification of regions of recurrent SCNA used by the TCGA, also provides the 
option of calculating a gene-based score based on all the alterations that target a gene. GISTIC2 
detects regions containing the four genes with RB1, PTEN and MAP2K4 as top of their regions. 
However, BIN3 is selected a part of a large deletion covering the span of 15 Mbp (chr8:20154149-
35523298), where it is the 64th candidate (TCGA, 2012).   Hence the sensitivity of ISAR-del was 
crucial in identifying BIN3 as a potential tumor suppressor from primary samples. 
Although the analysis obtained by ISAR-DEL suggests that BIN3 is the most likely tumor 
suppressor in the region, the evidence provided by the SCNA analysis is not definitive. First, the 
difference in score with the second most altered gene in the region, PEBP4, is not compelling 
enough to discard BIN3 as a passenger of a driver alteration in PEPB4. Second, the 8p21.3 region 
could altogether be recurrently altered not due to the presence of a driver but to it possibly being a 
 
Figure VI-3 – ISAR-DEL analysis for the 13q14 region 
ISAR S-score and ISAR-DEL S-score for the genes in the 13q14 SCNA region. The S-score improves 
once all deletions harbored by each gene are considered (gene S-score delta) clearly pinpoints RB1 as 




common fragile site. For example, large genes such as WWOX or GRID2 are recurrently deleted 
but their alteration does not contribute to tumor fitness (Zack et al., 2013). In the following section 
I will show how the integration with a shRNA screen provided functional evidence of the role of 
BIN3 as a tumor suppressor. 
 
 
Integration with Anoikis screen 
In order to identify novel tumor suppressors that influence anoikis response, we performed a 
shRNA screen designed to uncover genes that positively modulate anoikis. A pooled lentiviral 
library of 58,493 unique shRNA-mirs (Silva et al., 2005) targeting 18652 known human genes was 
used to transduce human mammary epithelial cells that were engineered to model triple negative 
breast cancers (Pires et al., 2013). We used a variant of the non-transformed cell line, MCF-10A; 
a human mammary epithelial cell line that has been classically used as model to study anoikis 
 
Figure VI-4 – ISAR-DEL analysis for the 8p21 region 
ISAR S-score and ISAR-DEL S-score for the genes in the 8p21 SCNA region. The S-score improves once 
all deletions harbored by each gene are considered (gene S-score delta) deems BIN3 as the most likely 




(Collins et al., 2005; Marani et al., 2004; Wen et al., 2011). In this manuscript, we will call this 
variant MCF-10A-Triple Modified (MCF-10A-TM). MCF-10A-TM cells transduced with the shRNA-
mir library were exposed to three rounds of anoikis. In each round cells were plated in low-
attachment plates for 5 days, after which the surviving cells were recovered and plated in normal 
culture conditions for a week. 
Next, we identified the shRNAs that were enriched in the surviving anoikis resistant cells by 
using customized microarrays, as we have previously described (Silva et al., 2008). Not 
surprisingly, David pathway analysis revealed that the most enriched shRNAs (4FC and FDR<0.1) 
were shRNAs that targeted genes involved in intrinsic and extrinsic apoptotic signaling (Table VI-2). 
In fact, Capase-8 was the top hit in our screen.  
The anoikis screen resulted in a very large number of enriched shRNAs that implicate their 
cognate gene as potentially important in anoikis. To filter this list and identify potential tumor 
suppressor genes we selected those genes in the regions of recurrent deletion identified by ISAR-
DEL. BIN3 ranked 553 out of the 617 genes that were deemed significant in the screen. However, 
not only was the most significantly altered gene in its region, it was also the gene with the top S-


























cellular process 1.71E-05 336 10729 0.00226 
positive regulation of biological process 2.78E-04 101 2597 0.01801 
cation transport 5.47E-04 29 532 0.01801 
apoptosis 0.00101 31 606 0.01801 
reproductive process 0.00102 43 935 0.01801 
positive regulation of cellular process 0.00107 90 2349 0.01801 
toll-like receptor 4 signaling pathway 0.00131 8 76 0.01801 
Toll signaling pathway 0.00131 8 76 0.01801 
programmed cell death 0.00135 31 617 0.01801 
cell death 0.00136 36 753 0.01801 
death 0.00156 36 759 0.01878 
toll-like receptor 3 signaling pathway 0.00190 7 63 0.01924 
metal ion transport 0.00228 24 452 0.01924 
MyD88-independent toll-like receptor signaling pathway 0.00228 7 65 0.01924 
positive regulation of cellular metabolic process 0.00238 48 1122 0.01924 
protein metabolic process 0.00243 100 2732 0.01924 
toll-like receptor signaling pathway 0.00290 8 86 0.01924 
ion transport 0.00310 37 819 0.01924 
toll-like receptor 2 signaling pathway 0.00322 7 69 0.01924 
toll-like receptor 1 signaling pathway 0.00322 7 69 0.01924 
positive regulation of metabolic process 0.00324 50 1199 0.01924 
peptidyl-serine modification 0.00329 6 52 0.01924 
immune response-activating signal transduction 0.00335 12 171 0.01924 
pattern recognition receptor signaling pathway 0.00384 8 90 0.02030 
immune response-regulating signaling pathway 0.00385 12 174 0.0203 
innate immune response-activating signal transduction 0.00440 8 92 0.0203 
MyD88-dependent toll-like receptor signaling pathway 0.00442 7 73 0.0203 
negative regulation of intracellular protein transport 0.00454 5 39 0.0203 
polysaccharide metabolic process 0.00465 9 113 0.0203 
cellular response to abiotic stimulus 0.00476 7 74 0.0203 
cell-matrix adhesion 0.00476 7 74 0.0203 
activation of innate immune response 0.00501 8 94 0.02068 
negative regulation of protein metabolic process 0.00531 15 252 0.02126 
negative regulation of intracellular transport 0.00626 5 42 0.02424 
regulation of protein localization 0.00642 14 233 0.02424 
 
Table VI-2 – Biological enrichments in shRNA anoikis screen.  
Hypergeometric enrichment of GO biological functions of the genes selected by the anoikis screen. The rable 





Chapter VII – BIN3 is a novel 8p21 tumor 
suppressor gene that regulates the 
attachment checkpoint in epithelial cells 
 
In the previous chapter I described how I identified BIN3 as putatite tumor suppressor and driver 
of anoikis in breast cancer. This genes is located on the chromosomal region 8p21.3, one of the 
most frequently lost regions in epithelial cancers and that is thought to contain several tumor 
suppressors(Cooke et al., 2008; Xue et al., 2012). Specific analysis of the CNV for BIN3 in The 
Cancer Genome Atlas (TCGA) data sets (http://cancergenome.nih.gov/) shows that there is 
about 50% heterozygous (Ht) and homozygous (Ho) loss of the BIN3 locus in ovarian and breast 
cancers (Figure VII-2A). Next, we focused our studies on breast cancers and analyzed two data 
sets (TCGA (Cancer Genome Atlas, 2012) and METABRIC (Curtis et al., 2012) ); together these 
two data sets contained clinical and molecular information for about 3,000 breast primary tumors. 
These studies showed that BIN3 expression is strongly driven by CNV (Figure VII-1) and that loss 
of BIN3 gene is associated with poor prognosis characteristics, such as high pathological grade, 
high stage, and increased probability of lymph node infiltration (Figure VII-2B-C). BIN3 is lost at 
comparable levels in the most relevant breast cancer clinical subtypes (hormone receptor positive 
 
Figure VII-1 – Association between BIN3 copy number and expression  
Loss of the BIN3 locus strongly correlates with reduced expression of BIN3 mRNA in two different primary 
breast cancers datasets (Metabric and TCGA). Statistical significance of the association is computed using 




(HR+), triple negative (TNT), and HER2+). Importantly, loss of BIN3 has a significant impact on the 






Figure VII-2 – Association of BIN3 with clinical variables  
(A) Percentage of BIN3 deletion in human cancers (data from TCGA). (B) Association of BIN3 copy number 
and expression with clinical grade and stage. Statistical significance of the association with expression is 
computed using ANOVA while association with copy number is computed using the chi-square statistic   
(C) Association of BIN3 copy number status with lymph node metastases. Statistical significance estimated 
using the chi-square statistic (D) Association of BIN3 copy number and expression status with clinical 
survival (E) Association of BIN3 copy number status with clinical survival in clinical subtypes of breast 





Silencing of BIN3 promotes tumorigenesis 
All the above suggests BIN3 as putative tumor suppressor in breast cancers; consequently, we 
decided to individually validate the impact of its loss during tumorigenesis. First, we selected a 
series of shRNAs targeting BIN3. This series included shRNAs that were enriched in our pooled 
screen (shRNA#4) as well as new ones (Figure VII-3A). This series was used to knock down BIN3 
in MCF-10A-TM cells. As expected, efficient silencing of BIN3 increased cell survival when 
attachment was prevented as demonstrated by the quantification of the absolute number of 
surviving cells (Figure VII-3B) as well as by anoikis competition assay (Figure VII-3C). Additionally, 
 
Figure VII-3 – Silencing of BIN3 promotes tumorigenesis in vitro 
(A) Characterization of a series of shRNAs targeting BIN3. Silencing of BIN3 promotes resistance of MCF-
10A-TM cells to detachment as shown by (B) total cell number and (C) competition assays. Silencing of 
BIN3 in MCF-10A-TM cells enhances (D) their ability to form colonies in agar. In all panels the red asterisk 




knock-down of BIN3 also enhanced the ability of MCF-10A-TM cells to form colonies in semisolid 
media (Figure VII-3D).  
Next, we transitioned our studies in vivo. When breast cancer cells are injected intravenously 
into the tails of recipient mice, the cells travel through the circulatory system and are deposited in 
the lungs. There, the majority of the cells die due to the lack of proper microenvironment, including 
lack of proper ECM attachment. We engineered MCF-10A-TM-Control and -BIN3 knock-down cells 
to express a luciferase reporter gene and followed the fate of these cell lines after intravenous tail 
injection into SCID mice. Control cells rapidly cleared within ∼24 hours, while the knockdown of 
BIN3 allowed the cells to survive for a significantly longer period of time (Figure VII-4A). Despite 
having a survival advantage, MCF-10A-TM-BIN3 knocked down cells were not tumorigenic and 
were unable to form lung metastases. Thus, we turned our experiments to MDA-MB-231 cells; a 
breast cancer cell line that does not present deletion of the BIN3 locus, expresses BIN3 protein 
(Figure VII-4B), and is well known to be able to form metastasis(Minn et al., 2005). Similarly to 
MCF-10A-TM cells, MDA-MB-231 cells were engineered with luciferase and injected intravenously 
into the tails of recipient mice. The cells transported to the lung and quickly cleared. However, in 
control cells, lung metastases were detectable about four weeks after injection. Importantly, 
silencing BIN3 in MDA-MB-231 cells enhanced lung metastases formation and we were able to 
detect luciferase signal in the lungs as soon as one week after injection (Figure VII-4B). As 
expected, after sacrificing the mice, we noted the presence of significantly more metastatic colonies 
in the lungs of the mice that had BIN3 knock-down cells injected. Since loss of BIN3 was detected 
in our genomic studies in primary human tumors, we assessed the effect of BIN3 loss on tumor 
growth. Thus, we orthotopically transplanted MDA-MB-231 cells into the mammary fatpads of SCID 
mice and followed the growth of the tumors. These experiments showed that BIN3 knock-down 
cells generated significantly bigger tumors than wild type counterparts (Figure VII-4C). 














Figure VII-4 – Silencing of BIN3 promotes tumorigenesis in vivo 
(A) Silencing of BIN3 in MCF-10A-TM cells enhances their survival after tail vein injection in SCID mice. 
Silencing of BIN3 in MDA-MB-231 enhances (D) its ability to form lung metastases after vein tail injection 
and (C) growth of primary tumors after orthotopictransplantation in the mammary fat pad of SCID mice. In 




Restoration of BIN3 attenuates tumorigenesis 
To further demonstrate the role of BIN3 in modulating the response to anoikis and tumor 
suppression, we restored BIN3 expression in breast cancer cells with homozygous deletion of the 
BIN3 locus. We took advantage of a large collection of cancer cell lines with publically available 
CNV and expression microarray data (Barretina et al., 2012b). In this collection, out of 38 breast 
cancer cell lines analyzed, 15 (39.5%) had heterozygous deletion of the BIN3 locus, while 3 (7.9%) 
had homozygous deletion (Figure VII-5A). Competitive PCR using oligos for the BIN3 and the β-
ACTIN genomic loci confirmed the homozygous loss that was detected by the microarray in two 
selected cell lines, HCC-38 and HCC-70 (Figure VII-5B). As expected, BIN3 protein was 
undetectable in these cells (Figure VII-5C). 
Restoration of BIN3 expression in HCC-38 and HCC-70 by lentiviral delivery of a cDNA 
construct enhanced the sensitivity to detachment (Figure VII-5D-E) and reduced the ability of these 
cell lines to form colonies in semisolid media (Figure VII-5F).  
Finally, we intravenously injected HCC-38 variant cells expressing luciferase into the tails of 
recipient mice. Here, cells re-expressing BIN3 protein were cleared from the lungs significantly 
faster that control counterparts (Figure VII-6A). Unfortunately, parental cells were unable to 
generate lung metastasis, which prevented us from studying the impact of BIN3 restoration in 
colonization and metastases in this organ. Notably, re-expression of BIN3 in both HCC-38 and 
HCC-70 cells reduced primary tumor formation and growth when these cell lines were transplanted 
orthotopically (Figure VII-4B). Interestingly, re-expression BIN3 did not affect the growth of these 






Figure VII-5 – BIN3 restoration reduces survival during anoikis in vitro and colony formation in agar 
(A) The upper panel shows the CNV and the expression data for BIN3 in seven breast cancer cell lines 
(cell lines with homozygous deletions (Ho) are indicated in red). The lower panel shows the length of the 
deletion in HCC-70 and HCC-38. (B) Competitive genomic PCR validating the Ho deletions of the BIN3 
locus in HCC-70 and HCC-38. (C) Western blots demonstrating the absence of BIN3 protein expression 
in cell lines with Ho deletions. Restoration of BIN3 expression reduces cell survival during anoikis as shown 
by (D) competition assay and (E) total number of cells. (F) Restoration of BIN3 expression reduces the 







Figure VII-6 – BIN3 restoration reduces migration and growth capabilities in vivo 
(A) Restoration of BIN3 expression reduces the ability of breast cancer cells to survive after tail vein 
injection in SCID mice, and (B) to grow primary tumors after orthotopic transplantation in the mammary 




Molecular mechanism of BIN3’s role as tumor suppressor 
Our genetic data demonstrated the role of BIN3 as tumor suppressor. Next, we explored the 
mechanism that underlies the function of BIN3. We utilized the reverse phase protein array data 
(RPPA) available from the TCGA breast cancer data set and we used the cBioPortal software and 
its analytical tools for these analyses(Cerami et al., 2012). These studies provided quantitative 
information regarding the protein expression levels and phosphorylation status of ~200 proteins. 
Here, we found that BIN3 loss (Ho and Ht) was associated with tumors with enhanced translation, 
as exemplified by the significant association with higher levels of phosphorylation (inactivation) of 
the translation inhibitory factor EIF4EBP1 (Table VII-1) and with mutations in TP53 (Fisher's Exact 
Test p-value 0.5E-6). Importantly, in BIN3 deleted tumors, there were significantly lower levels of 
activation (phosphorylation) of MAPK14/P38-α protein. P38-α mitogen-activated protein kinase is 
a well-known stress response protein that modulates cell differentiation, apoptosis, and autophagy 
after exposure to different stress stimuli. Importantly, P38-α has been shown to be a positive 
modulator and regulator of the anoikis response by inducing the stabilization of the apoptosis 
facilitator BimEL(Rosen et al., 2002; Wen et al., 2011) .  
 
gene Residue Change p-value 
EIF4EBP1 pS65 Increased 9.63E-06 
EIF4EBP1 pT170 Increased 8.64E-05 
MAPK14 pT180 Decreased 7.77E-04 
EIF4EBP1 pT37 Increased 1.00E-03 
CCKN1B pT157 Increased 1.00E-03 
PRKAA1  Decreased 1.55E-06 
CASP8  Decreased 4.03E-05 
TP53  Increased 1.93E-04 
MSH6  Increased 3.22E-04 
ATM  Decreased 7.48E-04 
 
Table VII-1 – Proteins associated with BIN3  





To validate the involvement of BIN3 in the activation of P38-α we compared the phosphorylation 
levels of P38-α in control and BIN3 knock-down cells during detachment. As previously shown, 
plating MCF-10A cells in low-attachment conditions induced strong phosphorylation of P38-α and 
increased the total levels of BimEL (Figure VII-7A). Remarkably, the expression of BIN3 was 
strongly upregulated upon detachment (Figure VII-7A). In contrast, BIN3 knock-down cells showed 
a very mild activation of P38-α and low accumulation of BimEL. Notably, there was also less 
activation of the p38-α /BimEL axis observed in BIN3 knock-down in the tumors generated by 
orthotopic transplantation of MDA-MB-231 cells (Figure VII-7B). Importantly, restoration of BIN3 
expression in cells with homozygous deletion of the locus increased the activation levels of p38-α 
upon detachment and increased the levels of BimEL in vitro (Figure VII-7C) and in primary tumors 
generated after orthotopic transplantation of these cells in the mammary fatpad of SCID mice 
(Figure VII-7D).   
BIN3 is a member of the BAR (Bin/amphiphysin/Rvs) adapter superfamily(Prendergast et al., 
2009). This domain mediates dimerization in to crescent shaped structures(Peter et al., 2004) that 
can bind curved membranes, small GTPases, and other proteins(Bhatia et al., 2009; Habermann, 
2004; Tarricone et al., 2001). These abilities put the BAR domain members at the center stage of 
transmitting cell signals by sensing structural changes in cell membranes. In particular, genetic and 
biochemical approaches have shown that the fission yeast ortholog of human BIN3 (hob3p) 
regulates the activity of the small GTPase cdc42p by forming a complex with guanine nucleotide 
exchange factor gef1p (Coll et al., 2007) . This regulation has been recently described to be 
conserved in mammals (Simionescu-Bankston et al., 2013). Since p38 is a known downstream 
effector of CDC42 during stress(Chan et al., 2008; Seo et al., 2004), including stress caused by 
the disruption of attachment(Bourdoulous et al., 1998), these data suggest a model in which BIN3 
is able to detect detachment due to its ability to sense changes in the structure of the cell 
membrane, then assist in the activation of CDC42 by bringing its GEF activator, which in turns 





Figure VII-7 – BIN3 effect in P38-α and BimEL 
Western blots showing that silencing BIN3 blocks the activation (phosphorylation) of P38-α and the 
induction of the apoptosis facilitator BimEL when (A) cells are exposed to anoikis in vitro (24 hours 
detached) and (B) during the growth of primary tumors in vivo. Western blots showing that restoration of 
BIN3 expression enhances the activation of P38-α and expression of BimEL (C) during anoikis in vitro and 
(D) during the growth of primary tumors in vivo. (E) Proposed model for the anoikis response in the 





To test our model we first studied the localization of these proteins upon detachment from the 
ECM. Cell fractionation experiments (Figure VII-9A) together with immunofluorescence studies 
(Figure VII-9B) showed that while cells are attached BIN3, TUBA (the human homolog of gef1p), 
and CDC42 are found independently in the cytoplasm of attached cells. However, a significant 
fraction of these proteins colocalized at the cell membrane when attachment was prevented. 
Remarkably, the total levels of BIN3, TUBA and CDC42 proteins also increased in detached cells 
and this increase was attenuated in BIN3-knock-down cells suggesting that formation of the 
proposed complex also stabilizes the proteins. One important remaining question is whether 
upregulation of BIN3 by itself was able to induced apoptosis independently of attachment. 
Interestingly, re-expression of BIN3 in HCC-38 (Figure VII-8B) did not have any effect on the cell 
growth of attached cells indicating that the effect of BIN3 is dependent on cell detachment. 
    Next we performed immunoprecipitation (IP) of V5-tagged-BIN3 in MCF-10A-TM cells to 
demonstrate that in mammary epithelial cells BIN3 and TUBA are easily detected by co-IP after 
cell detachment (Figure VII-9C) which demonstrates that they form a complex. We were not able 
to Co-IP endogenous CDC-42 together with BIN3-V5. This result is not surprising as it has been 
shown in yeast that the most stable interaction occurs between BIN3 and GEF1 homologs while 
the presence of CDC42 in the complex seems more unstable (Coll et al., 2007).  Importantly, in 
 
Figure VII-8 – BIN3 expression does not modify the growth of cells in culture. 
Growth curve studies showing that in tissue culture (a) silencing of BIN3 does not modify the growth of 




BIN3 knocked down cells, TUBA relocation to the cell membrane was significantly reduced (Figure 
VII-9D).  
Finally, we study the activation level of CDC42 (CDC42 bound to GTP) after cells are exposed 
to anoikis conditions. These studies showed that while CDC42 is activated during detachment the 
absence of BIN3 prevented its activation (Figure VII-9E). 
Thus, we reasoned that if CDC42 function was compromised during detachment by the absence 
of BIN3, then experimental activation of CDC42 should restore the anoikis response. In fact, this 
was the case and addition of Rho activator-I (R.A.), a compound that activate Rho family members 
including CDC42, was able to restore the activation of P38-α and reverse the resistance to anoikis 
of MCF-10A-TM Bin3 knock-down cells (Figure VII-10A). To complete our studies, we used a 
specific inhibitor of CDC42 (ML-141). Treating MCF-10A-TM with this compound significantly 
inhibited both the activation of P38-α and the loss of cell viability induced when parental cells were 
exposed to detachment (Figure VII-10B). 
In this chapter I describe novel molecular explanation of how epithelial cells sense detachment 
from a substrate and activate a stress pathway that leads to apoptosis. Importantly, we do so by 
providing for the first time, functional and mechanistic evidence of the tumor suppressor role of 
BIN3.  
How does BIN3 exert its tumor suppressor function in epithelial cells? BIN3 belongs to the 
superfamily of BAR adapter proteins. The crystal structures of the Arpfaptin-2 and Amphiphysin 
BAR domains have shown that BAR proteins dimerize at coiled-coil structural motifs to form 
banana-shaped dimers(Peter et al., 2004; Tarricone et al., 2001). These dimers have been shown 
to bind to small GTPases and lipid membranes. Importantly, BAR proteins are able to sense 
changes in membrane curvature by using their positively charge extremities and the presence of 
internal amphipathic motifs(Bhatia et al., 2009; Peter et al., 2004). Upon detachment from the ECM, 
epithelial cells lose polarization and change their shape to more spherical forms termed “rounding”. 
Cell rounding has been found to be an important inducer of cell death independently of integrin 
signaling(Chen et al., 1997). 
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Figure VII-9 – BIN3, CDC42 and TUBA localization in attachment and anoikis 
(A) Cell fractionation and (B) Immunofluorescence (IF) studies showing the independent cytoplasmic 
localization of BIN3, CDC42, and TUBA when cells are attached and show that a significant fraction of 
these proteins colocalize at the cell membrane when cells are exposed to anoikis. In the IF panel additional 
3D projection and intensity profile information of the channels is provided for cells in anoikis. The white 
arrow in the 3D image indicates the direction of the intensity profile. (C) Immunoprecipitation (IP) studies 
showing that TUBA and BIN3 co-IP during anoikis. (D) Cell fractionation experiments showing reduced 
relocation of TUBA at the cell membrane after detachment in BIN3 knock down cells. The IF panel shows 
the location of TUBA during anoikis in parental and BIN3 knocked down cells (coexpressing a shRNA 
against BIN3 and GFP) co-cultured together. (E) CDC42 activation assay showing that CDC42 is activated 
(bound to GTP) upon exposure to anoikis conditions and that knock down of BIN3 abrogates this induction. 





However the molecular mechanism behind this is unknown. Based on our data, we propose a 
model in which the changes in cell membrane structure induced by loss of attachment are sensed 
by BIN3. BIN3 then moves to the cell membrane and modulates the relocation and function of 
CDC42 at the cell membrane. In these conditions, CDC42 transmits the signal that leads to the 
activation of the stress protein P38-α and programmed cell death mediated by accumulation of the 
apoptotic facilitator BimEL (Figure VII-10C). Our results present, for the first time, BIN3 as a novel 
Figure VII-10 – CDC42 effect in anoikis 
(A) Experimental activation of CDC42 by addition of a Rho activator to the culture media restores the 
sensitivity of BIN3 knockdown cells to anoikis conditions (left panel) and restores the phosphorylation 
levels of P38α. (B) Inhibition of CDC42 by adding the specific inhibitor ML141 increases the survival of 
cells in anoikis conditions and inhibits the phosphorylation of P38. (C) Proposed model for the activation 
of P38-α mediated the ability of BIN3 to bring together CDC42 and its activator TUBA. In all panels the red 




breast cancer tumors suppressor, provides molecular clues about how breast cancer cells sense 




Chapter VIII Identification of tumor 
vulnerabilities using shRNA screens 
Introduction 
Cancer is a collection of distinct genetic diseases united by common hallmarks such as 
sustained angiogenesis and limitless replicative potential (Luo et al., 2009). The acquisition of these 
oncogenic hallmarks, however, comes at a cost for tumors: the disruption of key cellular networks 
in cancer cells impairs their ability to react to certain perturbations. These tumor-specific 
vulnerabilities are vital for targeted cancer therapy, as they establish a therapeutic window to 
selectively kill cancer cells over normal cells.  
There are many types of lethalities associated with carcinogenesis, such as those related to 
processes of DNA damage (Ashworth, 2008) , glucose deprivation (Birsoy et al., 2014), oxidative 
stress (Chen et al.), proteotoxic stress (protein folding) (Trepel et al., 2010) and epigenetic 
perturbations (Rius and Lyko, 2012). Different tumors display different vulnerabilities and even 
within tumor types there is great variability of sensitivity to oncogenic lethalities (Heiser et al., 2011). 
It is therefore necessary to not only detect such lethalities, but to also identify the biomarkers that 
can predict which tumors will be susceptible to which treatment.  
Most tumor lethalities have been discovered by traditional reductionist biological research or by 
costly screens of large number of compounds. Unfortunately, there is no viable systematic method 
for the efficient identification of these Achilles heels. Given that the current therapeutic options are 
limited by the lack of drug targets (Collins and Workman, 2006), it is of the utmost importance to 
develop systematic methods for the identification of tumor lethalities. 
One potentially powerful unbiased tool for detecting tumor vulnerabilities is genome-wide pooled 
shRNA screens. These assays combine the power of high–throughput screening with RNAi 
techniques, facilitating the systematic assessment of essentiality of genes across cancer genomes. 
In a lentiviral vector-based pooled shRNA assay, an RNAi library is delivered to a cell population 




(Figure VIII-1A). The representation of each shRNA is compared between the initial transfection 
and a later time-point. If the shRNA poses a lethality, the representation is expected to significantly 
decay between the former and the later time-point. To detect shRNA abundance at each time-point 
a sequence barcode is used, where in some cases the barcode is the gene targeting sequence 
itself. Hairpins targeting non-essential genes are not expected to display change in representation, 
while those that target gene vulnerabilities would drop out of the population significantly (Figure 
VIII-1B). For this reason these assays are commonly referred to as “drop out” screens. The details 
 
Figure VIII-1 – Pooled shRNA assays 
(A) A cell culture is infected with lentiviruses containing different hairpins, which are represented in the 
figure with different colors.  (B) Each hairpin has a unique barcode that is measured at infection and 
response. Hairpins targeting essential genes will be underrepresented and therefore will display a decay 





of how the replicates of the time series are summarized in a dropout score that characterizes the 
changes in hairpin representation are provided in the next chapter.  
Unfortunately, genome-wide dropout screens pose several problems that significantly impede 
their capacity to explore the landscape of tumor lethalities.  Although several large-scale datasets 
of this type have become available during the last few years, the dividends obtained from them 
have been quite modest (Cheung et al., 2011; Marcotte et al., 2012). In the rest of this section I will 
describe the main pitfalls of these assays. 
Figure VIII-1C shows the dropout score resulting from assaying a breast cancer cell line with a 
library of ~80000 hairpins. Although a heavy negative tail can be observed (corresponding to 
hairpins that have a negative impact on cell survival), the majority of hairpins exhibit a score close 
to zero. This is expected because mammalian cells are resilient to genetic perturbations and 
silencing most genes does not have a significant impact on cell survival. However, the experiment 
has significant false negative rates, as not all hairpins that target vulnerable genes display a 
negative score. Although hairpins are designed to silence specific genes, in practice a large 
percentage of shRNAs have extremely low or even void performance. Designing efficient hairpins 
is a difficult task, as hairpin potency is not only affected by binding affinity to the target sequence, 
but by secondary structure, mRNA turnover and by other yet unknown factors (Willingham et al., 
2004). Since typical dropout experiments do not measure the expression of the target gene, it is 
difficult to assess on target efficiency. However, the promise from suppliers is that one out of three 
hairpins targeting a certain gene would reduce gene expression by at least 70% (Boettcher and 
Hoheisel, 2010). The large false negative rate induced by the variable efficiency of hairpins is 
important when interpreting the results of these assays. Concretely, we cannot use negative results 
to draw biological conclusions.  
From the clinical point of view, a large false negative rate is acceptable as long as the screen 
allows us to identify true positive results that can lead to novel drug targets. Unfortunately, RNAi 
screens are also hampered by a large number of false positive results. shRNA hairpins are 
designed to silence a specific target gene, but in practice many hairpins silence unintended genes 




by as few as 6–7 nucleotides of partial sequence complementarity, making the computational 
prediction of likely off-target effects unfeasible (Sigoillot et al., 2012). Off-target effects in siRNA 
assays are ubiquitous, even more prevalent than on-target signals (Franceschini et al., 2014). 
While shRNA are less prone to off-target effects than siRNA (Rao et al., 2009), these assays are 
also strongly affected by this type of problem (Kaelin, 2012). 
Theoretically, the introduction of redundancy through the use of several shRNA hairpins 
targeting each gene alleviates some of these problems. In practice, the percentage of on-target 
efficient hairpins is small and the analysis of these datasets therefore remains challenging. 
Genome-wide drop out screens pose additional challenges beyond those associated to RNAi 
technologies. Specifically, the large pool complexity of genome-wide shRNA assays, on the order 
of thousands of hairpins, substantially affects in the signal to noise ratio.  The cause is simple: the 
larger the number of different shRNA hairpins, the smaller the number of cells transfected by each 
hairpin sequence. If the number of cells transfected by a hairpin is too small, the signal can be 
strongly hampered by both technical noise and biological noise. The technical noise is due to the 
barcode reporting mechanism (microarray or sequencing). Even more significant is the effect of 
biological noise. Infection and growth in culture are stochastic processes that involve the random 
loss of some cells. The impact of these random effects on the signal depends on the number of 
 
Figure VIII-2 – Off-target effects in shRNA experiments 
shRNA hairpins are designed to act through the RNAi pathway, targeting specific genes through binding 
18-24 nucleotide (nt). However, hairpins can also present microRNA-like off-target effects, unintendedly 




cells that represent each hairpin: if each hairpin is represented by a large number of cells, the signal 
will be robust to this type of effect, but if the number of cells carrying a hairpin is small, the random 
loss of a few cells can have a dramatic effect in the score. While the total amount of cells in a 
culture is approximately constant across different experimental designs, the number of distinct 
hairpins depends on the library used. Because the number of different hairpins in a genome-wide 
library is typically very large, each hairpin sequence in only represented by a very small number of 
infected cells. For this reason, some of the top experts in the field of RNAi have expressed strong 
skepticism about the technical feasibility of genome-wide pooled RNAi assays (Berns and 
Bernards, 2012; Kaelin, 2012). 
The goal of this part of the thesis is to systematically explore the variability in lethality displayed 
by different cell lines. The identification of such context dependent lethalities provides the bases 
for a personalized treatment of the disease. In order to achieve this goal, I focus on analyzing 
experiments that do not comprise a single cell line across two conditions, but a panel of different 
cell lines in a single condition. This is contrary to the typical experimental design for shRNA assays, 
which compares lethalities of a tumor cell line between two experimental conditions. For example, 
these assays have been extremely successful at identifying mechanisms of drug resistance by 
identifying shRNAs that synergize with drugs on resistant cell lines (Huang et al., 2012; Mendes-
Pereira et al., 2011; Whittaker et al., 2013).  
From the analytical standpoint, analyzing dropout screens across different cell lines is a more 
challenging problem. In the design of a single cell line across two conditions, we perform a 
comparison between the replicates in the two conditions and we expect significant changes in a 
very small set of hairpins. In the case of the panel of cell lines, the genetic and epigenetic 
heterogeneity of the cohort is likely to cause changes of different magnitude across many hairpins. 
The largest datasets contains ~50 samples per tumor type and each cell line usually differs from 
any other in hundreds, if not thousands, of genetic and epigenetic alterations.  In the assays of drug 
resistance, it was clear that the task was to test the differences between the two conditions. In a 
dropout screen of a panel of cell lines, given the overwhelming genotypic diversity, it is unclear how 




These cross cell line experiments introduce yet another undesired source of variability. 
Specifically, the efficiency of shRNA silencing can be cell line dependent in a hairpin-dependent 
fashion (Boettcher and Hoheisel, 2010). Therefore, variability in the signal can be observed without 
any underlying variability in the lethality of target gene. Unfortunately, very little is known about this 
source of variability and currently the only way to differentiate between these two types of variability 
is to perform laborious experimental follow-up.   
Typical analysis of genome-wide shRNA screens across cell lines proceeds by assessing the 
association of lethality with a binary qualifier of the cell lines, such as a specific tumor type or 
presence/absence of point mutations in a key driver (Figure VIII-3). Two approaches are usually 
employed to overcome the large false positive rate of this type of analysis. The first is a naive 
integrative approach that intersects the list of top scoring genes with either regions of amplification 
or top overexpressed genes (Cheung et al., 2011). The second approach focuses on identifying 
those genes that contain more than one significant hairpin, as two different hairpins are unlikely to 
 
Figure VIII-3 – Association with binary qualifier 
Hairpins that display the most significant subtype specific lethality to luminal tumors. Columns represent cell 
lines and rows represent hairpins. The target of each hairpin is indicated in parenthesis next to the name of the 
hairpin. The data for each hairpin has been normalized and standardized. Note that a negative score (yellow) 




have the same off-target effects (if their target sequence is indeed sufficiently distinct). These 
methods significantly reduce the sensitivity of the analysis, which is tolerated as the only available 
option to increase the specificity to yield an acceptable validation rate. 
 
 
A critical limitation of these methods is not the low sensitivity, but the need for an a-priori binary 
split. Unfortunately, characterization of tumor subtypes and driver alterations are still open 
challenges in the field. Even in the case of breast cancer, one of the most-studied tumor types, the 
definition of subtypes continues to be refined and redefined by different authors based on the recent 
availability of large cohorts (Curtis et al., 2012; Herschkowitz et al., 2007; Kao et al., 2009; Lehmann 
et al., 2011). Importantly, despite all the efforts to catalogue tumors, current classifications are 
unable to explain the large variability in drug response (Heiser et al., 2011; Niepel et al., 2013). 
    An alternative approach aims at creating shRNA profiles for those genes that display several 
correlated shRNA (Shao et al., 2013). The presence of two or more correlated shRNA hairpins for 
a gene boosts the confidence in the on-target nature of the signal. However, the approach is too 
restrictive, as it requires at least two hairpins with good signal per gene.  
The limitations of available methods to analyze this type of data has prevented this technology 
from fulfilling its potential for the discovery of novel drug targets.  In the next chapters I propose a 
method that aims at systematically identifying tumor lethalities and their associated biomarkers by 
making use of an integrative approach that combines observational data from cell lines with 
knowledge extracted from the analysis of primary tumors. 
In the next sections I give an overview: First, I will provide a general description of the dataset. 
Second, I will give a general description of the computational pipeline I developed to use these 





In collaboration with Ben Neel’s group at the Ontario Institute for Cancer Research, we obtained 
a dataset that extends their previously published shRNA screen (Marcotte et al., 2012) from 31 
breast cancer cell lines to 70 cell lines.   
The screen is performed using a library of 78,432 shRNAs targeting 16,056 unique Refseq 
genes, developed by The RNAi Consortium (Ketela et al., 2011). Each line was screened in 
triplicate and microarray technology was used to measure 3 time points for overall shRNA 
abundance during the populations’ outgrowth. The dataset contains more than 50 million data 
points from more than 200 independent cell populations. These breast cancer cell lines are also 
genomically characterized for copy number (Illumina OmniQuad SNP array) and mRNA abundance 




The study of cancer lethalities in breast cancer cell lines provides a great opportunity for the 
development of general methodology for the systematic exploration of the landscape of oncogenic 
vulnerabilities. On one hand, breast cancer is one of the most heterogeneous types of cancers both 
in terms of genetic alterations (Curtis et al., 2012; TCGA, 2012) and drug response (Heiser et al., 
2011; Rehman et al., 2010; Wagner et al., 2013), providing a good system to explore the 
heterogeneity of lethalities in cancer. On the other hand, breast cancer is one of the best-studied 
oncogenic malignancies and there is a set of well-known lethalities associated with different breast 
cancer subsets, which constitute a gold standard.  
A key concern when working with cancer cell lines is whether they are good models of the 
biology of primary malignancies (Ertel et al., 2006; Gillet et al., 2011; Masters, 2000). Indeed, for 
some tumors types such as ovarian cancer it has recently been observed that many of the most 
commonly used cell lines clearly differ from primary tumors (Domcke et al., 2013). 
 
Figure VIII-4 – Expression clustering in cell lines recapitulate breast cancer subtypes 
Hierarchical clustering of the mRNA of the genes with top 10% variance. Complete linkage and Euclidean 




As shown in Figure VIII-5, the breast cancer cell lines in our study recapitulate the main 
alterations in breast cancer both in terms of copy number alterations and point mutations. The 
clustering of the gene expression of these cell lines also recapilaturales the main subtypes of breast 
cancer (Figure VIII-4). As we will see in Chapter XI, the analysis the shRNA screen reveals that 
these cell lines also recapitulate lethality to the main drug targets used in the clinical treatment of 
breast cancer. 
 
 Analytic pipeline overview 
The computational pipeline I developed to analyze shRNA screens is divided in two parts 
(Figure VIII-6). First, for each cell line, we summarize the time-course information across replicates 
 
Figure VIII-5 – Genetic alterations in cell lines recapitulate those of primary tumors 
(A) Profile of copy number alterations of breast cancer cell lines (above) and primary tumors (below). The 
height represents the average G-score across samples. (B) Percentage of somatic SNP mutations in 
primary tumors and cell lines. SNP mutations for the cell lines were obtained from the Cosmic database. 




of the screen into an individual dropout value for each hairpin. This value, the dropout score, 
embodies the essentiality of each hairpin. In Chapter IX I describe a novel score that significantly 
outperforms the score previously used for this type of data. 
In the second part of the pipeline, which is described in Chapter X, genomic data is integrated 
with the shRNA screen to identify signatures of lethality. This novel integrative method, based on 
regression trees, is capable of identifying, de novo, the main known vulnerabilities of breast tumors, 
as we will see in Chapter XI. 
 
 
Figure VIII-6 – shRNA Pipeline 
Block diagram of the proposed pipeline. The barcode intensity data is used by the hairpin model method to 
compute the dropout score for each hairpin in each cell line assayed. The resulting matrix of dropout scores is 




Chapter IX Hairpin dropout model 
Introduction 
The dataset generated by Marcote et al. (Figure IX-1) is the output of a shRNA infection 
experiment performed in triplicate for each cell line. The representation of each hairpin, which is 
assessed using a microarray designed to hybridize to the barcode of the hairpin, is measured at 
the time of infection and in two later timepoints. Therefore, for each combination of cell line and 
hairpin the experiment produces 9 outputs O , r  where O  and r  represents the number of 
doublings and hairpin barcode intensity respectively. Note that most datasets for shRNA and siRNA 
screens assess dropout at two data points (infection and response) (Berns and Bernards, 2012; 
Boettcher and Hoheisel, 2010; Hannon and Rossi, 2004; Rodriguez-Barrueco et al., 2013). 
However, Marcotte’s dataset is assessed across three timepoints because Marcotte et al. reasoned 
that additional time points would provide a detailed history of individual shRNA performance, enable 
 
Figure IX-1 – shRNA pool experiment 
The panels show two cartoons that represent (A) the performed experiment and (B) the resulting measure, 
considering a single distinct hairpin sequence. Each plate in (A) represents a single time point and each 
box a repeat of the experiment, which is performed in triplicate. (B) The Y axis shows the measured hairpin 
barcode intensity, which is a proxy for hairpin representation. The X axis represents the time at which each 
measure is collected, which is presented in terms of cell doublings in order to improve comparison across 
cell lines. Each point, colored according to doubling, represents a single measure of a hairpin in one of the 




modeling of shRNA kinetics during population outgrowth, and increase confidence in the 
essentiality score derived for each gene (Marcotte et al., 2012). 
The focus of this chapter is to describe how to summarize the time-course information across 
replicates to obtain a single score per hairpin and cell line that quantifies how sensitive the cell line 
is to the the hairpin. This is a necessary first step for the pipeline I proposed in the previous chapter. 
Some hairpins display low hybrization across all time points and cell lines. This is due mainly to 
two reasons. First, the hairpin may pose problems for DNA infection and may never get integrated 
into the DNA. Second, the problem may be due to poor hybridization between the hairpin barcode 
and the microarray. These hairpins should be removed from further analysis because in both cases 
the output for the hairpin is not representative of gene lethality. Specifically, I filter hairpins that 
have low intensity in the infection timepoint in 75% of samples (below 9 in log2 scale, which was 
previously observed to be a good threshold for non-hybridized probes this dataset (Koh et al., 
2012)). 
 Because most scoring algorithms for dropout 
screens assess dropout at two time points, 
Marcotte et al. had to devise a new scoring metric. 
This score summarizes the nine data points for 
each hairpin (three timepoints across three 
replicates) into a numeric value that characterizes 
the hairpin’s depletion. The score the authors 
proposed, called “shARP” (shRNA Activity Rank 
Profile), averaged the slope of the microarray 
intensity of the hairpin barcode at each time point 
with respect to the first time point. This method 
produces an average of the fold-change across 
time and is formally defined using the following 
equation: 
 
Figure IX-2 – shARP score 
The figure diagram represents the data for a 
single hairpin and cell line as in the previous 
figure. The two dotted lines represent the slope 
of the dropout between the dropout in the time 
of infection (Xo) and the two other time points 
respectively (X1 and X2). The solid line 
represents the shARP score, which is computed 





 <ℎ4t3 = 1u 	 r − r:O − O:
?
  Eq. 13 
 
where n is the number of time points, r is the average expression intensity of the shRNA probe at 
time i and O is the number of doublings for the cell line at time i. 
This simple model is not computationally intensive, which is key since more than five million 
scores need to be computed (80000 hairpins x 70 cell lines). In addition, the simplicity of the model 
safeguards from overfitting the data. Overfitting becomes a serious concern for complex models 
with larger number of parameters, especially in cases where the number of observations is 
relatively small. In this case, because the dropout score is computed using only 9 data points, it is 
essential to use a simple model.  
The shARP score, although useful, has significant drawbacks, the most problematic being its 
sensitivity to noise. The presence of noisy data points -especially outliers- results in large variation 
to the score. Because genome-wide dropout assays are hampered by extensive noise, a more 
robust score is crucial. In the next section, I will demonstrate how this can be achieved by making 
better use of the information in the replicates. Additionally, since most hairpins are expected to 
have no effect on essentiality (Figure IX-3C, void response), it would be advantageous to increase 
the robustness of the model to prevent spurious signals from achieving a large score.  
In addition to sensitivity to noise, the shARP score is unsuitable for modeling all the types of 
responses observed in these experiments. Marcotte et al. observed three different types of 
responses: The majority of hairpins have no effect on essentiality (Figure IX-3C, void response). 
The second type of response is a linear depletion (Figure IX-3C, linear response). However, in 
many cases (40% of hairpins that display lethality) the depletion is not linear, but a fast dropout that 
reaches saturation in the second time point (Figure IX-3B, saturated response). This type of 
response is unlikely to be the result of technical artifacts because genes targeted by hairpins with 
a saturated response were enriched for highly conserved housekeeping functions and most (80%-
93%) of the fast dropout hairpins inhibited growth in follow-up validations.  Marcotte et al. also 




validation rate for hairpins with this effect was significantly lower (29-39%). The shARP score is 
appropriate for modeling linear and void responses, but it is unsuitable for modeling the non-linear 
behavior of the saturated response, as it underestimates the observed depletion. Capturing hairpins 
with saturated response are of great importance, since those also displays a significantly higher 
validation rate. Therefore ensuring that these hairpins obtain a score that appropriately represent 
the higher degree of dropout is highly desirable.  
BMA score 
I developed a Bayesian score that tackles the two main problems of the shARP score (sensitivity 
to noise and unsuitability for non-linear modeling) while maintaining the advantages of the shARP 
model (fast computation and resilience to over-fitting). To simultaneously consider the three types 
of effects described in Figure IX-3 while avoiding over-fitting the data, we use Bayesian model 
averaging (BMA). BMA averages over competing models, incorporating model uncertainty into the 
estimation of the parameters of interest (Hoeting et al., 1999). BMA offers a natural solution to deal 
with uncertainty in model selection that provides good performance even in cases with small 
sample size (Montgomery and Nyhan, 2010). 
For a parameter of interest L and data D, L being the slope of the dropout in our case, in 
Bayesian model averaging we calculate both the posterior distribution of L over each one of the j 
models v=, cVL|v= , ;X and the posterior probability of each model v=, cVv=|;X. Applying averaging 
over the j=3 types v= of hairpin response (linear, saturated and void), the expected value for β is 
 
Figure IX-3 – Types of shRNA effects 
The panels show the three types of effects observed in response to shRNA infection: (A) linear dropout, 




the average of the posterior distributions under each of the models, weighted by their posterior 
model probability: 





Computing cVL|v= , ;X is straightforward for our models if we take into account that the three 
cases can be modeled with simple linear regression (Figure IX-4). If we center the data and assume 
Gaussian noise x with precision C we have: 
 r = LO J x    x~x|0, CD yℎ'A' O = 0 , r = 0    Eq. 15 
 The posterior probability of each model v= can be computed as: 
 cVv=|;X = \V;|v=XcVv=X∑ \;|vcvw  Eq. 16 
where cVv=X is the prior probability for each model and \;|v is the marginal likelihood of the 
data given the model v . In Bayesian Inference, the marginal likelihood of the data \;|v is 
computed by integrating over model parameters, which provides a safeguard against over-fitting. 
 
Figure IX-4 – Linear models for shRNA observed responses 
The slope for the three types of shRNA responses ((A) linear, (B) saturated and void (C)), which are 
represented on the left, can be computed by considering the equivalent slope of the linear regression 




Because the model with no effect has one parameter less than the other two models, it will be 
preferred over them, in the absence of evidence in favor of the other models. 
The slope L is modeled with a normal distribution with unknown mean and precision. I use a 
Normal-Gamma conjugate prior scheme with hyperparameters a,b,k  to efficiently compute the 
posterior (Morris, 1970): 
 cL, C = L|0, zCD%C|%, { 
Eq. 17 
Therefore the analytical solution for \;|v for the linear and saturated cases is 
 \;|v = 2c?Γ[u/2 J %] u< − u_<_u< J z J 2{
D?/_,
 Eq. 18 
and for the model with no effect 
 \V;|v,9X = Γ[u/2 J %]Γ[%] {, zz J u 2cD? _⁄ { J u2 <
D?/_,
 Eq. 19 
where 
 < = 1u 	 O_         < = 1u 	 r_       < = 1u 	 Or Eq. 20 
For each model, we consider the mean estimate for L instead of the full distribution cVL|v=, ;X, 
which for the linear and saturated model is computed as : 
 L= = N[cVL|v=, ;X] =  << J z/u Eq. 21 
For the model with no effect the mean estimate is trivial: 
 L?>D//9 = NcVL|v=, ;X = N[0] = 0 Eq. 22 
Therefore, using the mean estimate of Equations 11-12, we obtain our Bayesian Model 
Averaging score (BMA score): 





This Bayesian score, which accounts for the three different types of effects in a robust and 




Cell lines differ in key properties that determine the output of the experiment, such as growth 
and infection efficiency. In order to improve the comparison of hairpins across cell lines, I perform 






In this section I describe the differences of the results obtained using the BAM and the shARP 
models in order to assess the suitability of the new model. I will first compare the properties of the 
scores obtained for a single cell line and then assess the performance when the score is compared 
across cell lines. 
Figure IX-5 illustrates some examples of the models obtained with shARP and BMA score. The 
largest differences in the score are due to hairpins that exhibit saturation, as we can see in Figure 
IX-5A-B, which shows the two hairpins with largest difference in score for a randomly selected cell 
line. In these cases the second time point reaches the lower limit of the dynamic range of the 
microarray and the third point is clearly saturated. The saturation model fits the first 2 time points 
as the 3rd is saturated while the shARP score obtains a milder slope because it considers that the 
third time point follows the same linear dynamics. The inclusion of a model with no effect provides 
more robust results against noisy measures for both examples of negative shARP score such as 
the one shown in Figure IX-5C-D and positive shARP scores such as the ones shown in Figure 
IX-5E-F. 
Figure IX-6 displays the shARP score against the BMA score across all hairpins for a single 
sample. The dynamic range of the measured slope for negative values is larger in the BMA score 
due to the saturated model. In addition, the distribution of BMA scores is heavily concentrated in 
zero, consistent with the belief that most hairpins should not have an effect in essentiality. The 
capability of the BMA model to preferentially drive the score to zero is caused by the inclusion of 
the void response sub-model, which is favored in the absence of evidence due to its lower model 
complexity (one parameter less than the other models). Indeed, the shARP score shows a 
significantly larger positive tail which is likely due to lack of robustness in the score, as it has been 
shown that in this type of assay hairpins with positive score are not enriched for any significant 
biological process (Cheung et al., 2011; Marcotte et al., 2012). In summary, the comparison of 
scores across a single cell line shows that the BMA score both increases the dynamic range and 
provides better resilience to noise, displaying a score histogram that better reflects our biological 






Figure IX-5 – Examples of regression fit for shARP and BMA scores 
Each plot displays the response of cell line to a given hairpin. The x axis represent the cell line doublings (as a 
measure of “time”) while the Y represents the barcode intensity. The dotted line shows the slope represented 
by the BAM score while the solid line displays the slope for the shARP score. The numeric values for both 
scores and the probability of the three types of effect computed by the BAM score are shown in the textbox at 






Figure IX-6 –shARP score versus BMA score for a cell line 
This figure displays the shARP score versus the BMA score across hairpins for a randomly selected cell line in 
the screen, both in terms of each individual hairpin score (A) and score histograms (B). The discontinuous line 





The most prominent molecular characterization of breast cancer tumors is the distinction 
between basal and luminal tumors (Eroles et al., 2012; Neve et al., 2006; Perou et al., 2000). 
Importantly, this division of samples also displays the largest differences in terms of signals of 
lethality (Heiser et al., 2011; Marcotte et al., 2012; Niepel et al., 2013; Wagner et al., 2013). 
Because of the large number of genes that display differential lethality between these two sets, I 
considered it would be informative to assess which score identifies more hairpins that display 
differential signal. Figure IX-7 shows the Q-Q plots for the statistical significance of the difference 
in dropout score between the two sets for all hairpins. After multiple testing correction, 866 hairpins 
are significant with the BMA score and 288 hairpins with the shARP score with an overlap of 226 
hairpins, highlighting the superior capability of the BAM score to detect differences in lethality. To 
confirm that the larger number of hairpins captured by the BMA score is not due to outliers we 
 
Figure IX-7 – Q-Q plot for q-value of basal-luminal split for shARP and BMA  
The FDR corrected p-value for the differential essentiality of hairpins between basal and luminal cell lines 
was calculated for both shARP (x axis) and BMA (y axis) using welsh t-test. Each point represents the q-
value for a single hairpin and colored in blue are those that were deemed significant (above q-value 




performed the same analysis for 1000 random permutations of the samples, where the average 
number of significant hairpins was 0.03 and 0.05 for the BMA score and shARP score respectively.  
The BMA score not only identifies more hairpins with significantly different lethality between the 
two main subtypes, it also obtains more extreme q-values for many of those that were deemed 
significant, as exemplified in Figure IX-8, which shows the two scores across cell lines for hairpins 
targeting FOXA1. The figure, which groups cell lines according to the basal and luminal lineage, 
shows that the BMA score consistently achieves better p-values for this gene, which is an essential 





Figure IX-8 – BMA and shARP score for hairpins targeting FOXA1 across basal/luminal subtypes  
The two rows display the shARP and BMA scores for the hairpins targeting FOXA1. For each hairpin the boxplots 
and actual values are represented for the two main subtypes of breast cancer (basal and luminal). The p-value of 








Chapter X Identification of signatures of 
lethality in cancer 
Introduction 
The main challenges posed by genome-wide shRNA screens include off-target effects, low 
signal to noise ratio and variable hairpin efficiency (Chapter VIII). The combination of these factors 
has profound consequences for the analysis of the data obtained from these assays. The severe 
impact of these problems can be observed in Figure X-1, which illustrates the pairwise correlation 
across cell lines between the BMA score of each pair of hairpins that target the same gene. Since 
each pair of hairpins measures the same phenotype, the lethality of their putative target gene, 
theoretically they can be considered replicates.  Surprisingly, we observe that the correlation seems 
to follow a normal distribution centered in zero, with most pairs of ‘replicate’ hairpins not displaying 
any significant correlation.  
 
Figure X-1 –Histogram of correlation across hairpins that target the same gene 
The plot represents the histogram of the Pearson correlation coefficient computed across pairs of hairpins that 
target the same gene. Hairpins that did not display lethality across cell lines were not considered for this figure. 




The lack of computational methods to tackle these problems has prevented genome-wide 
dropout screens from fulfilling their potential for the discovery of novel drug targets.  The goal of 
the algorithm proposed in this chapter is to further exploit the data in these assays to enable a 
systematic search of tumor lethalities and their associated biomarkers. Specifically, the method 
focuses on the identification of clusters of hairpins with coherent signal across cell lines. These 
clusters, which I denominate profiles of lethality, may consist of hairpins that target the same or 
different genes. An additional characteristic of the model is that not all hairpins will be assigned to 
a module of lethality. In practice, as we will see in the next chapter, most hairpins will remain 
unassigned.    
Why do we expect to find genes with correlated essentiality across cell lines? The activity of the 
genes in the genome is orchestrated to perform different cellular biological functions (Segal et al., 
2003). Since cancer dependencies usually relate to the activity of whole biological pathway/process 
(Dobbelstein and Moll, 2014), genes that are essential for such biological activities become 
liabilities in tumors. For instance, several members of the ERBB2 pathway are essential in HER2 
tumors (Heiser et al., 2011) and vital genes for base excision repair such as PARP are well-known 
vulnerabilities of BRCA mutated tumors (Rehman et al., 2010). 
Additionally, genes associated to different biological pathways/processes may also present 
correlated phenotypes. Tumorigenesis is a complex process that requires cells to acquire a set of 
oncogenic hallmarks (Hanahan and Weinberg, 2000). Tumor subtypes frequently differ in the 
mechanisms used to achieve those hallmarks, relying on the alteration of completely different sets 
of biological pathways. It is likely to find correlated essentiality of genes belonging to different 
pathways as a result of the correlation of biological pathways/processes in tumor subtypes. An 
extreme example is the definition of tumor subtypes associated with different cellular lineages, such 
as the basal/luminal subtypes in breast cancer. In this case many hairpins will display correlation 
due to their involvement in cellular activities essential to each lineage.        
By grouping hairpins in modules the algorithm simultaneously tackles the two main sources of 
spurious signals in this type of assays: low signal to noise ratio and off-target effects. I will elaborate 




Dropout screens are strongly hampered by noise, which renders the signal of a single hairpin 
unreliable. If we are able to find hairpins with correlated phenotypes, the signal to noise ratio could 
be significantly increased by averaging the signal over them. This principle has been widely used 
to analyze other types of genomics data such as mRNA microarray data (Akavia et al., 2010; 
D'Haeseleer, 2005; Segal et al., 2003). Therefore, by aggregating the signal across hairpins, the 
model provides more resilience to noise. 
A key difficulty when dealing with shRNA screens is the pervasiveness of off-target effects. 
Since hairpins combine on-target and off-target effects, the phenotype observed for a single hairpin 
has no obvious biological interpretation. Indeed, we are currently unable to discern whether a single 
hairpin suffers from off-target effects. Ideally, a hairpin would only displays on-target silencing, in 
which case the phenotype represents the essentiality of the target gene. However, if the hairpin 
silences both the intended and unintended targets, the output is not easily interpreted due to our 
inability to separate the phenotypes corresponding to each target. There is an interesting third case 
that will be useful for reasons that I will discuss below: a hairpin that only displays a single off-
target. In this case, although we might be unable to identify the silenced element, the signal may 
still be useful. Specifically, these hairpins can be aggregated to on target hairpins to define 
statistically robust signals.  
Profiles of lethality help deal with off-target effects because the existence of a robust profile 
strongly suggests that the phenotype observed in these hairpins is the result of silencing a single 
target per hairpin. It is unlikely that a set of hairpins will display the same phenotype as a result of 
silencing a combination of several essential targets. There might be some exceptions, but the 
majority of hairpins will display the phenotype due to either silencing their intended target or to 
silencing a single off-target element.  
A key difficulty is posed by the small percentage of hairpins that are expected to display 
biologically relevant – and unfortunately noisy- signal across tumor cell lines. It is anticipated that 
only a small set of genes will display the dramatic changes in lethality required to produce a 




to undesired signals such as the variability of hairpin efficiency across cell lines or the strong 
stochastic noise that characterizes this type of assays.  
We are therefore presented with the seemly hopeless task of finding needles (small sets of 
correlated hairpins) in a haystack (the genome-wide library of hairpins). To enable this search I 
propose an integrative approach that combines observational data from cell lines with knowledge 
extracted from the analysis of primary tumors. The key assumption that enables the integration is 
that I expect that the signal associated with a set of correlated hairpins defines a cellular state and 
that this cellular state can be represented succinctly using observational features from those cell 
lines. The observational data are therefore used as molecular biomarkers that represent cellular 
state that are associated with lethalities.  
For example, the HER2 subtype, which is associated to several lethalities, can be represented 
by the overexpression of ERBB2. In this case the expression of ERBB2 is used as biomarker and 
the overexpression of ERBB2 defines a cellular state (the HER2 subtype) that is associated with 
several lethalities.  Instead of clustering hairpins, the method defines cellular states as functions of 
biomarkers, selecting those that explain a significant portion of lethalities (hairpins). 
Computationally, instead of approaching the data using clustering, the question is posed as a multi-
task regression problem in which biomarkers are used to predict the phenotype observed in the 
hairpins.   
The output of the algorithm is comprised of a set of profiles defined by a set of hairpins and a 
definition of cellular state based on biomarkers. If the biomarkers are appropriately selected, this 
strategy significantly increases the chances of success because it reduces the vast search space 
to signals that can be represented by simple combinations of biomarkers. The underlying 
assumption of this model is that oncogenic lethalities of the cell lines are associated with cellular 
states that can be represented by those biomarkers.  
Once a profile has been discovered further investigation is needed to discern its biological 
meaning. The identification of the vulnerable elements that define the lethality can be accomplished 
through several complementary methods. For example, one option is to perform enrichment 




hairpins. Another possibility is to investigate the genetic, genomic and proteomics signals that 
characterize the profile. A third option to increase our understanding of the module is to focus on 
identifying off-target hairpins by studying their off-target seed region (Franceschini et al., 2014; 
Marine et al., 2012). 
In the following section I will describe the method in detail. First I will describe the features used 
to characterize cellular states. Then I will discuss the regression model that combines these 
features of cell state with the shRNA data in order to define signatures of lethality. Finally, I describe 
how the proposed model can be learnt efficiently.  
Modeling approach 
Features of cell state 
It has been previously observed (Heiser et al., 2011; Niepel et al., 2013) that current tumor 
characterizations into subtypes are insufficient to explain the observed variability in tumor lethality 
and drug response. In this section I will describe the features that can enable a finer representation 
of cellular state. 
Since cellular behavior is controlled by gene activity, it is reasonable to expect that genome-
wide measures of gene expression would provide a reasonable proxy for cell state (Akavia et al., 
2010; Santarius et al., 2010). Indeed, the most widely accepted definitions of breast cancer 
subtypes have been obtained through clustering of gene expression data in large tumor cohorts 
(Curtis et al., 2012; Lehmann et al., 2011; Perou et al., 2000; Ross and Perou, 2001). 
Directly selecting the expression of each gene across the whole genome would be unfeasible 
for most models due to the large feature size (~20,000 genes). I therefore aim at producing a small 
set of features that maintain the most relevant information of cell state.  
Since the activity of genes is coordinated in different biological processes (Segal et al., 2003), 
gene expression can be clustered to obtain set of genes that depict the underlying cellular activities 
(D'Haeseleer, 2005). I propose to use traditional clustering methods to identify expression clusters. 
The average expression of these clusters represents the activity of coordinated biological 




However, the coarse expression features obtained from clustering are likely to miss some 
elements of cellular state that have key associations to lethalities. Because the alteration of driver 
genes is vital for cells to achieve tumorigenic states, information regarding the activity of these 
genes can provide important cues to identify cellular states. I therefore propose to include the 
expression of driver genes as a feature of cell state. 
It is important to note that the algorithm does not assume a causal relationship between these 
biomarkers and the identified cellular vulnerabilities. The algorithm merely employs these features 
as biomarkers to identify cellular states associated with lethalities. Each cellular state involves the 
disruption of many different biological processes and it should not be assumed that the correlation 
between biomarker and lethalities implies causality.  
The combination of the information provided by the expression of drivers and clusters offers a 
rich and powerful set of features for cellular state. In the next section I will describe the regression 
model that combines the features of cell state with the shRNA data to define profiles of lethalities. 
Modelling the association between features of cell state and lethalities 
The relationship between the descriptors of cell state X and the vulnerabilities characterized by 
the shRNA dropout data Y (BMA score) across cell lines can be understood as a regression 
problem in which we predict the matrix Y using as covariates the features X. Focusing the search 
on those hairpins that show correlation with features of cellular state facilitates the identification of 
tumor vulnerabilities. This approach has been employed by others (Barretina et al., 2012; Chen et 
al., 2009; Garnett et al., 2012) to model tumor lethalities in the form of response to drug. However, 
the challenges that those approaches tackle are different in nature. The goal of such research is to 
identify biomarkers to enable the effective clinical use drugs through targeted treatment. In our 
setup it is necessary to identify such biomarkers but, most importantly, it is vital to identify 




There are some important characteristics of the association between state features and 
lethalities that should be taken into account in order to select the model of regression. The 
relationship between the state features and the lethalities is strongly nonlinear, as Figure X-2 
exemplifies. Therefore, traditional linear regression models would not be suitable.  
Another important characteristic is that some states (and their associated lethalities) have a 
hierarchical structure. For example, basal tumors get further categorized in basal A and Basal B 
subtypes (Perou et al., 2000). Also, some lethalities may present context dependencies, for 
example, based on the disruption of two driver genes or the disruption of a driver gene within a 
given subtype.  
The use of a multivariate regression model, in which several outcome variables are modelled 
simultaneously is highly recommended for two different reasons. First, shRNA data is semi-
quantitative and has a small sample size, as we can see in Figure X-2. Multitask regression takes 
advantage of the structure of the Y matrix to increase the power of the analysis (Chen et al., 2010; 
Kim and Xing, 2010; Lee et al., 2010; Peng et al., 2010; Puniyani et al., 2010). By aggregating 
hairpins in shared regression models we can obtain robust signals from limited and noisy data. 
 
Figure X-2 – Examples of association between mRNA and shRNA 
Two examples of subtype dependent lethalities in breast cancer. The expression of a gene that defines 
the cellular subtype/state is displayed in the X axis while the dropout score of a hairpin targeting a gene 




Second, by looking for coherent signals across hairpins we ensure that the profile of lethality is 
biologically meaningful, as it is highly unlikely that there would be the same exact combination of 
on-target and off-target effects present in several independent hairpins. 
Finally, we anticipate a sparse representation of the cell states that are relevant towards 
predicting lethalities. We also expect that within the large number of hairpins in the experiment only 
a small set will display strong variability associated with the diversity in cellular backgrounds. 
Therefore, some form of penalty for complexity should be used in order to identify robust signals 
and avoid over-fitting the data. 
Regression model 
I use a multivariate model based on 
regression trees to represent each profile of 
lethality (Figure X-3). A regression tree is a 
binary tree where the internal nodes 
represent binary functions on features of X 
and external nodes or leaves represent the 
prediction for the variable Y (Breiman et al., 
1984). Given an input vector X1, we start 
from the root node evaluating the functions 
in the internal nodes, continuing with the left 
branch if the result is false and with the right 
branch otherwise, until a leaf node is 
reached. The leaf node is characterized by a 
value used as a prediction for the variable Y.  
Regression trees, as models based on 
regression stumps, are particularly well 
suited for modeling non-linear signals. Given the hierarchical structure of the tree, they are also 
capable of capturing combinatorial and context-dependent interactions 
 
Figure X-3 – Regression model 
A tree model (top) describes the lethality profile of a set 
of hairpins (bottom). The dropout profiles of all hairpins 
in the tree are depicted, where the rows are hairpins, 
and the columns are cell lines. Queries proceed from 
the root downwards, if the biomarker is above the 
threshold, the queries proceed to the right and 
otherwise to the left of the split (dotted orange line). 
Each leaf of the tree has assigned a binary value (entry 
of the state vector) that represents the index of the 
continuous distribution that the hairpins in the tree 




Although in regression tree models each leaf usually models an independent distribution, given 
the semi-quantitative nature of the data and the small sample size, it is unlikely that a regression 
model would be able to identify more than two different levels of lethality. Therefore we take a 
different approach for modeling the leaves of the tree. Each leaf of the tree is associated to a binary 
variable that corresponds to two different distributions. These two distributions effectively 
correspond to two states of lethality. This model is less prone to overfitting and is more suitable 
given the semi-quantitative nature of the data. I model these two distributions using Gaussian 
distributions, an approximation frequently employed for this type of data (Shain et al., 2013; 
Whitehurst et al., 2007). 
The model is multivariate as each tree is associated with several hairpins. Each hairpin is 
associated with a single tree, although it may be an empty tree, that is, a tree that contains a single 
leaf node and no inner nodes. 
As usual the unscaled posterior probability can be written as  
  logV3;, vX = logV3;|vX J log 3v Eq. 24 
 
Where 3;|v is the likelihood of the data given the model and 3v is the prior probability for 
the model, which expresses our preferences for certain models, which in this case is a preference 
for simpler models. 
The likelihood of the data given the model is computed considering each hairpin h and the tree 
6= to which the hairpin is assigned : 
 
 logV3;|vX = 	 3M|6=M  Eq. 25 
 




of the assignment of h to the tree 6= are the statistics of the distributions of the hairpin at the leaves 
of the tree. For each leaf l in the tree, and for each data instance y[h,m], we let =[] denote the 




a product of two terms k=[0,1] corresponding to the two distributions of lethality. Each term is the 
likelihood for the Gaussian distributions . , . , with the sufficient statistics for a Gaussian 
distribution: 
 








=,.,_ = 	 .,[+]+ r[ℎ, ]_ 
 
Eq. 28 
where  is Kronecker's delta function. 
Similarly to other recent models for regression trees (Akavia et al., 2010; Segal et al., 2003), I 
use a Normal-Gamma prior for the Gaussian distributions: letting . = 1 .̂_⁄  stand for the precision 
of the Gaussian distribution k, I define: 3., . = 3.|.3. , with 3. ∼ ΓI:, L:  and 
3.|. ∼ :, C:.D, where we assume that both distributions are associated with the same 
prior. Letting 
=,.,  be defined as in Eq.26-28, we have that the component of the log marginal 
likelihood associated with the distribution k of the tree j is given by: 
 
 3VMW6=X = 	 − 12 
=,.,: 2c J 12 log  C:C: J 
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So far I have discussed the likelihood of the data 3;|v, I will now described the prior for 
the model 3v. Similarly to previous work (Akavia et al., 2010; Segal et al., 2003), I use 3v to 
impose complexity penalties on the model, therefore avoiding model overfitting. The selected 




model (NT), the number of hairpins assigned to a tree (NS) and the number of leaves used to model 
each hairpin (NL) respectively: 
 logV36X = −* − H
 − 6   
 
Eq. 31 
The model has five parameters: the complexity parameters *, H,  and the parameters 
for the leaf distributions I:, L:. These parameters are selected using 10-fold cross validation. 
Model learning 
The model proposed in the previous section can be learnt efficiently using a simple greedy 
algorithm (Figure X-4) that optimizes the Bayesian scoring function through stepwise changes, a 
strategy previously employed by others (Lee et al., 2006).  
 
The model is initialized with a single empty tree to which all hairpins are assigned. In each 
iteration the algorithm considers extending the model by adding a new tree. Each candidate tree is 
created by splitting a single leaf node of a tree in the current model. The algorithm considers any 
splits on all values of each feature in X.  
The method contemplates those candidate trees for which the Bayesian scoring function 
increases, selecting the new tree that provides the largest gain in score across hairpins. Note that 
the gain in score of a signature is computed following Eq. 12 as the sum of the gains in score of 
Input: Y: shRNA data , X: features of cell state  
Begin Tree set R with an single empty tree and all hairpins assign to it 
• while( true ) 
o Candidate trees C = each possible extension of trees in R with a single node using 
features in X 
o Select candidate tree Cw that provides largest score improvement 
 Cw=Ci| maxi Score(Y, R U Ci) 
o if Score(Y, R U Cw) ≤ Score(Y, R) 
 break 
o else 
 R=R U Cw 
 Reassign each hairpin to top scoring tree in R 





those hairpins that display a positive gain when assigned to the signature (Eq. 17) minus penalties 
(Eq. 19). Then an additional criterion is imposed to ensure the robustness of the signature. 
Specifically, the statistical significance of the score of the signature is verified by randomly 
permuting the values of the state feature while keeping the hairpin values fixed. The score for the 
signature is computed for 10,000 of these permutations. Finally, the p-value of the score of the 
unpermuted data is computed against the score of these 10,000 permutations and if the signature 
displays a p-value > 0.01 it is discarded. Once the model has been augmented with the new tree, 
hairpins that reassign to the optimal tree in the model.  
The algorithm iterates until no candidate tree provides a significant additional contribution to the 
score. The final output is a set of trees and the shRNA hairpins that are associated with them 
(shRNA hairpins that are predicted by the tree, which I will refer to as the shRNA hairpins that 
belong or are assigned to the tree). 
A naïve implementation of this approach requires significant computation time. However, a great 
percentage of that computational cost is due to operations that are unnecessarily recomputed in 
each iteration. Specifically, the score for every split of each candidate tree is re-evaluated for all 
hairpins. In order to avoid this burden, I modified the algorithm to maintain a list of shRNA with 
positive score for each candidate tree and only evaluate those in each iteration. Since only a small 
percentage of hairpins have positive scores for each tree, the computational gain of this approach 
is significant. 
Since in each iteration hairpins are reassigned to the top scoring tree, some trees may not have a 
significant number of hairpins assigned at the end of the learning process. The algorithm therefore 
applies a post-processing stage in which it evaluates the score improvement provided by removing 
each tree and reassigning the corresponding hairpins to other trees. This stage is performed in a 
step-wise greedy fashion, removing one tree at a time by selecting at each step the tree that 





Chapter XI Computational analysis of 
the landscape of vulnerabilities of 
breast cancer 
Introduction 
Breast cancer is not only the second most frequent type of cancer (Maxmen, 2012) but also one 
of the most heterogeneous forms of this disease, both in terms of genetic alterations (Curtis et al., 
2012; TCGA, 2012) and drug response (Heiser et al., 2011; Rehman et al., 2010; Wagner et al., 
2013). In order to develop rational therapeutic strategies against this malignancy it is necessary to 
understand the key characteristics of each individual tumor and how those result in the staggering 
heterogeneity in treatment outcome that is observed in the clinic. Dropout screens offer an 
unprecedented opportunity to study tumor heterogeneity with regards to a phenotype that has 
utmost clinical relevance: sensitivity against perturbations. Even more this is the case for the 
dataset used in this dissertation, since with 70 samples it constitutes the largest genome-wide 
shRNA screen for a single tumor type performed to date. 
The current method of choice for the identification of groups of tumor cell lines in dropout 
screens is hierarchical clustering. Figure XI-1 shows how this method segregates breast cell lines 
in those of luminal lineage (luminal and a large percentage of ERBB2 cell lines) and basal lineage 
(basal, claudin-low, immortalized subtypes and a small number of ERBB2 cell lines). Unfortunately, 
hierarchical clustering is unable to recapitulate any known breast cancer subtype beyond the 
dramatic lineage distinction.  
Previously, I argued (Chapter X) that by aggregating signals across hairpins, we can overcome 
two key problems of dropout screens: poor signal to noise ratio and off-target effects. Although 
hierarchical clustering performs aggregation of hairpins, it fails at identifying breast cancer 
subtypes. Why? Unlike the method proposed in this dissertation, hierarchical clustering enforces 
that all hairpins are modeled using a single tree. Since agglomerative clustering optimizes the 




undesired signals. In contrast, the method proposed in this dissertation focuses on set of hairpins 
associated with biomarkers. In fact, in the next section we will see that the method here described 
only assigns 3.52% of the input hairpins to signatures.  
Additionally, agglomerative clustering defines all lethal states – or subtypes - in a hierarchical 
fashion. However, it is clear that a single tree is insufficient to represent all biological states 
associated with tumor lethalities. For example, since the ERBB2 subtype is associated with tumors 
of both basal and luminal lineage, it is not possible to represent the basal/luminal lineage and the 
ERBB2+/ERBB2- subtypes simultaneously as a tree. Indeed, Figure XI-1 confirms that hierarchical 
clustering is unable to identify the ERBB2 subtype.  
On the other hand, methods that cluster hairpins have not been successfully employed to 
analyze this type of dataset. Although these methods aggregate hairpins without enforcing a single 
signal, they face significant difficulties to identify biologically meaningful clusters due to several 
factors, including the small sample size, the large number of hairpins with undesired signals and 
the poor signal to noise ratio. 
By restricting selected models to those clusters that can be succinctly represented using 
biomarkers of cellular state, the method here proposed provides more flexibility than hierarchical 
clustering of samples while avoiding the difficulties to find true biological signal of traditional 
clustering methods applied to aggregate hairpins.   
In this chapter I dissect the heterogeneity of lethalities of breast cancer through the application 
of the method proposed in Chapter X to the shRNA dataset described in Chapter VIII. This 
approach overcomes the limitations of current methods to analyze dropout screens, enabling the 








Figure XI-1 –Hierarchical clustering of shRNA dataset 
The figure shows the results of clustering the samples of the shRNA dataset using hierarchical clustering. Each 
row represents a hairpin while each column represents a cell line (using average linkage and correlation as 
distance metric). The cell lines are characterized according to the subtypes described in (Heiser et al., 2011), 
the largest study of drug response in breast cancer cell lines to date, which was performed as a collaboration 





After processing the data (78,432 shRNAs) using the pipeline described in Chapter IX and 
further filtering those hairpins that were non-lethal across the 70 cell lines in the screen, the 
resulting dataset contained 43,049 hairpins that targeted 15,340 genes. This processed dataset 
was used as input for the algorithm together with two different types of descriptors of cellular state: 
the expression of driver genes (90 features) and expression profiles obtained from clustering the 
genome-wide mRNA data across cell lines (19 Features). (See methods) 
The algorithm identified 24 signatures of lethality containing 1,517 hairpins (3.52% of total input 
hairpins) associated with 1,434 genes, with an average of 60 hairpins per signature (Table VI-2). 
Id State Tree #Hairpins #Genes 
1 ( [KATNAL1<=-1.4486] L-8 | H-62 ) 118 117 
2 ( [NAV2<=1.0238] H-63 | L-7 ) 64 64 
3 ( [basalmodule<=0.042773] H-35 | L-35 ) 57 57 
4 ( [basalmodule<=0.042773] L-35 | H-35 ) 78 71 
5 ( [KATNAL1<=-1.4486] L-8 | ( [KIAA1539<=1.293] H-58 | L-4 )) 78 78 
6 ( [basalmodule<=0.042773] H-35 | ( [ZNF839<=-0.054042] H-21 | L-14 )) 29 28 
7 ( [basalmodule<=0.042773] H-35 | ( [ZNF839<=-0.054042] H-21 | ( 
[FGFR1OP2<=0.11354] H-7 | L-7 ))) 
197 191 
8 ( [claudinextendedmodule<=0.65269] H-57 | L-13 ) 59 59 
9 ( [PRELID1<=-0.96183] L-11 | H-59 ) 67 66 
10 ( [TAF4B<=-0.93378] L-8 | H-62 ) 60 60 
11 ( [ANKRD17<=0.9092] H-63 | L-7 ) 62 61 
12 ( [cellclyclemodule<=-0.91862] L-9 | H-61 ) 69 68 
13 ( [ADAM15<=1.0639] H-61 | L-9 ) 56 55 
14 ( [claudinmodule<=-0.30218] L-18 | H-52 ) 44 44 
15 ( [DNAJB6<=-0.67579] L-15 | H-55 ) 37 37 
16 ( [her2module<=0.13867] H-54 | L-16 ) 38 33 
17 ( [ANKRD46<=1.1511] H-62 | L-8 ) 72 72 
18 ( [ermodule<=0.68669] H-49 | L-21 ) 43 43 
19 ( [RBM12<=-1.3332] L-7 | H-63 ) 50 50 
20 ( [basalmodule<=0.042773] H-35 | ( [AUTS2<=-0.90916] H-13 | L-22 )) 37 36 
21 ( [ANKRD46<=1.1511] ( [YEATS4<=-0.70107] L-15 | H-47 )| L-8 ) 55 55 
22 ( [basalmodule<=0.042773] ( [histonemodule<=-0.69887] L-6 | H-29 )| ( 
[ZNF839<=-0.054042] H-21 | ( [FGFR1OP2<=0.11354] H-7 | L-7 ))) 
65 65 
23 ( [NOTCH3<=0.78588] H-60 | L-10 ) 40 40 
24 ( [module8<=-1.0762] L-11 | H-59 ) 42 40 
 
Table XI-1 – Signature overview  
This table summarizes the signatures identified by the approach. The state tree is defined as follows: each 
parenthesis represents a subtree, where the condition of the node is indicated in brackets, followed by the left and 
right subtrees separated by the symbol |. Leaf nodes are described by the type of node: H for high dropout score 
and L for low dropout score followed by the number of samples in the node. Note that the score is a measure of 




The tree that defines each signature contained on average 1.4 nodes, which suggests the 
hierarchical structure of some, but not all, cellular states.  
Computational analysis recapitulates the main subtypes of breast cancer 
The method displayed a remarkable capability to recapitulate the current knowledge of the 
molecular taxonomy of breast cancer (Figure XI-2). Among the 24 signatures identified by the 
algorithm there are signatures that discriminate the basal and luminal lineages (Signatures 3 and 
 
Figure XI-2 –Signature map 
The figure shows the binary state of each signature across cell lines: rows represent signatures of lethality, 
columns denote cell lines and the color of each cell indicates the binary state, where grey and white represent 





4 respectively), ERBB2 subtype (Signature 16), claudin-low subtype (Signature 14) and even 
Estrogen receptor positive (ER+) tumors (Signature 18). 
 
The method identified the basal and luminal lineages (signatures 3 and 4 respectively), which 
were also distinguished using hierarchical clustering. The luminal signature (Figure XI-3) contained 
several known vulnerabilities associated to this lineage such as FOXA1 (Hurtado et al., 2011), 
 
Figure XI-3 – Luminal signature 
The figure shows the regression tree and the hairpins that define signature 4. The dropout score for the 
hairpins associated the signature are presented at the center, where each row represents a hairpin and 
each column represents a cell line. The regression tree that is associated with the signature is represented 
at the top. In signature 4 the tree has a single node that splits the cell lines based on the of the basal 




CCND1 (Musgrove et al., 2011) and GATA3 (Theodorou et al., 2012) . The basal signature grouped 
basal tumor cell lines and immortalized breast cell line, similarly to the grouping identified by (Heiser 
et al., 2011).  
 
Several of the signatures identified by the algorithm were orthogonal to the basal/luminal 
lineage. Note that, as described earlier, hierarchical clustering is unable to capture this type of 
signals. A well-known example is the ERBB2 subtype, which is found in both basal and luminal 
tumors. In contrast, the integrative approach identifies the ERBB2 subtype as Signature 16 (Figure 
Figure XI-4 – Basal signature 




XI-6). Hairpins associated to known lethalities of this subtype, such as ERBB2, PIK3CA and ERBB3 






  Interestingly, the algorithm was able to identify within luminal tumors those that depend on 
estrogen signaling (Signature 18, Figure XI-5), and some of their associated lethalities, such as 
estrogen receptor (ESR1) and TRIM27 (Townson et al., 2006).   
Figure XI-5 – Estrogen signature 
Representation of signature 18. 
Figure XI-6 – ERBB2 signature 






Signature 14 (Figure XI-7) segregates claudin-low cell lines from other cancer cell lines, 
identifying putative vulnerabilities of this less well-studied subtype.   
Novel putative breast cancer lethality signatures 
The remainder of this section provides an initial exploratory analysis of some of the putative 
lethalities identified by the method. Further work (both computational and biological) would be 
necessary to validate the hypotheses obtained from this preliminary examination. Unfortunately, 
such comprehensive analysis falls beyond the scope of this dissertation. 
Interpreting signatures of lethality is a challenging task due to the small number of hairpins in 
each signature and the difficulty to distinguish on-target from off-target signals. To explore the 
nature of the novel signatures identified by the algorithm, I performed hypergeometric enrichment 
analysis of curated gene sets. Despite the difficulties posed by the task, enrichment analysis 
yielded statistically significant results that were coherent with the biology of several bona-fide 
modules (Supplementary tables 3-4). Concretely, the analysis identified sound results for ERBB2 
 
Figure XI-7 – Claudin-low signature 




signature (ERBB signaling, q-value=9.27E-3), luminal signature (luminal genes, q-value= 2.37E-3 
and estrogen targets, q-value=2.96E-3) and basal signature (genes up-regulated in basal tumors, 
FDR corrected q-value=0.034).  
Interestingly, the signatures display enrichment for a rich variety of biological processes, such 
as RNA splicing (Signature 24, q-value=1.16E-2), gene repair (Signature 1, q-value=5.47E-3), 
response to estrogen (Signature 4, q-value=2.96E-2) and insulin (Signatures 20 and 22, q-
value=5.52E-3), protein digestion (Signature 10, q-value=9.27E-3), EMT (Signature 7, q-
value=3.38E-6) and signaling pathways such as PIK3CA (Signature 4, q-value=2.94E-2) and 
ERBB2 (Signature 16, q-value=9.27E-3).   
Signature 7 (Figure XI-8) displayed the most significant enrichment across all signatures, which 
was related to stem cell (q-value=3.38E-6). The signature depicted a small subset of basal cell 
lines that presented dramatic increase in sensitivity to hairpins targeting cell differentiation related 
genes such as SOX9, HOXD12, HOXC12, SSH, DLX5 and DLL4. Basal tumors can be divided in 
in 6 subtypes according to a classification performed by Lehmann (Lehmann et al., 2011). The cell 
lines displaying the lethalities observed in Signature 7 present overrepresentation of Lehmann’s 
mesenchymal stem-like subtype (p-value= 6.6E-3). This subtype is characterized by 
overexpression of cell differentiation genes, such as those related to stem cell ( ENG, PER1, 
ABCB1, …) and numerous HOX genes (HOXA5, HOXA10, MSX1, …). 
Signature 1 (Figure XI-9) is significantly enriched for genes related to the CHK2-BRCA1 tumor 
suppressor pathway (q-value=5.47E-3). Interestingly, the gene whose expression is selected as 
the biomarker that define this signature, Katanin, has been identified as a transcriptional target of 
BRCA1 in breast cells (Lamber et al., 2010). Although genes that are differentially expressed in 
this signature are enriched for cell cycle (q-value=1.25E-13), this signature is distinct from the state 
of low proliferation, which is depicted by signature 12 and includes low proliferative tumor cell lines 













This chapter has assessed the ability of the algorithm described in the previous chapter to 
identify tumor lethalities by integrating genomics and functional data. The method provided an 
unbiased exploration of the landscape of lethalities in breast cancer that recapitulated the main 
subtypes and lethalities of this malignancy. In addition, the algorithm provided a succinct set of 
hypotheses for novel putative lethalities. A more comprehensive analysis followed by in vivo 





validations would be required to elucidate the biological and clinical interest of these new 
predictions.  
Even though breast cancer is probably the most studied type of cancer, the integrative approach 
described here was capable of identifying vulnerabilities related to virtually all the targeted therapies 
that are currently exploited to treat this disease. Since the method is generally applicable to study 
other types of cancer, this strategy has the potential to pinpoint therapeutic targets for less 
understood oncogenic malignancies for which currently there is no suitable clinical strategy. 
However, it is important to note that to enable this analysis, reasonably large dropout datasets 
should be collected for those malignancies.  
Provocatively, out of the 1517 hairpins associated to signatures, in only 24 cases did the 
algorithm identify more than one hairpin targeting the same gene in a signature. This raises serious 
questions about the limitations of those approaches that analyze dropout screens by relying solely 
on the identification of multiple coherent hairpins for each gene, such as ATARIS (Shao et al., 
2013). Although such approaches reduce the false discovery rate caused by off-target effects, they 
are also likely to dramatically decrease the sensitivity of the analysis, discarding a large percentage 
of the valuable information contained in these assays.  
The method here described is not limited to use mRNA data as the single source of features of 
cell state. Indeed, features obtained from other types of data are likely to provide additional 
information. For instance, protein activity and sequence data for these cell lines are currently being 
collected by our collaborators and will be included in future analysis.  
Collectively, the analysis described in this chapter demonstrates that the novel integrative 
approach here proposed can exploit shRNA datasets to characterize the lethalities associated with 
each individual tumor, providing an opportunity for the identification of new drug targets and the 






The shRNA data was preprocessed using the method described in Chapter IX. As expected, a 
significant proportion of hairpins did not display essentiality across cell lines, probably because 
either the hairpin was ineffective or the target gene was not essential in any cell line. Therefore, I 
further filtered out 19888 hairpins (31.6%) that were not among the 25% most essential hairpins in 
at least 4 cell lines. The resulting dataset contained 43049 hairpins for 70 cell lines. 
State features 
The algorithm used two types of features of cell state, both of which were based on mRNA data. 
The first type is the mRNA expression of a set of selected driver genes, which include the 83 Helios 






































Table XI-2 – Expression modules  





selected by the analysis of regions of deletion performed in Chapter VI and 3 bona fide tumor 
suppressors (BRCA1, BRCA2 and CDK2NA) that are frequently mutated in cancer patients (TCGA, 
2012).  
The second type of descriptor of cellular state reflects the average expression of 19 sets of 
genes obtained from applying agglomerative clustering to the mRNA of the genome across cell 
lines (Table XI-2). Hierarchical clustering with average linkage and Euclidean distance metric was 
first applied to the expression data. The resulting tree was inspected and those subtrees that 
represented coherent biological processes or displayed a compelling signal were selected. Most of 
the selected sets correspond to previously described breast cancer gene sets (Kao et al., 2009; 
Perou et al., 2000; Prat and Perou, 2011; Ross and Perou, 2001).   
Parameter selection and robustness 
The scoring function has 5 parameters, which include the hyperparameters for the Normal-
Gamma prior for the Gaussian distributions I:, L: and the complexity parameters *, H, . 
These parameters were selected using 10-fold cross validation and the parameters used were I: 
= 1, L: = 1, * = 2, H = 20 and  = 100. Using those parameters the algorithm identified 26 
signatures of lethality.  
I stablished an additional criteria to filter spurious signals and ensure the robustness of the final 
result. I performed 100 random subsamples containing 90% of the samples and computed the 
number of subsamples in which each signatures was identified, selecting those signatures that 







I performed hypergeometric enrichment analysis of curated gene sets to discern the biological 
nature of the detected signatures of lethality. I downloaded the C2 subcomponent of the MSigDB 
signature database version 3.1 from http://www.broadinstitute.org/gsea/msigdb/index.jsp on May 
9th, 2013 (Subramanian, Tamayo, et al. 2005, PNAS 102, 15545-15550). I computed hyper-
geometric enrichment based p-values combined with False Discovery Rate to account for multiple 
testing on this set and on the Kegg pathway database (Kanehisa and Goto, 2000) using the 
Genatomy software (Supplementary tables 3-4).  
 
Figure XI-10 – Subsampling analysis 
(A) Histogram of the number of subsample runs that identified each signature. (B) Number of subsample 




Chapter XII Conclusions 
 
This dissertation has investigated different computational approaches for the systematic 
integration of high throughput observational and functional data in cancer. Specifically, I developed 
integrative methods to tackle two crucial problems in cancer research: the identification of driver 
genes and the discovery of tumor lethalities. I used these algorithms to analyze breast cancer, the 
second most common form of cancer behind lung cancer (Grayson, 2012). However, since the 
methods described in this thesis are not particularly tailored to breast cancer, the outlined 
approaches can also be employed to study other oncogenic malignancies.  
The first part of the dissertation focuses on the analysis of regions of copy number alteration for 
the identification of driver genes. I demonstrate how even the simplest integrative method can 
facilitate the identification of novel driver genes (Chapter VI). Specifically, I intersected regions of 
recurrent deletion obtained by the novel algorithm ISAR-DEL with putative candidates obtained 
from a shRNA screen designed to uncover genes that positively modulate anoikis.  
The benefits of this straightforward integration are two-fold: the combination of genetic and 
functional data not only enabled the identification of BIN3 as a novel tumor suppressor that is 
frequently altered in primary tumors, but also linked the activity of this gene to a specific oncogenic 
phenotype, resistance to anoikis. Chapter VII describes how BIN3 was experimentally validated as 
an epithelial tumor suppressor gene, provides insights on the mechanisms of attachment tumor 
suppressor checkpoint and highlights the importance of anoikis escape in driving cell 
transformation and metastasis in human cancer.  
The simple integrative method employed to identify BIN3 enabled us to extract knowledge from 
a functional screen that assayed a single cellular background for a singular oncogenic phenotype. 
However, this approach has significant shortcomings when applied to the integration of a larger 
and more comprehensive set of data sources. Ideally, methods for data integration should leverage 
information across sources without discarding valid candidates. Instead, the intersection of 




not deemed significant in the partial views. An additional limitation of the method is that it does not 
provide a framework for prioritizing the remaining candidates across data sources. In the absence 
of a robust prioritization framework, researchers typically resort to suboptimal and less principled 
methods such as prioritizing based on one independent data source or performing ad hoc selection 
of candidates based on previous biological knowledge. 
To overcome these limitations I developed Helios, an unsupervised method for the identification 
of driver genes in regions of SCNA that integrates different data sources into a single probabilistic 
score (Chapter III). The algorithm displayed a remarkable capability to pinpoint bona fide cancer 
drivers when used to analyze the SCNA landscape of breast cancer (Chapter IV). Additionally, 12 
novel candidate drivers identified by Helios were selected for experimental investigation, of which 
10 induced increased anchorage independent growth when over-expressed in vitro. In Chapter V I 
describe how we extensively tested the tumorigenic potential of a candidate driver selected by 
Helios, Rsf-1. These experiments showed that Rsf-1 is oncogenic in vivo and suggest a role for 
Rsf-1 in metastasis and clinical survival in Breast Cancer.  
The second part of this dissertation undertakes the problem of identifying tumor vulnerabilities 
using genome-wide shRNA screens across tumor cell lines. Although several datasets of this type 
are available (Cheung et al., 2011), (Marcotte et al., 2012), there is a notorious lack of 
computational methods to tackle the challenges posed by these assays. The goal of this part of the 
dissertation is to develop a method that enables the unbiased exploration of tumor-specific 
lethalities, seeking to identify those genes and pathways that could be exploited as drug targets.   
I approach this endeavor using a novel integrative method that uses different biomarkers of 
cellular state to facilitate the identification of clusters of correlated hairpins. The problem, which is 
posed as multi-task regression, is modeled using regression trees and learned using a step-wise 
greedy algorithm. When applied to breast cancer data, the method not only recapitulates the main 







The capability of the methods developed in this thesis to provide novel biological insights is 
largely enabled by the vital functional information provided by shRNA screens. It has previously 
been observed that genome-wide RNAi screens could potentially be extremely valuable tools due 
to their capability to blend the ability of ‘omics’ technologies to perform genome-wide assays with 
the phenotype-driven approach of traditional biology (Weinberg, 2010). However, in order to unlock 
the great potential of these assays, it is necessary to tackle their problems. The methods developed 
here exemplify how the major limitations posed by RNAi screens can be overcome by integrating 
these functional screens with observational data. 
In this thesis I use RNAi screens that interrogate the genome for two different phenotypes: 
essentiality and resistance to anoikis. There are, however, many other phenotypes that could be 
assessed using functional screens, including DNA damage (Adamson et al., 2012), resistance to 
hypoxia (Yoshino et al., 2012) and even complex phenotypes such as cell morphology (Chia et al., 
2012) or expression signatures (Vempati et al., 2014).  
Assays in which a phenotype is assessed after silencing of a functional element, such as RNAi 
experiments, are designated loss-of-function screens. The complementary type of assays, in which 
a phenotype is assessed after the functional element has been activated, are known as gain-of-
function assays. Although I have not used gain-of-function assays in this dissertation, retroviral 
libraries of cDNAs are also readily available for performing gain-of-function assays in mammalian 
genomes (Boehm et al., 2007). 
During the last year of the development of this dissertation CRISPR emerged as a powerful new 
technology for functional assays in mammalian genomes (Cong et al., 2013; Mali et al., 2013). 
CRISPR, which stands for clustered regularly interspaced short palindromic repeat, promises to 
overcome some of the main limitations of RNAi technology (partial knockdown and off-target 
effects). Although the first results of the application of CRISPR to genome-wide pool assays are 
promising (Shalem et al., 2014), a thorough evaluation would be required in order to understand 
the caveats and limitations of this exciting technology. Despite the differences with RNAi assays, 




Data integration in cancer genomics 
The significance of the biological insights obtained from integrative methods critically depends 
on the choice of biological question, datasets and modeling approach. Tackling these three tasks 
requires a blend of biological knowledge and quantitative expertise. On one hand, it is necessary 
to identify interesting biological questions that can be addressed considering the data available and 
the pitfalls of the technologies used to generate them. On the other hand, it is vital to possess a 
sound understanding of the strengths and weaknesses of different learning paradigms and how 
those can be employed to harness the knowledge encoded in the data.  
If the datasets are potentially informative about the selected question and a suitable modeling 
approach is chosen, solving the model may not require a groundbreaking mathematical 
breakthrough but merely some mathematical skill. Indeed, although the methods developed for this 
dissertation make use of a variety of computational paradigms such as hierarchical mixture models, 
regression trees and Bayesian networks, I always aimed at using the simplest computational tool 
that would enable the discovery of novel biology. 
Biological question and data 
In practice, the choice of biological question and main datasets are intimately linked strategic 
decisions. On the one hand, the type of biological questions that we can address is limited by the 
availability of data. On the other hand, the selection of datasets (or the experimental design of 
assays to generate new datasets), is guided by the potential of the data to provide valuable 
biological insights. In some cases, the starting point is an exciting dataset collected using a novel 
technology, while in other cases the researcher becomes interested in a biological question without 
a specific dataset in mind. Indeed, one of the benefits of high-throughput data is that they can be 
employed to answer many different biological questions. In a sense, computational biologists have 
the opportunity to reuse datasets in a myriad of in silico assays that test many different hypotheses. 
This capacity to define in silico assays is even greater when we consider integrative analysis, as 




Before moving forward, the researcher may want to consider additional sources of information 
that can help to answer the biological question. For example, Helios uses other data types in 
addition to SCNA and RNAi to identify driver genes, such as DNA-Seq and RNA-Seq. RNA-Seq 
can be employed, for instance, to estimate which genes are expressed. A gene that is not 
expressed is an extremely unlikely amplified driver, as it would be the computational equivalent of 
a section of code that is repeated multiple times but that is never reached when the program is 
executed. Considering that approximately 30% of the genome is not expressed in a given tissue, 
this type of information can help to discard almost one third of potential candidates in regions of 
SCNA. Despite the wide availability of RNA-Seq data, most computational methods for the 
identification of driver genes do not make use of these data. 
Modeling choices 
Once a biological question has been chosen and the datasets that can help answer it have been 
identified, the researcher has to consider several modeling questions: How to design a model that 
integrates heterogeneous data types in meaningful ways? How to conceive a model that not only 
is semantically correct, but that also exploits the characteristics of the data? How to tackle 
integrative problems that are typically unsupervised in nature but unsuitable for traditional 
clustering? Unfortunately, since each problem poses different challenges and characteristics, it is 
impossible to define a systematic recipe to approach these questions. 
A key property used in Helios’ design is that although in most cases alteration frequency is 
insufficient to narrow down SCNA regions to a single gene, it is nevertheless the most insightful 
information to identify drivers in those regions. Consequently, Helios uses an asymmetric model 
that focuses on predicting the copy number landscape based on all other features. The semantics 
of the predictor are not only encoded in the model, but in the definition of the predictive features. 
For example, the phenomenon of oncogene addiction is the concept behind the score that links the 
functional data from the shRNA screens to the task of predicting driver genes.   
For the problem of identifying vulnerabilities in shRNA dropout screens, a crucial observation 




noise, can be tackled by identifying sets of hairpins with coherent signals. Unfortunately, 
straightforward clustering approaches are unsuitable for this problem because we are searching 
for needles in a haystack. In order to ‘navigate the haystack of hairpins’ I use biomarkers of cell 
state, as I expect oncogenic lethalities to be associated with observed features of cell state. By 
restricting the model to those solutions in which the signals can be expressed in terms of features 
of cell state, the search space is reduced dramatically while still allowing the algorithm to identify 
interesting biological signals. Since computational biologists are often challenged by problems that 
require exploring an intractable search space, strategies that prioritize solutions that are biologically 
probable are frequently the best option to obtain novel insights.        
Garbage in, garbage out 
A typical mistake in data integration is to focus attention on the design of the integrative method 
while neglecting to maximize the information extracted from each individual dataset. Data 
integration can significantly increase the power of the analysis by leveraging information across 
different sources, but by no means emancipates us from the tasks of quality control, data 
preprocessing and even modeling of the individual data sources.  
In two different parts of the development of Helios the work in the individual datasets was crucial. 
First, I explored different data sources and devised predictive features that Helios could use as 
input. Second, I developed a novel algorithm for the identification of regions of recurrent SCNA 
largely motivated by the need to increment the sensitivity of this type of analysis (ISAR, Chapter 
II). Since the performance of the learning process depends on the number of instances used to fit 
the model, the increase in number of identified regions not only boosted the sensitivity of the 
predictions, but also helped to increase their specificity.  
Examples of this type of effort can also be found in the second part of the thesis. For instance, 
in order to identify signatures of lethalities, I first defined a novel dropout score to assess the 
essentiality of each hairpin (Chapter IX). This substantial pre-processing effort facilitated the 
posterior analysis by making possible to filter a large number of hairpins (~40%) and by increasing 






This study aimed at exploiting the power of integrating observational and functional data to 
provide novel biological insights. In the first half of this dissertation, I show how the analysis of the 
landscape of copy number alterations not only led to the identification of vital drivers of breast 
cancer metastasis such a RSF-1 and BIN3, but also has enabled the first systematic validation of 
driver genes and expanded the landscape of high-confidence breast cancer drivers by more than 
two fold. In the second half of this dissertation, I develop a novel method that explores the 
landscape of oncogenic lethalities in an unbiased and systematic manner. The algorithm not only 
recapitulated virtually all the main lethalities of breast cancer, but also identified novel putative 
lethalities for this disease. Although the number of remaining problems is significantly larger than 
a reasonable length of a thesis chapter, I will describe in the rest of this chapter some interesting 
open computational and biological challenges.  
Identifying driver genes  
Although I used Helios to analyze the landscape of copy number amplifications, the algorithm 
could also be employed to analyze the landscape of deletions, provided that a good set of predictive 
features is defined. In that regard, it is unclear how the dropout screens used in this thesis to identify 
amplified drivers could be employed to define features that would help to identify drivers in deleted 
regions. However, different types of RNAi and cDNA assays can be used to aid in the identification 
of tumor suppressors (Gumireddy et al., 2009; Ly et al., 2012; Schramek et al., 2014; Solimini et 
al., 2012).  
In addition to RNAi screens, there are a number of other data sources that can be used to define 
predictive features. For example, although in this thesis I make use of sequence mutations through 
a feature that scores the significance of their frequency, other features of the footprint of SNP 
mutations could indicate the oncogenic nature of a gene. Some potentially exploitable 
characteristics of sequence mutations in driver genes are the recurrence in specific positions or the 




An interesting potential source of novel features is the study of cross-species comparative 
genomics. When comparing human tumors with those in other species, we can exploit the 
disparities in chromosomal architectures of different species. Specifically, if two recurrently altered 
regions in tumors of two species share a single homologous gene, it is likely that this gene is indeed 
an oncogenic driver (Maser et al., 2007; Tang et al., 2014). The search does not have to be limited 
to naturally occurring tumors. For example, insertional mutagenesis approaches, such as 
transposon mutagenesis, can be employed to identify alterations that promote carcinogenesis 
(Genovesi et al., 2013; Mann et al., 2012; March et al., 2011; Starr et al., 2009). Indeed, since the 
alterations introduced in insertional mutagenesis assays are focalized, the location of the driver can 
be narrowed down to a small region even with a reasonable number of repeats of the experiment.   
Another potential source of features is the use of curated biological data, such as curated gene 
sets, networks or pathways. An idea recently explored by several groups is to use curated biological 
networks to identify driver genes (Amar et al., 2013; Bashashati et al., 2012; Vandin et al., 2010). 
These methods, based on the “guilty by association” principle, estimate the statistical significance 
of the presence of disease-related genes in the local vicinity of each candidate driver. Such 
approaches should be used with caution, as the quality of the results strongly relies on the input 
network. For example, these methods are unsuitable for the identification of uncharacterized driver 
genes.  
This dissertation focuses on the analysis of tumor types independently. However, it is clear that 
different tumor types share driver genes and mutational processes (Kandoth et al., 2013; The 
Cancer Genome Atlas Research et al., 2013; Zack et al., 2013). Consequently, it would be 
interesting to explore methods to leverage information across tumor types. Indeed, this avenue will 
be explored by a recently launched subproject of TCGA (Kandoth et al., 2013; The Cancer Genome 
Atlas Research et al., 2013; Zack et al., 2013).    
Ultimately, the identification of driver genes is not the culmination of our quest but an initial step 
towards a deeper understanding of cancer. Further work will be needed to elucidate the role of 




Identifying tumor vulnerabilities 
A noteworthy avenue of research that has not been explored in this thesis is to directly model 
the main pitfalls of RNAi technologies: hairpin efficiency and off-target effects. Although some 
recent computational work has aimed at identifying and designing efficient hairpins (Filhol et al., 
2012; Sciabola et al., 2013), the performance and insights provided by these methods have been 
modest and more work is needed to elucidate the design principles of efficient RNAi hairpins. On 
the other hand, since off-target sequences are small and only require partial complementarity, 
predicting unintended targets appears to be a problem that is computationally unapproachable.  
Interestingly, identifying the sequences within hairpins that cause off-target effects is partly 
feasible a posteriori through the analysis of the correlation of hairpin sequences with phenotypes. 
Since it has been observed that off-target sequences are predominantly localized in residues 1–8 
of hairpins, the denominated seed region, the analysis can focus in that small region instead of 
studying the whole sequence of the hairpin (Jackson and Linsley, 2010). Although some 
computational work has tackled the problem of identifying off-target seeds in assays comparing 
two conditions (Franceschini et al., 2014; Marine et al., 2012; Sigoillot et al., 2012), these 
approaches have not been extended to screens across panels of cell lines. It would be interesting 
to extend the model proposed in this dissertation to take the seed region into consideration.  
It is important to note that the vulnerabilities observed in cell line models may not be present in 
primary tumors due to the effect of tissue structure and microenvironment (Michor and Weaver, 
2014). This problem may be overcome by performing these assays in vivo, an approach that is 
technically feasible for small library sizes (Dunn et al., 2014; Gumireddy et al., 2009; Murugaesu et 
al., 2014; Possemato et al., 2011). A reasonable compromise using current technologies would be 
to employ a two-stage process where in the first step a genome-wide functional assay is perform 
in cell line models while in the second step an in vivo functional assay follows up on putative 
candidates obtained from the in vitro screen. These assays may aid not only in the identification of 
tumor lethalities that are functional in vivo, but also may help to understand the differences in 




An additional limitation of this dissertation is that tumors are implicitly considered uniform 
masses. However, these malignancies are composed of populations of cells that display 
remarkable phenotypic variability. The heterogeneity of tumor masses has profound consequences 
for the clinic as this variability has a dramatic effect on the long-term response to treatment, playing 
a significant role in relapse and the development of drug resistance (Fisher et al., 2013; Marusyk 
et al., 2012).  
The development of combinatorial targeted therapies is considered the best avenue of research 
to deal with intra-tumor heterogeneity However, the success of these approaches strongly depends 
on the source of heterogeneity. If the variability in phenotype is the result of the genetic 
heterogeneity produced by the Darwinian-like clonal evolution of tumors (Chen et al., 2012; Su et 
al., 2012; Szerlip et al., 2012), combinatorial therapies are likely to succeed, as discussed in 
Chapter I. However, in some cancers the cause of intra-tumor heterogeneity is not genetic but 
epigenetic (Easwaran et al., 2014). For example, in the cancer stem cell (CSC) hypothesis, tumor 
cells have different functional properties despite being genetically identical (Magee et al., 2012; 
Nguyen et al., 2012; Vaillant et al., 2008; Yamamoto et al., 2013). In those cases, there is no 
guarantee that therapies developed to target the majority of tumor cells would also be effective to 
treat those small subpopulations that display completely different functional characteristics.  
Examples of this phenomenon have been observed in glioma (Bao et al., 2006) and in mammary 
tumors (Cleary et al., 2014). In those cases, to understand how to avoid tumor relapse, it is 
necessary to increase the granularity of the analysis. The recent development of single cell 
technologies (Bendall et al., 2011; Jaitin et al., 2014; Snijder et al., 2012; Yuan et al., 2012) will 
enable the identification and characterization of functional subpopulations within tumors.   
From tumor lethalities to clinical therapies 
Drug toxicity is a key issue that is frequently overlooked in academic research despite its utmost 
importance for therapeutic treatment. Targeted therapies were conceived as means to effectively 
target tumor cells without the toxic effects that characterize chemotherapy and radiotherapy. 




et al., 2012; Widakowich et al., 2007). This problem is aggravated in combinatorial therapies, where 
either the toxicity of each drug may be enhanced or new toxicities might unexpectedly develop due 
to the interaction between drugs (Park et al., 2013; Yap et al., 2013). In order to enable quantitative 
analysis of this important aspect of cancer therapeutics, comprehensive datasets of drug toxicity 
will need to be collected. 
Ultimately, the successful identification of tumor lethalities can be a fruitless triumph if we lack 
the technologies to translate those vulnerabilities into clinical therapies. Among the approximately 
20,000 genes that comprise the human genome, only 324 (<2%) are currently druggable 
(Overington et al., 2006). In order to succeed in our quest against cancer, more effort will need to 
be focused on extending the druggable genome. An approach that could extend the number of 
druggable genes dramatically is the exploration of RNA interference for therapeutical use. Although 
RNAi technology has not been translated into the clinic yet, this avenue of research is gaining 
momentum as some of the key obstacles to develop RNAi-based therapies have recently been 
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Appendix I - Supplementary tables 
Supplementary Table 1 - ISAR amplified regions in TCGA breast cancer dataset 
 
Index Chromosome Start End ISARScore 
1 1 1720000 2940000 7.332 
2 1 38400000 40400000 2.108 
3 1 41800000 43400000 4.479 
4 1 61000000 62400000 3.335 
5 1 93800000 94100000 2.243 
6 1 149000000 149000000 4.893 
7 1 153000000 154000000 3.206 
8 1 159000000 161000000 6.57 
9 1 201000000 204000000 3.483 
10 1 233000000 233000000 3.257 
11 2 9820000 10200000 3.138 
12 2 38400000 38600000 2.342 
13 3 4370000 5230000 3.882 
14 3 14500000 15400000 2.821 
15 3 171000000 172000000 2.047 
16 3 180000000 181000000 2.204 
17 4 1290000 2080000 3.706 
18 4 73400000 75900000 6.632 
19 4 76400000 77800000 2.516 
20 4 144000000 145000000 2.665 
21 5 936053 1350000 2.527 
22 5 13000000 14600000 4.778 
23 5 44300000 44800000 3.492 
24 5 176000000 177000000 2.595 
25 6 41600000 42200000 2.121 
26 6 43700000 44200000 2.016 
27 6 63800000 64800000 2.119 
28 6 105000000 109000000 19.9 
29 6 135000000 136000000 2.921 
30 6 151000000 152000000 4.549 
31 7 5370000 5660000 2.396 
32 7 23000000 23500000 2.671 
33 7 32900000 33000000 2.073 
34 7 55000000 56400000 4.989 
35 7 68500000 68800000 2.083 




37 7 156000000 157000000 4.341 
38 8 9800000 10600000 2.369 
39 8 37100000 39300000 15.74 
40 8 81000000 82100000 5.064 
41 8 101000000 103000000 4.131 
42 8 116000000 118000000 5.829 
43 8 128000000 129000000 14.65 
44 9 33400000 36600000 5.477 
45 9 127000000 130000000 5.444 
46 10 61200000 63700000 3.859 
47 10 76000000 76900000 3.048 
48 10 80000000 81700000 3.048 
49 10 123000000 124000000 6.728 
50 11 19100000 19900000 2.11 
51 11 32000000 35700000 4.843 
52 11 68300000 70700000 54.1 
53 11 76400000 78000000 8.904 
54 11 118000000 118000000 3.258 
55 12 416712 1000000 3.52 
56 12 26700000 27100000 2.757 
57 12 56300000 56600000 3.433 
58 12 67000000 69300000 11.36 
59 12 122000000 123000000 3.98 
60 13 26300000 26900000 2.17 
61 13 29100000 30200000 4.17 
62 14 34300000 35400000 2.202 
63 14 37000000 37400000 2.202 
64 14 48900000 49900000 4.096 
65 14 102000000 103000000 2.162 
66 15 47900000 51000000 3.395 
67 15 96000000 97600000 6.478 
68 16 10300000 11800000 2.857 
69 17 23600000 25100000 11.66 
70 17 33700000 35800000 73.95 
71 17 44300000 46900000 7.123 
72 17 54500000 56900000 14.53 
73 17 57300000 58700000 2.527 
74 18 13400000 13700000 2.059 
75 18 22100000 24000000 3.531 
76 18 58200000 60100000 4.498 
77 19 14800000 15500000 2.724 




79 19 60200000 61000000 3.265 
80 20 33100000 34400000 3.246 
81 20 51000000 52600000 17.84 
82 21 15600000 16300000 2.844 









Supplementary Table 2 - Helios selected genes in Breast cancer analysis 
 
Gene_entrez Gene_symbol HeliosScore Peak Chromosome PeakSubtype GoldStandard 
3169 FOXA1 0.987 63 14 - YES 
5290 PIK3CA 0.985 16 3 Basal YES 
595 CCND1 0.952 52 11 Luminal YES 
1019 CDK4 0.951 57 12 Luminal YES 
4602 MYB 0.931 29 6 Basal YES 
2064 ERBB2 0.877 70 17 Basal YES 
3480 IGF1R 0.841 67 15 - YES 
9908 G3BP2 0.838 19 4 Basal NO 
596 BCL2 0.833 76 18 - YES 
2099 ESR1 0.827 30 6 - YES 
57178 ZMIZ1 0.822 48 10 - NO 
1956 EGFR 0.815 34 7 Basal YES 
7204 TRIO 0.814 22 5 Basal NO 
283149 BCL9L 0.809 54 11 Basal NO 
8751 ADAM15 0.799 7 1 - NO 
253959 RALGAPA1 0.795 62 14 - NO 
10207 INADL 0.794 4 1 Basal NO 
898 CCNE1 0.793 78 19 Basal YES 
5590 PRKCZ 0.789 1 1 Basal NO 
3268 AGFG2 0.785 36 7 Basal NO 
3954 LETM1 0.779 17 4 - NO 
705 BYSL 0.769 25 6 Basal NO 
10114 HIPK3 0.769 51 11 - NO 
6875 TAF4B 0.758 75 18 Basal NO 
2029 ENSA 0.746 6 1 Basal NO 
80028 FBXL18 0.746 31 7 - NO 
2263 FGFR2 0.744 49 10 - YES 
55290 BRF2 0.742 39 8 Luminal NO 
29964 PRICKLE4 0.741 25 6 Basal NO 
11097 NUPL2 0.741 32 7 - NO 
65986 ZBTB10 0.738 40 8 - NO 
283358 B4GALNT3 0.725 55 12 Basal NO 




4170 MCL1 0.722 6 1 Basal YES 
1945 EFNA4 0.718 7 1 - NO 
7036 TFR2 0.716 36 7 Basal NO 
80129 C6orf97 0.709 30 6 - NO 
26127 FGFR1OP2 0.709 56 12 Basal NO 
2549 GAB1 0.697 20 4 - NO 
7227 TRPS1 0.697 42 8 Basal NO 
51043 ZBTB7B 0.692 7 1 - NO 
116113 FOXP4 0.692 25 6 Basal NO 
60 ACTB 0.687 31 7 - YES 
7884 SLBP 0.683 17 4 - NO 
7469 WHSC2 0.68 17 4 - NO 
10643 IGF2BP3 0.68 32 7 - NO 
4817 NIT1 0.679 8 1 - NO 
7764 ZNF217 0.671 81 20 Luminal YES 
55778 ZNF839 0.67 65 14 - NO 
286205 SCAI 0.666 45 9 - NO 
26053 AUTS2 0.665 35 7 Basal NO 
84922 FIZ1 0.663 79 19 - NO 
5287 PIK3C2B 0.655 9 1 Luminal NO 
51768 TM7SF3 0.652 56 12 Basal NO 
26508 HEYL 0.65 2 1 Basal NO 
10723 SLC12A7 0.65 21 5 Basal NO 
27166 PRELID1 0.65 24 5 - NO 
85414 SLC45A3 0.646 9 1 Luminal NO 
79676 OGFOD2 0.646 59 12 - NO 
10137 RBM12 0.641 80 20 Luminal NO 
6497 SKI 0.64 1 1 Basal NO 
89797 NAV2 0.639 50 11 - NO 
55915 LANCL2 0.637 34 7 Basal NO 
79733 E2F8 0.633 50 11 - NO 
2782 GNB1 0.632 1 1 Basal NO 
81607 PVRL4 0.628 8 1 - NO 
3709 ITPR2 0.628 56 12 Basal NO 
10105 PPIF 0.61 48 10 - NO 
196383 RILPL2 0.61 59 12 - NO 




8089 YEATS4 0.603 58 12 Luminal NO 
4010 LMX1B 0.602 45 9 - NO 
4792 NFKBIA 0.602 62 14 - NO 
84056 KATNAL1 0.599 61 13 - NO 
284252 KCTD1 0.587 75 18 Basal NO 
147807 ZNF524 0.581 79 19 - NO 
4069 LYZ 0.577 58 12 Luminal NO 
399687 MYO18A 0.572 69 17 - NO 
26057 ANKRD17 0.569 18 4 Basal NO 
157567 ANKRD46 0.568 41 8 - NO 
11160 ERLIN2 0.566 39 8 Luminal NO 
80256 KIAA1539 0.563 44 9 Basal NO 
23239 PHLPP1 0.562 76 18 - NO 
5584 PRKCI 0.555 15 3 Basal YES 
163033 ZNF579 0.546 79 19 - NO 
126823 KLHDC9 0.542 8 1 - NO 
3590 IL11RA 0.541 44 9 Basal NO 
6812 STXBP1 0.536 45 9 - NO 
5893 RAD52 0.534 55 12 Basal NO 
9525 VPS4B 0.531 76 18 - NO 
8462 KLF11 0.529 11 2 Basal NO 
9886 RHOBTB1 0.529 46 10 Basal NO 
8553 BHLHE40 0.528 13 3 - NO 
53917 RAB24 0.528 24 5 - NO 
5010 CLDN11 0.525 15 3 Basal NO 
51773 RSF1 0.525 53 11 - NO 
4609 MYC 0.523 43 8 Basal YES 
288 ANK3 0.523 46 10 Basal NO 
79647 AKIRIN1 0.522 2 1 Basal NO 
10457 GPNMB 0.52 32 7 - NO 
219333 USP12 0.519 60 13 - NO 
51742 ARID4B 0.51 10 1 - NO 
9804 TOMM20 0.507 10 1 - NO 
4854 NOTCH3 0.507 77 19 Basal NO 
11328 FKBP9 0.504 33 7 - NO 
2264 FGFR4 0.503 24 5 - NO 




152273 FGD5 0.49 14 3 - NO 
753 C18orf1 0.475 74 18 Basal NO 
142891 SAMD8 0.441 47 10 - NO 
51250 C6orf203 0.44 28 6 Basal NO 
57673 BEND3 0.44 28 6 Basal NO 
56204 KIAA1370 0.44 66 15 - NO 
4482 MSRA 0.429 38 8 - NO 
55168 MRPS18A 0.421 26 6 Basal NO 
1968 EIF2S3 0.375 83 23 Luminal NO 
22834 ZNF652 0.364 71 17 - NO 
10465 PPIH 0.326 3 1 Basal NO 






Supplementary Table 3 - ISAR-DEL deleted regions in TCGA breast Cancer dataset 
 
Chromosome Start End ISAR S-core 
1 87305283 87746386 2.12557 
1 238533051 239359132 2.0142 
1 239801732 240694710 2.0142 
2 5691 245456 3.5565 
2 50597993 51044857 2.33112 
2 174258740 174653191 2.15971 
2 241612631 241921194 2.48024 
3 176618877 177229628 2.19086 
4 25403772 25913570 2.07703 
4 64414626 68005725 3.26848 
4 115407938 117186641 4.72957 
4 133369009 134847306 4.24366 
5 6772782 6818644 2.07805 
5 106846689 106972246 5.64128 
6 49362641 49886993 2.13685 
6 108845221 109598576 2.97527 
6 167919303 168067726 2.05554 
7 671087 984743 2.1299 
7 124030081 125786183 3.29702 
7 150905014 152932983 6.74691 
8 3319632 3618710 3.49939 
8 11389938 11882721 4.00513 
8 22062977 23758536 7.85304 
9 9031738 9721921 3.83677 
9 16083724 16498403 2.05558 
9 21486896 24509939 21.7735 
10 62797 299301 10.5062 
10 27974852 29058929 2.3367 
10 89432418 90516347 10.528 
10 108033351 108580807 2.18124 
11 63899397 64405950 2.47027 
11 112923676 114697119 2.35104 
12 12382888 14725723 4.82012 
12 50093054 52867319 2.80153 
13 20945336 21596493 2.01973 
13 47747792 48734172 7.6777 
13 104844324 105440730 2.31549 
14 25560616 27708654 3.43336 
15 27268203 28153509 3.79883 
16 3599460 3910006 4.82262 
16 87944082 88042612 4.93302 




17 28673654 30896358 4.47724 
17 38522427 41436889 3.64734 
18 6651934 7049870 2.55805 
18 8157038 8402744 2.06205 
18 46394224 47608365 5.54206 
19 846626 2445233 14.9642 
19 47289591 53692211 5.91644 
20 152689 376916 2.00781 
22 34939568 35082752 2.86737 
















7 BENPORATH_ES_WITH_H3K27ME3 34 946 1.06E-07 8.39E-06 
7 BENPORATH_EED_TARGETS 28 908 2.91E-05 0.001149 
4 CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP 8 289 9.00E-05 0.002371 
24 CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2 6 325 2.65E-04 0.004584 
7 BENPORATH_SUZ12_TARGETS 25 880 2.90E-04 0.004584 
1 MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN 6 116 3.79E-04 0.004996 
1 PUJANA_CHEK2_PCC_NETWORK 15 699 5.79E-04 0.005478 
7 GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN 11 252 5.88E-04 0.005478 
8 HADDAD_B_LYMPHOCYTE_PROGENITOR 6 255 6.24E-04 0.005478 
1 GAL_LEUKEMIC_STEM_CELL_DN 7 217 0.002054 0.016223 
7 BENPORATH_PRC2_TARGETS 16 555 0.003232 0.023212 
1 PUJANA_BRCA1_PCC_NETWORK 22 1467 0.003685 0.023356 
21 KIM_WT1_TARGETS_DN 6 396 0.004033 0.023356 
15 KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP 6 601 0.004139 0.023356 
15 RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIAT 6 624 0.00497 0.026176 
4 NUYTTEN_NIPP1_TARGETS_DN 9 664 0.005447 0.026896 
3 BENPORATH_PRC2_TARGETS 7 555 0.006333 0.02943 
21 KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP 10 1066 0.006891 0.029665 
1 BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP 8 343 0.007222 0.029665 
3 BENPORATH_SUZ12_TARGETS 9 880 0.007675 0.029665 
4 GOZGIT_ESR1_TARGETS_DN 8 593 0.00899 0.029665 
4 SMID_BREAST_CANCER_BASAL_DN 8 595 0.009165 0.029665 
15 KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN 6 711 0.009261 0.029665 
3 BENPORATH_EED_TARGETS 9 908 0.009342 0.029665 
11 BLALOCK_ALZHEIMERS_DISEASE_UP 13 1499 0.009613 0.029665 
20 ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_ 6 740 0.009763 0.029665 
13 SCHLOSSER_SERUM_RESPONSE_DN 7 631 0.010237 0.029953 
4 BENPORATH_SUZ12_TARGETS 10 880 0.011346 0.032011 
21 NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN 6 499 0.012034 0.032781 
3 SMID_BREAST_CANCER_LUMINAL_B_DN 6 491 0.013211 0.033599 
7 XU_GH1_AUTOCRINE_TARGETS_UP 6 145 0.013315 0.033599 
8 PUJANA_ATM_PCC_NETWORK 11 1267 0.01361 0.033599 
7 RODRIGUES_NTN1_TARGETS_DN 6 147 0.014166 0.033914 
1 LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN 11 637 0.015372 0.034798 
11 WEST_ADRENOCORTICAL_TUMOR_DN 6 474 0.015417 0.034798 
11 DODD_NASOPHARYNGEAL_CARCINOMA_UP 11 1257 0.016384 0.035954 
1 ODONNELL_TFRC_TARGETS_UP 7 323 0.016978 0.03625 
22 BENPORATH_SUZ12_TARGETS 9 880 0.017638 0.036669 
17 BENPORATH_ES_WITH_H3K27ME3 10 946 0.019787 0.039251 




16 DANG_BOUND_BY_MYC 6 958 0.020893 0.039251 
5 SCHLOSSER_SERUM_RESPONSE_DN 8 631 0.02155 0.039251 
13 DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP 10 1269 0.02168 0.039251 
18 DANG_BOUND_BY_MYC 7 958 0.02315 0.039251 
18 DACOSTA_UV_RESPONSE_VIA_ERCC3_DN 6 746 0.023347 0.039251 
7 HATADA_METHYLATED_IN_LUNG_CANCER_UP 9 311 0.024204 0.039251 
8 PUJANA_CHEK2_PCC_NETWORK 7 699 0.024483 0.039251 
1 HAN_SATB1_TARGETS_UP 6 274 0.025232 0.039251 
7 FERNANDEZ_BOUND_BY_MYC 6 169 0.026146 0.039251 
7 ACEVEDO_METHYLATED_IN_LIVER_CANCER_UP 34 1819 0.026408 0.039251 
4 ACEVEDO_LIVER_CANCER_DN 6 462 0.027125 0.039251 
11 SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN 6 543 0.027923 0.039251 
3 DACOSTA_UV_RESPONSE_VIA_ERCC3_DN 7 746 0.028207 0.039251 
24 ACEVEDO_LIVER_CANCER_UP 6 842 0.028508 0.039251 
10 KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN 7 711 0.028827 0.039251 
5 RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIAT 7 544 0.02887 0.039251 
1 PUJANA_ATM_PCC_NETWORK 17 1267 0.029003 0.039251 
19 NUYTTEN_EZH2_TARGETS_UP 7 859 0.029041 0.039251 
7 DACOSTA_UV_RESPONSE_VIA_ERCC3_UP 8 271 0.029507 0.039251 
12 NUYTTEN_EZH2_TARGETS_DN 8 775 0.030287 0.039251 
24 NUYTTEN_EZH2_TARGETS_UP 6 859 0.031048 0.039251 
3 LOPEZ_MBD_TARGETS 7 763 0.03137 0.039251 
1 FARMER_BREAST_CANCER_BASAL_VS_LULMINAL 6 289 0.031613 0.039251 
3 BLALOCK_ALZHEIMERS_DISEASE_DN 9 1117 0.031798 0.039251 
22 BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN 6 532 0.033659 0.040909 
23 DODD_NASOPHARYNGEAL_CARCINOMA_DN 7 1127 0.035134 0.042055 
10 DACOSTA_UV_RESPONSE_VIA_ERCC3_DN 7 746 0.036081 0.042542 
20 DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP 7 1269 0.036618 0.042542 
1 MOOTHA_PGC 6 302 0.03793 0.043427 
8 NUYTTEN_EZH2_TARGETS_DN 7 775 0.039717 0.044824 
11 GOZGIT_ESR1_TARGETS_DN 6 593 0.040343 0.044889 
21 WEI_MYCN_TARGETS_WITH_E_BOX 6 662 0.041067 0.045059 
13 BENPORATH_NANOG_TARGETS 7 856 0.044982 0.048304 
1 SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 7 399 0.045769 0.048304 
7 ACEVEDO_LIVER_CANCER_DN 11 462 0.046451 0.048304 
11 RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP 6 614 0.046469 0.048304 
10 KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_DN 7 796 0.048424 0.049087 
10 SCHLOSSER_SERUM_RESPONSE_DN 6 631 0.048465 0.049087 






Supplementary Table 5 - Enrichment of Kegg pathways in lethality signatures 
 









16 Bladder cancer 3 40 2.37E-04 0.005526 
9 ErbB signaling pathway 4 84 2.64E-04 0.005526 
20 Insulin signaling pathway 4 132 2.80E-04 0.005526 
22 Insulin signaling pathway 5 132 2.87E-04 0.005526 
16 Non-small cell lung cancer 3 53 5.47E-04 0.008019 
9 Focal adhesion 5 192 6.83E-04 0.008019 
3 Tight junction 4 119 8.20E-04 0.008019 
8 Pyruvate metabolism 3 41 9.30E-04 0.008019 
9 Endometrial cancer 3 52 9.85E-04 0.008019 
9 Non-small cell lung cancer 3 53 0.001041 0.008019 
16 Pancreatic cancer 3 70 0.001238 0.008663 
9 Glioma 3 62 0.001644 0.009272 
16 ErbB signaling pathway 3 84 0.002096 0.009272 
22 Acute myeloid leukemia 3 57 0.002162 0.009272 
9 Renal cell carcinoma 3 69 0.002238 0.009272 
10 Protein digestion and absorption 3 73 0.002277 0.009272 
9 Pancreatic cancer 3 70 0.002332 0.009272 
3 mRNA surveillance pathway 3 74 0.002367 0.009272 
9 Melanoma 3 71 0.002429 0.009272 
4 Non-small cell lung cancer 3 53 0.002444 0.009272 
9 Chronic myeloid leukemia 3 72 0.002529 0.009272 
4 Inositol phosphate metabolism 3 58 0.003164 0.011075 
24 Spliceosome 3 123 0.003472 0.011623 
4 Glioma 3 62 0.003825 0.012272 
9 Prostate cancer 3 88 0.004471 0.013769 
22 Alzheimer's disease 4 153 0.004888 0.014477 
4 Pancreatic cancer 3 70 0.005386 0.014784 
4 Melanoma 3 71 0.005604 0.014784 
12 Leishmaniasis 3 69 0.005717 0.014784 
4 Chronic myeloid leukemia 3 72 0.005827 0.014784 
12 Arrhythmogenic right ventricular cardiomyopathy 3 70 0.005952 0.014784 
22 ErbB signaling pathway 3 84 0.006484 0.015603 
9 Regulation of actin cytoskeleton 4 203 0.006961 0.016104 
4 Phosphatidylinositol signaling system 3 78 0.007281 0.016104 
9 HIF-1 signaling pathway 3 105 0.00732 0.016104 
12 Hypertrophic cardiomyopathy 3 79 0.008325 0.017807 
4 Small cell lung cancer 3 83 0.008643 0.017988 
9 Neurotrophin signaling pathway 3 114 0.009182 0.018424 
1 Inositol phosphate metabolism 3 58 0.009332 0.018424 




17 NF-kappa B signaling pathway 3 86 0.010507 0.019264 
12 Dilated cardiomyopathy 3 86 0.010507 0.019264 
9 Hepatitis C 3 123 0.011299 0.020233 
22 HIF-1 signaling pathway 3 105 0.011969 0.020946 
7 Sphingolipid metabolism 3 40 0.012409 0.021234 
9 MAPK signaling pathway 4 243 0.012976 0.02172 
9 Insulin signaling pathway 3 132 0.013679 0.02241 
22 Neurotrophin signaling pathway 3 114 0.01494 0.023966 
7 Mineral absorption 3 44 0.016071 0.025254 
2 Neuroactive ligand-receptor interaction 4 254 0.017766 0.02736 
22 Hepatitis C 3 123 0.018296 0.027623 
16 Focal adhesion 3 192 0.020706 0.029409 
22 Measles 3 130 0.021176 0.029409 
4 Oxidative phosphorylation 3 116 0.021285 0.029409 
4 PI3K-Akt signaling pathway 5 317 0.021554 0.029409 
4 Parkinson's disease 3 117 0.02177 0.029409 
5 Parkinson's disease 3 117 0.02177 0.029409 
5 Ubiquitin mediated proteolysis 3 123 0.02481 0.032938 
12 Cell adhesion molecules 3 120 0.025537 0.033328 
22 Hepatitis B 3 141 0.026182 0.0336 
12 Axon guidance 3 123 0.027225 0.034366 
4 Measles 3 130 0.028636 0.035062 
9 Chemokine signaling pathway 3 175 0.028804 0.035062 
9 Pathways in cancer 4 310 0.029143 0.035062 
17 Osteoclast differentiation 3 128 0.030169 0.035739 
17 Measles 3 130 0.031393 0.036625 
7 Protein processing in endoplasmic reticulum 5 146 0.031952 0.036721 
7 Arachidonic acid metabolism 3 58 0.033207 0.037602 
4 HTLV-I infection 4 243 0.03477 0.038776 
4 Hepatitis B 3 141 0.035251 0.038776 
7 Glutamatergic synapse 4 104 0.037391 0.040551 
7 Cholinergic synapse 4 106 0.03968 0.041986 
4 Neuroactive ligand-receptor interaction 4 254 0.039965 0.041986 
22 Calcium signaling pathway 3 167 0.04035 0.041986 
4 Jak-STAT signaling pathway 3 150 0.041207 0.042306 
22 Tuberculosis 3 170 0.042194 0.042307 
20 Pathways in cancer 3 310 0.042307 0.042307 
 
 
 
